https://oncdata.com/ https://oncdata.com/blog https://oncdata.com/news https://oncdata.com/contact https://oncdata.com/videos https://oncdata.com/videos/how-clinical-intuition-and-genomic-ai-solved-a-cancer-misdiagnosis-mystery 2026-11-11 https://i.ytimg.com/vi/M5wHIyl5q5E/maxresdefault.jpg How Clinical Intuition and Genomic AI Solved a Cancer Misdiagnosis Mystery Artificial intelligence is creating new opportunities to identify the origins of cancer, particularly when a diagnosis does not align with the clinical presentation. In this episode of Exploring AI in Oncology, Dr. Vitor Pastorini (Florida Oncology and Hematology) and Dr. George Sledge (Chief Medical Officer at Caris Life Sciences and former Chief of Oncology at Stanford University) sit down with host Dr. Waqas Haque to discuss how AI-enabled genomic profiling can resolve diagnostic dilemmas. Through the case of Erika Rios—a 38-year-old patient whose presumed metastatic triple-negative breast cancer was ultimately uncovered as Hodgkin lymphoma—they examine the potential of genomic prediction tools, the necessity of validating unexpected findings with orthogonal testing, and the irreplaceable role of clinical intuition in modern oncology care. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/48wiot0 What You Will Learn in This Episode 🔹 Clinical Intuition in Diagnostic Dilemmas: How recognizing atypical presentations—such as lymphadenopathy above and below the diaphragm without visceral involvement or a primary breast mass—prompted a re-evaluation of an outside metastatic breast cancer diagnosis. 🔹 How Genomic AI Uncovers Tumor Lineage: The molecular science behind Caris Life Sciences' Genomic Prediction Score AI (GPSai), deep learning algorithms trained on comprehensive next-generation sequencing, and achieving approximately 95% accuracy when predicting cancer origin. 🔹 Overcoming Cognitive Bias and Pattern Recognition: Why standard tumor board assumptions can lead oncologists and pathologists into diagnostic traps, and how objective molecular data protects against misclassification. 🔹 Systemic Impact Across Cancer Types: Reviewing data in squamous cell carcinoma of the lung where roughly 3% of cases represent metastases from other anatomical sites, and evaluating utility in cancers of unknown primary (CUP) or dual primaries. 🔹 Resolving Discrepancies with Orthogonal Testing: Utilizing targeted immunohistochemistry, mutational signatures (such as UV or viral footprints), and multidisciplinary tumor boards when AI predictions conflict with initial pathology. 🔹 Advocating for Broad NGS Access: The importance of securing comprehensive molecular profiling coverage across Medicare, Medicaid, and commercial payers, alongside the vital diagnostic role of general community oncologists. Chapter Timestamps (16:00) 00:00 Introduction: Clinical Intuition Meets Genomic Artificial Intelligence 01:45 The Clinical Picture: When Triple-Negative Breast Cancer Does Not Fit 03:50 Spotting Red Flags: Systemic Lymphadenopathy Without a Primary Breast Mass 06:10 Deploying GPSai: How Deep Learning Decodes Cancer Genetic Fingerprints 08:25 Reversing the Diagnosis: From Terminal Disease to 89% Overall Survival 10:15 Cognitive Bias in Tumor Boards and the Reality of Clinical Misdiagnosis 12:00 Scale of Misclassification: Squamous Cell Lung Carcinomas and CUP 13:40 Resolving Conflicting AI Results with Orthogonal Assays and Mutational Signatures 15:10 Expanding NGS Access and the Role of the General Medical Oncologist About the Speakers Vitor Pastorini, MD, is a Medical Oncologist at Florida Oncology and Hematology, specializing in breast and hematologic malignancies with a focus on clinical genomics and precision medicine. George Sledge, MD, is the Chief Medical Officer at Caris Life Sciences and the former Chief of Oncology at Stanford University School of Medicine. He is a nationally recognized leader in breast cancer research and genomic medicine. Waqas Haque, MD, MPH, is a medical oncology fellow and host of the Exploring AI in Oncology series on Oncology Data Advisor, focusing on digital health applications, clinical trials, and oncology innovations. About Oncology Data Advisor Oncology Data Advisor provides healthcare professionals with peer-to-peer discussions, clinical insights, and up-to-date research reviews across hematology and oncology. Website: https://oncdata.com/ Follow on X: @OncData 2026-11-05T14:53:03.430Z https://www.youtube.com/embed/M5wHIyl5q5E 1038 https://oncdata.com/videos/closing-the-gap-in-colorectal-cancer-screening-adherence-dr-ethan-halm 2026-11-11 https://i.ytimg.com/vi/JbKT1Fhxfv0/maxresdefault.jpg Closing the Gap in Colorectal Cancer Screening Adherence | Dr. Ethan Halm Stool-based testing is a cornerstone of noninvasive colorectal cancer screening, yet its effectiveness depends entirely on regular, repeated participation over time. In this interview, Dr. Ethan Halm (Vice Chancellor for Population Health at Rutgers University) sits down with Dr. Jasmin Hundal to discuss findings from his team’s 10-year National Cancer Institute–funded study evaluating longitudinal adherence to annual fecal immunochemical testing (FIT) among more than 500,000 individuals across four major US health systems. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/closing-the-gap-in-colorectal-cancer-screening-adherence What You’ll Learn in This Episode: 🔹 Health System Infrastructure as the Top Predictor: Why proactive health system outreach resulted in a 20-fold difference in annual FIT retesting adherence compared to physician-level reminders alone. 🔹 The Proactive Mailed-FIT Model: How health systems like Kaiser Permanente Northern California achieved high adherence by continuously mailing home stool test kits rather than waiting for doctor visits. 🔹 Lowering Distant-Stage Cancer Presentations: How 10 years of longitudinal data proved that consistent annual repeaters have significantly lower rates of distant-stage disease compared to "one-and-done" screeners. 🔹 Limitations of EHR Reminders: Why electronic alerts alone are necessary but insufficient, and how physical home kit delivery removes logistical friction for patients starting at age 45. 🔹 Evolving National Quality Metrics: How cancer screening metrics are shifting from cross-sectional single-point snapshots to longitudinal participation and follow-up colonoscopy rates for positive stool tests (including upcoming 2027 metrics). Chapter Timestamps: About the Speakers: Ethan Halm, MD, MPH, MBA, is the Vice Chancellor for Population Health at Rutgers University. He served as lead investigator on a 10-year, NCI-funded study evaluating longitudinal FIT adherence across major US health systems. Jasmin Hundal, MD, MS, MPH, is an oncologist whose clinical and research focus centers on population health, cancer outcomes, and survivorship. Stay Connected: Subscribe for more expert discussions on oncology practice, research, and technology. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Longitudinal Adherence in Colorectal Cancer Screening</li><li>02:15 – The 10-Year NCI Study: Evaluating FIT Adherence in 500,000+ Patients</li><li>05:00 – Health System Infrastructure: A 20-Fold Difference in Retesting Odds</li><li>08:20 – Lessons from High-Performing Systems: Proactive Mailed-FIT Strategies</li><li>11:45 – Longitudinal Outcomes: Consistent Retesting vs. "One-and-Done"</li><li>14:30 – Why EHR Nudges Alone Are Insufficient to Drive Screening</li><li>17:10 – Evolution of Quality Metrics: The 2027 Follow-Up Colonoscopy Benchmark</li><li>19:00 – Key Takeaways: "Check Your Rear Every Year"</li></ul> 2026-10-29T15:16:19.930Z https://www.youtube.com/embed/JbKT1Fhxfv0 1251 https://oncdata.com/videos/the-documentation-burden-in-oncology-ehr-workflows-burnout-patient-care 2026-11-11 https://i.ytimg.com/vi/mWm4H5_1ZRc/maxresdefault.jpg The Documentation Burden in Oncology: EHR Workflows, Burnout, & Patient Care When clicking regulatory checkboxes and managing inbox alerts takes more time than talking to patients, how do oncology clinicians protect the doctor-patient relationship? In this episode of Oncology Unfiltered, Melissa Cutrona, MS (Co-Founder and General Manager of i3 Health and Oncology Data Advisor), sits down with Editor in Chief Matthew Hadfield, DO (Brown University Legorreta Cancer Center), to examine the personal, clinical, and operational ramifications of modern medical documentation. Together, they explore how administrative demands have transformed clinical encounters and discuss pathways to restore focus to direct patient care. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/4i8pbNR What You’ll Learn in This Episode: 🔹 Balancing Detailed Recordkeeping With Cognitive Overload: How complex billing mandates have expanded chart length, and the clinical risk of burying critical genomic data or immune-related toxicities inside massive notes. 🔹 The "Hardware Shield" in the Exam Room: Why typing during visits and managing incoming electronic health record (EHR) inbox alerts creates physical and emotional barriers between clinicians and patients. 🔹 The Double-Edged Sword of Ambient AI Scribes: Weighing the clerical relief of automated note-drafting against the potential loss of active clinical synthesis that traditionally occurs while writing notes. 🔹 Medicolegal Pressure and Chart Anxiety: Navigating the emotional weight and malpractice scrutiny associated with completing 15 or more detailed, high-stakes oncology charts each day. 🔹 Demanding Systemic Redesign and Standardization: Why healthcare leadership must prioritize workflow simplification over fragmented software updates and additional interface tabs. Chapter Timestamps: About the Speakers: Matthew Hadfield, DO, is a Medical Oncologist and Assistant Professor of Medicine at Brown University Legorreta Cancer Center, and Editor in Chief of Oncology Data Advisor. Melissa Cutrona, MS, is the Co-Founder and General Manager of i3 Health and Oncology Data Advisor. Stay Connected: Subscribe for more expert discussions on oncology practice, research, and technology. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Ballooning Administrative Burden in Oncology</li><li>02:15 – Billing Mandates & The Explosion of Regulatory Checkboxes</li><li>04:45 – Balancing Complex Oncologic Detail With Cognitive Overload</li><li>07:20 – The Hardware Shield: Screens, Inboxes, & Exam Room Dynamics</li><li>10:00 – Ambient AI Scribes: Time-Saving Promise vs. Passive Reviewing</li><li>12:35 – Preserving the Cognitive Process of Clinical Synthesis</li><li>15:00 – Medicolegal Pressure & The Emotional Toll of High-Volume Charting</li><li>17:15 – Systemic Redesign: Advocating for Workflow Standardization</li><li>18:20 – Key Takeaways: Reclaiming the Bedside and Patient Presence</li></ul> 2026-10-22T14:46:05.337Z https://www.youtube.com/embed/mWm4H5_1ZRc 1128 https://oncdata.com/videos/metabolic-health-meets-oncology-glp-1-receptor-agonists-in-breast-cancer 2026-11-11 https://i.ytimg.com/vi/RsIhf-aZV1Y/maxresdefault.jpg Metabolic Health Meets Oncology: GLP-1 Receptor Agonists in Breast Cancer As GLP-1 receptor agonists surge in popularity for obesity and diabetes, how do they actually impact breast cancer biology, treatment safety, and patient survivorship? In this interview, Dr. Jasmin Hundal discusses her co-authored review published in JCO Oncology Practice, exploring the metabolic, clinical, and survivorship implications of GLP-1 receptor agonists in breast cancer. She examines the biological links between adipose dysfunction and tumor progression, the clinical risk of sarcopenic muscle loss, and why enthusiasm from retrospective headlines must be balanced with prospective evidence. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/4eyjjfM What You’ll Learn in This Episode: 🔹 Answering Daily Patient Inquiries: Evaluating the safety, drug interactions, and monitoring requirements when patients use GLP-1 therapies alongside chemotherapy or endocrine therapy. 🔹 Biological Interplay of Adiposity & Tumorigenesis: How metabolically dysfunctional adipose tissue drives estrogen production, insulin/IGF-1 signaling, chronic inflammation, and pathways relevant to breast cancer like PIK3CA. 🔹 Guarding Against Sarcopenia & Functional Decline: Why cancer-associated weight loss must not sacrifice lean muscle mass, which is directly tied to treatment toxicity, dose reductions, and worse outcomes. 🔹 Lifestyle & Nutritional Countermeasures: Prioritizing adequate protein intake, resistance training, and nutritional status to protect muscle preservation and maintain treatment tolerance. 🔹 Distinguishing Media Headlines from Prospective Proof: Why current recurrence and survival claims stem from retrospective database studies, and what prospective trials are needed to validate direct oncologic benefits. 🔹 The Emergence of Metabo-Oncology: Viewing host metabolism not as background medical history, but as an active driver intersecting cancer biology, therapy tolerance, and survivorship. Chapter Timestamps: About the Speaker: Jasmin Hundal, MD, MS, MPH, is an oncologist whose clinical and research work focuses on the intersection between cardiometabolic health, cancer biology, and survivorship outcomes. She is the co-author of a review published in JCO Oncology Practice evaluating the clinical, metabolic, and oncologic implications of GLP-1 receptor agonists in breast cancer. Stay Connected: Subscribe for more expert discussions on oncology practice, research, and technology. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Intersection of GLP-1 Receptor Agonists & Breast Cancer</li><li>01:15 – Addressing Daily Clinic Inquiries: Safety, Chemo, & Endocrine Therapy</li><li>02:30 – Adipose Biology: Estrogen, Insulin, Chronic Inflammation, & PIK3CA</li><li>03:50 – Body Composition Risks: Guarding Against Lean Muscle Loss & Sarcopenia</li><li>05:10 – Nutritional Countermeasures: Protein Intake, Resistance Training, & Function</li><li>06:30 – Retrospective Headlines vs. Prospective Evidence: What the Data Shows</li><li>07:45 – Defining Metabo-Oncology & Future Clinical Priorities</li></ul> 2026-10-15T14:40:38.117Z https://www.youtube.com/embed/RsIhf-aZV1Y 576 https://oncdata.com/videos/bridging-the-regulatory-gap-real-world-data-quality-in-cancer-research 2026-11-10 https://i.ytimg.com/vi/rFZ8B5zpNQ4/maxresdefault.jpg Bridging the Regulatory Gap: Real-World Data Quality in Cancer Research Real-world data holds immense potential to strengthen oncology research, regulatory decisions, and clinical care, but raw electronic health record (EHR) data must undergo continuous standardization and rigorous validation before it can generate reliable evidence. In this interview, Dr. Jessica Paulus explores how Ontada operationalized FDA and EMA data quality frameworks across its ON.Genuity platform, moving data quality from subjective review to continuous, measurable governance across 4 million patient records. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/4AQPjW2 What You’ll Learn in This Episode: 🔹 Shift to Enterprise Data Quality: How FDA Q-CARD and EMA Data Quality Frameworks (DQF) transition quality evaluation from one-off study checks to platform-wide, reproducible measurement. 🔹 Operationalizing Frameworks in ON.Genuity: Standardizing 250+ oncology variables using FHIR and mCODE principles across 4 million patients and 700+ community oncology clinics. 🔹 External Survival Validation: Assessing data accuracy by comparing EHR-derived overall survival against National Death Index (NDI) mortality data in metastatic pancreatic cancer. 🔹 Quality Monitoring in Action: Interpreting standard edit checks, discrepancy resolution, and why identifying logical conflicts proves continuous monitoring is working. 🔹 Defining Fitness for Purpose: Evaluating how level of completeness and quality must align with specific regulatory, clinical, or payer decision-making needs. Chapter Timestamps: About the Speaker: Jessica Paulus, ScD, is the Vice President of Real-World Research at Ontada, where she leads real-world evidence research initiatives and the operationalization of data quality frameworks across oncology datasets. Stay Connected: Subscribe for more expert discussions on oncology practice, research, and technology. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Need for Measurable Real-World Data Quality</li><li>02:30 – Moving from Subjective Review to Platform-Wide Measurement (FDA Q-CARD & EMA DQF)</li><li>05:40 – Operationalizing Quality Frameworks Across ON.Genuity’s 4 Million Records</li><li>08:40 – External Validation: Concordance with National Death Index Survival Data</li><li>11:15 – Edit Checks & Managing Discrepancies Through Clinical Expertise</li><li>13:30 – Understanding "Fitness for Purpose" in Regulatory & Clinical Decisions</li><li>15:10 – Key Takeaways: Bridging the Regulatory Gap with Continuous Quality Governance</li></ul> 2026-10-08T13:29:13.237Z https://www.youtube.com/embed/rFZ8B5zpNQ4 973 https://oncdata.com/videos/human-in-the-loop-ai-in-medical-education-and-board-preparation 2026-11-11 https://i.ytimg.com/vi/Y9RVKpbVRWI/maxresdefault.jpg Human-in-the-Loop AI in Medical Education and Board Preparation New clinical trials, guideline updates, therapeutic approaches, and diagnostic technologies are continually reshaping how oncology clinicians learn and practice, far beyond traditional board-review methods. In this episode of Exploring AI in Oncology, Dr. Roupen Odabashian and Dr. Waqas Haque explore how human-guided AI can transform medical education, why clinician oversight is non-negotiable in content creation, and how oncology professionals can build practical AI literacy. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/reimagining-oncology-education-with-ai What You’ll Learn in This Episode: 🔹 From Fellowship to AI Development: How Dr. Odabashian transitioned from clinical training to independently learning Python, calculus, and multi-agent systems to bridge oncology and software engineering. 🔹 Building Adaptive Learning Platforms: Developing MeducationAI with question banks, flashcards, notes, visual materials, and podcasts to support diverse learning styles for trainees and attendings. 🔹 The "Human in the Loop" Imperative: Why physician review is essential when using AI tools for literature retrieval, question drafting, and determining board examination relevance. 🔹 Identifying AI Pitfalls & Limitations: Analyzing clinical scenarios where AI models fail without expert oversight, including defaulting to incorrect patient demographics or missing updated guideline changes. 🔹 Practical Pathways to AI Literacy: Defining three levels of clinician engagement—from basic AI literacy and workflow development ("plumbing") to technical model creation. 🔹 AI as a Clinical Capability Multiplier: Why AI resembles PCR testing and DNA sequencing as a powerful tool that expands clinical potential rather than replacing the physician-patient relationship. Chapter Timestamps: About the Speakers: Roupen Odabashian, MD, is a Medical Oncologist at Abbotsford Regional Hospital and the founder of @MeDucationAI, an AI-enabled learning platform for cancer care professionals. Waqas Haque, MD, MPH, is a second-year Hematology/Oncology Fellow at the @UChicago. He completed his Internal Medicine Residency at New York University (NYU) in a Clinical Investigator Track, with research focusing on innovative clinical trial design, value-based care delivery, and clinical investigation. Stay Connected: Subscribe for more expert discussions on oncology practice, research, and technology. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Rapidly Accelerating Pace of Oncology Knowledge</li><li>02:15 – From Cardiology Aspirations to Hematology/Oncology & AI</li><li>05:00 – Learning Technical Fundamentals: Python, Math, & Model Architecture</li><li>08:10 – Building MeducationAI: Tailoring Educational Tools to Diverse Learning Styles</li><li>11:30 – Why Human Oversight ("Human in the Loop") Is Non-Negotiable</li><li>14:45 – AI Pitfalls: Discrepancies in Rare Populations & Evolving Guidelines</li><li>17:30 – Educational Needs Across Career Stages: Fellows vs. Practicing Attendings</li><li>19:20 – Practical Pathways to AI Literacy & Workflow Development for Clinicians</li><li>21:00 – AI as a Powerful Tool, Not a Replacement for Physicians</li></ul> 2026-10-01T14:05:07.732Z https://www.youtube.com/embed/Y9RVKpbVRWI 1320 https://oncdata.com/videos/treatment-selection-at-first-relapse-in-multiple-myeloma-car-t-vs-bispecifics 2026-11-11 https://i.ytimg.com/vi/ejmJ5t5RR4E/maxresdefault.jpg Treatment Selection at First Relapse in Multiple Myeloma: CAR T vs. Bispecifics How can off-the-shelf bispecific antibodies bring advanced, life-saving multiple myeloma care directly to community practices? 🩸 In this interview, Dr. Rahul Banerjee (Fred Hutchinson Cancer Center / University of Washington) speaks with Dr. Hans Lee (Sarah Cannon Research Institute) about treatment selection at first relapse, establishing safe outpatient step-up dosing, proactive supportive care, and the future of time-limited, fixed-duration therapy in local community settings. Watch the full video & read the article on Oncology Data Advisor: https://oncdata.com/bringing-bispecific-antibodies-into-community-myeloma-care What You’ll Learn in This Episode 🔹 Treatment Selection at First Relapse: Comparing CAR T-cell therapy (single infusion, specialized center access required) with off-the-shelf bispecific antibodies that can be administered closer to home. 🔹 Safe Outpatient Step-Up Dosing: Assembling a multidisciplinary team (oncologists, APPs, pharmacists, infusion nurses, triage nurses) to map the outpatient journey and manage adverse events like cytokine release syndrome. 🔹 Proactive Supportive Care & Infection Mitigation: Implementing immunoglobulin replacement, antiviral, and PJP prophylaxis, as well as managing talquetamab-specific toxicities (taste changes, dry mouth, skin/nail issues). 🔹 Dose De-Escalation Strategies: Why reducing dosing frequency after achieving deep responses lowers treatment burden and minimizes ongoing side effects. 🔹 The Future of Time-Limited Therapy: Exploring fixed-duration approaches to prevent prolonged immune suppression while maintaining disease control and improving daily quality of life. Chapter Timestamps: About the Speakers: Rahul Banerjee, MD, FACP, is an Assistant Professor at @fredhutch and the University of Washington. Hans Lee, MD, is the Director of Myeloma Research at Sarah Cannon Research Institute. Stay Connected: Subscribe for more deep dives into oncology research and healthcare AI. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Bringing Bispecifics to Community Myeloma Care</li><li>01:45 – Treatment Selection at First Relapse: CAR T vs. Bispecific Antibodies</li><li>04:10 – Establishing a Safe Outpatient Step-Up Dosing Process</li><li>06:20 – Multidisciplinary Collaboration & Managing Adverse Events</li><li>08:15 – Supportive Care: Infection Risk & Prophylaxis Management</li><li>10:30 – Managing Talquetamab Toxicities: Taste, Skin, and Nail Care</li><li>12:00 – Dose De-Escalation & Fixed-Duration Treatment Horizons</li><li>13:15 – Key Takeaways for Community Myeloma Care</li></ul> 2026-09-22T15:37:03.742Z https://www.youtube.com/embed/ejmJ5t5RR4E 892 https://oncdata.com/videos/beyond-the-headlines-ai-s-growing-role-in-breast-oncology 2026-11-11 https://i.ytimg.com/vi/YOqOODSXRTY/maxresdefault.jpg Beyond the Headlines: AI’s Growing Role in Breast Oncology Artificial intelligence is reshaping breast cancer care from laboratory drug discovery to bedside clinical decision-making, far beyond sensationalized news headlines. In this interview, Dr. Matthew Kurian and Dr. Jasmin Hundal explore where AI holds the greatest promise in breast oncology, how clinicians can leverage AI as a clinical copilot, and how to effectively navigate patient use of large language models like ChatGPT. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/beyond-the-headlines-ai-in-breast-oncology What You’ll Learn in This Episode: 🔹 Transformative Impacts in Screening & Discovery: Evaluating AI's role in accelerating oncology drug development and enhancing mammography sensitivity through landmark studies like the MASAI trial. 🔹 Expanding Precision Medicine: Moving beyond tumor genomics to incorporate metabolic health, cardiovascular comorbidities, social determinants, and continuous wearable data into treatment planning. 🔹 AI as a Clinical Copilot: Utilizing AI tools to rapidly synthesize complex medical evidence, streamline provider workflows, and optimize care delivery without replacing human clinical judgment. 🔹 Navigating Patient-Led AI Search: Practical strategies for managing appointments when patients bring AI-generated information, including privacy guidance and effective prompting techniques. 🔹 The Frontier of Multimodal AI: Integrating clinical, radiologic, genomic, and social data into unified predictive platforms to solve complex treatment sequencing and response prediction. Chapter Timestamps: About the Speakers: Matthew Kurian, MD, is a Medical Oncologist at St. Elizabeth Healthcare and an Assistant Professor of Medicine at the University of Kentucky College of Medicine. He specializes in the treatment of breast cancer, focusing on clinical trial enrollment, health equity, and medical education in the community setting. Jasmin Hundal, MD, MS, MPH, is a Hematology/Oncology Fellow at the Cleveland Clinic. Her primary clinical and research interests center on the intersection between cardiometabolic health and oncology outcomes in breast cancer patients and survivors. Stay Connected: Subscribe for more expert discussions on oncology practice, research, and technology. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: AI's Unseen Potential in Breast Oncology</li><li>03:15 – Beyond Headlines: Drug Discovery & Screening (MASAI Trial)</li><li>07:00 – Precision Medicine: Wearables, Metabolic Health & Comorbidities</li><li>11:15 – AI as a Clinical Copilot: Synthesizing Complex Evidence</li><li>14:45 – Managing Patient-Led AI Searches, Privacy, & Smart Prompting</li><li>18:30 – Multimodal AI & Optimizing Treatment Sequencing</li><li>22:00 – Key Takeaways: Escalate vs. De-escalate in Precision Care</li></ul> 2026-09-15T12:38:08.242Z https://www.youtube.com/embed/YOqOODSXRTY 1453 https://oncdata.com/videos/personalizing-surgical-risk-assessment-in-lung-cancer-with-ai 2026-11-11 https://i.ytimg.com/vi/9OMxBiN8ZGI/maxresdefault.jpg Personalizing Surgical Risk Assessment in Lung Cancer With AI For patients with lung cancer, surgery often offers the best chance for a cure, but estimating individual postoperative risk—especially in older or complex patients—remains a persistent clinical challenge. In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Dr. Kenneth Patrick Seastedt about MIRACLE, an innovative AI-enabled platform combining clinical data, CT radiomics, and large language model (LLM) explanations to deliver personalized surgical risk predictions while keeping surgeons in full control. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/personalizing-surgical-risk-assessment-in-lung-cancer What You’ll Learn in This Episode: 🔹 Moving Beyond the "Eyeball Test": Understanding why standard risk calculators and clinical intuition struggle to account for individual variations in surgical tolerance and recovery. 🔹 The MIRACLE Multimodal Architecture: How fusing structured clinical variables, CT radiomic imaging features, and LLM narrative summaries creates tailor-made risk estimates instead of population averages. 🔹 Comparing AI to Clinical Judgment: Examining study data where MIRACLE demonstrated 77% sensitivity compared to 45% among experienced thoracic surgeons at a matching 20% false-positive rate. 🔹 Keeping Clinicians in the Loop: Utilizing editable LLM narrative summaries so surgeons can input qualitative context (like frailty or neoadjuvant therapy history) without overriding core risk calculations. 🔹 Building Guardrails Against Hallucinations: Locking factual variables (e.g., BMI, age, pulmonary function test values) to preserve ground-truth data integrity while leveraging LLMs safely. 🔹 The Imperative for Clinician-Led AI: Why oncology professionals must lead AI design from scratch to ensure tools address true clinical needs, fit hospital workflows, and prioritize patient outcomes. Chapter Timestamps: About the Speakers: Waqas Haque, MD, MPH, is a Hematology/Oncology Fellow at the University of Chicago. He completed his Internal Medicine Residency at NYU in the Clinical Investigator Track and focuses his research on innovative clinical trial design, value-based care delivery, and clinical investigation. Kenneth Patrick Seastedt, MD, MBA, FACS, is an Assistant Professor of Oncology in the Department of Thoracic Surgery at Roswell Park Comprehensive Cancer Center. He specializes in minimally invasive thoracic surgical oncology and AI applications to improve perioperative outcomes, advanced surgical techniques, and precision risk prediction. Stay Connected: Subscribe for more deep dives into oncology research and healthcare AI. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Challenge of Surgical Risk in Lung Cancer</li><li>02:15 – Limitations of the "Eyeball Test" and Standard Calculators</li><li>04:30 – Inside MIRACLE: Multimodal Data, Radiomics, and LLMs</li><li>07:00 – Model Performance: MIRACLE vs. Experienced Thoracic Surgeons</li><li>09:45 – Surgeon-in-the-Loop Design: Interactive and Editable Context</li><li>12:15 – AI Guardrails: Locking Factual Data to Prevent Hallucinations</li><li>14:30 – Future Directions: Prospective Testing and External Validation</li><li>16:15 – Key Takeaways: Why Clinicians Must Lead Oncology AI</li></ul> 2026-09-10T12:54:48.484Z https://www.youtube.com/embed/9OMxBiN8ZGI 1023 https://oncdata.com/videos/clinical-trial-enrollment-barriers-awareness-isnt-the-same-as-access 2026-11-09 https://i.ytimg.com/vi/q-op7KRP7QQ/maxresdefault.jpg Clinical Trial Enrollment Barriers: Awareness Isn’t the Same as Access While clinical trials represent the cutting edge of modern cancer therapy, significant disparities persist in determining who actually enrolls in them. In this episode of Oncology Unfiltered, Dr. Matthew Hadfield and Melissa Cutrona discuss the practical, structural, and clinical hurdles that prevent eligible patients from accessing potentially lifesaving investigational therapies, and how the oncology community can translate trial availability into meaningful access. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-clinical-trial-enrollment-barriers What You’ll Learn in This Episode: 🔹 Shifting Mindsets to Frontline Therapy: Understanding how clinical trials have evolved from last-resort options to representing preferred frontline strategies and the most promising avenues in modern cancer care. 🔹 Dismantling Patient Misconceptions: Debunking common anxieties surrounding placebos and "test subject" perceptions by clarifying open-label study designs and standard-of-care backbones. 🔹 Balancing Safety with Real-World Eligibility: Analyzing the impact of overly rigid eligibility criteria and advocating for drug-specific, rationalized inclusion rules that reflect true patient populations. 🔹 Navigating "Life Eligibility" and Logistics: Addressing travel burdens, intensive monitoring schedules, and the need for empathetic, iterative patient counseling to overcome practical access barriers. 🔹 Building Community and Academic Partnerships: Strengthening reciprocal referral channels and relationships between local practices and academic cancer centers to drive trial identification and enrollment. Chapter Timestamps: About the Speakers: Matthew Hadfield, DO, is the Editor in Chief of Oncology Data Advisor. He is a practicing oncology professional specializing in early-phase clinical trials, developmental therapeutics, and immunotherapy toxicities, dedicating his work to improving both clinician workflows and patient-centered survivorship care. Melissa Cutrona, MS, is the Co-Founder and General Manager of i3 Health and Oncology Data Advisor. She is committed to developing cutting-edge, evidence-based continuing medical education (CME/CE) programs and digital resources that optimize multi-professional collaboration and advance oncology care outcomes. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Access Gap in Clinical Trials</li><li>03:15 – Shifting Mindsets: Trials as Frontline Therapeutic Options</li><li>06:45 – Dismantling Placebo Fears and Patient Misconceptions</li><li>10:30 – Balancing Protocol Safety with Real-World Eligibility</li><li>14:15 – Navigating "Life Eligibility" and Logistical Hurdles</li><li>18:00 – Strengthening Community and Academic Partnerships</li><li>20:30 – Key Takeaways: Expanding Clinical Trial Participation</li></ul> 2026-09-03T14:31:58.485Z https://www.youtube.com/embed/q-op7KRP7QQ 1375 https://oncdata.com/videos/how-simulation-modeling-reduces-oncology-clinic-wait-times-dr-andrew-evens 2026-11-10 https://i.ytimg.com/vi/rlfpA8X3kdU/maxresdefault.jpg How Simulation Modeling Reduces Oncology Clinic Wait Times | Dr. Andrew Evens How can a busy cancer center nearly double its daily patient capacity without adding staff or expanding physical space? In this interview, Dr. Andrew Evens (Rutgers Cancer Institute) details how his team used simulation modeling to uncover hidden operational bottlenecks in a high-volume blood cancer and bone marrow transplant unit—reducing wait times and transforming clinic flow. Watch the full video & read the article on Oncology Data Advisor: https://oncdata.com/simulation-modeling-reducing-oncology-clinic-wait-times What You’ll Learn in This Episode 🔹Mapping Multi-Step Oncology Workflows: Why sequential visits—encompassing check-in, consent, lab testing, vitals, physician evaluation, and infusion—create compound delays across cancer centers. 🔹 Leveraging Simulation Modeling: How partnering with healthcare analytics researchers allowed the team to simulate operational changes (such as staffing levels and lab turnaround times) before implementing them in the clinic. 🔹 Uncovering Hidden Bottlenecks: Why the simulation model revealed laboratory turnaround times and a unified intake queue for all infusion patients as the real barriers, rather than staffing ratios. 🔹 The "Fast Track" Redesign: How separating supportive care patients (transfusions, IV fluids) from those receiving anticancer therapy reduced congestion and nearly doubled daily treatment capacity. 🔹 Operational AI & Cross-Disciplinary Leadership: How disease-agnostic modeling serves as a strategic application of operational AI, and why institutions can solve complex operational challenges by leveraging internal multidisciplinary talent. Chapter Timestamps: About the Speaker Andrew Evens, DO, MBA, MSc, is the Deputy Director for Clinical Services at Rutgers Cancer Institute, Chief Physician Officer at the Jack and Sheryl Morris Cancer Center, System Director of Medical Oncology at RWJBarnabas Health Medical Group, and Associate Vice Chancellor for Clinical Innovation and Data Analytics at Rutgers Biomedical and Health Sciences. A specialist in lymphoid malignancies, Dr. Evens has served as principal investigator on more than 100 clinical trials investigating novel therapeutics for lymphomas. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Overcoming Persistent Wait Times in Oncology Clinics</li><li>01:15 – Mapping the Multi-Step Complexity of Cancer Visits</li><li>02:40 – Outside-the-Box Collaboration: Partnering with Rutgers Business School</li><li>04:00 – Using Simulation Models to Test Operational Changes</li><li>05:15 – Uncovering the Real Bottlenecks: Lab Turnaround & Intake Funnels</li><li>06:45 – Redesigning Workflow: Creating a Fast Track for Supportive Care</li><li>08:00 – Scalability & Operational AI: Disease-Agnostic Solutions</li><li>09:15 – Internal Collaboration & Key Takeaways</li></ul> 2026-08-25T17:46:12.583Z https://www.youtube.com/embed/rlfpA8X3kdU 599 https://oncdata.com/videos/managing-relapsed-refractory-ctcl-dual-mechanisms-toxicity-workflows 2026-11-11 https://i.ytimg.com/vi/R1MUKrPBmr4/maxresdefault.jpg Managing Relapsed/Refractory CTCL: Dual Mechanisms & Toxicity Workflows Cutaneous T-cell lymphoma (CTCL) is a rare, chronic form of non-Hodgkin lymphoma that imposes a severe clinical and quality-of-life burden due to persistent pruritus, disfiguring skin lesions, and systemic progression risks. In this interview, Dr. Myron Czuczman, physician-scientist and Chief Medical Officer at Citius Oncology, explores the evolving CTCL treatment landscape. He highlights the FDA approval of denileukin diftitox-cxdl (Lymphir®), its unique dual immunotoxin mechanism targeting malignant T cells and regulatory T cells (Tregs), key trial data in heavily pretreated disease, and practical strategies for managing toxicities like capillary leak syndrome while prioritizing patient quality of life. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/new-paths-forward-in-cutaneous-t-cell-lymphoma What You’ll Learn in This Episode 🔹 CTCL Clinical Burden & Treatment Limitations: Understanding the challenge of managing chronic cutaneous and systemic lesions, and why cumulative toxicities (such as irreversible peripheral neuropathy and bone marrow suppression) restrict historical options like chemotherapy, brentuximab vedotin, and HDAC inhibitors. 🔹 Dual Mechanism of Denileukin Diftitox: How combining an IL-2 protein with diphtheria toxin directly kills IL-2 receptor–expressing malignant T cells while depleting immunosuppressive regulatory T cells (Tregs) to reactivate the patient's immune system. 🔹 Pivotal Trial Activity in Relapsed/Refractory Disease: Analyzing trial findings in heavily pretreated patients (median of four prior therapies) showing a 36% objective response rate, a 9% complete response rate, and a rapid median time to response of 1.4 months. 🔹 Managing Treatment-Related Toxicities: Implementing clinical workflows for mitigating infusion reactions and utilizing baseline albumin levels (≥3.0 g/dL) to evaluate and reduce the risk of capillary leak syndrome. 🔹 Prioritizing Quality of Life & Future Combination Horizons: Why alleviating 24/7 debilitating pruritus serves as a crucial clinical outcome, and how denileukin diftitox's short half-life creates potential synergy with checkpoint inhibitors and novel immunotherapies. Chapter Timestamps About the Speaker Myron Czuczman, MD, is a physician-scientist, academic oncologist, and Chief Medical Officer and Executive Vice President of Citius Oncology. With decades of experience in the global development of novel therapies for hematologic malignancies, he previously served for over 20 years at Roswell Park Cancer Institute as Chief of the Lymphoma/Myeloma Service and Head of the Lymphoma Translational Research Laboratory.<h3>Timestamps</h3><ul><li>00:00 – Introduction: Understanding Cutaneous T-Cell Lymphoma (CTCL)</li><li>02:30 – Historical Treatment Challenges: Chemotherapy & Cumulative Toxicities</li><li>05:15 – A New Immunotoxin Mechanism: How Denileukin Diftitox Targets IL-2 & Tregs</li><li>08:45 – Clinical Trial Evidence: Objective Response Rates in Relapsed/Refractory Care</li><li>12:00 – Toxicity Mitigation: Baseline Albumin & Managing Capillary Leak Syndrome</li><li>15:10 – Patient-Centered Metrics: Addressing 24/7 Pruritus & Quality of Life</li><li>17:40 – Emerging Combinations & The Challenge of T-Cell Targeted Therapies</li><li>19:15 – Key Takeaways: Expanding Clinical Trial Access in Rare Lymphomas</li></ul> 2026-08-18T16:14:31.151Z https://www.youtube.com/embed/R1MUKrPBmr4 1223 https://oncdata.com/videos/building-trust-in-real-world-evidence-with-ai-and-high-quality-data 2026-11-11 https://i.ytimg.com/vi/gLzHEYcWvJY/maxresdefault.jpg Building Trust in Real-World Evidence With AI and High-Quality Data As artificial intelligence (AI) rapidly transforms oncology research, generating reliable real-world evidence (RWE) depends on high-quality, transparent, and rigorous clinical data. In this episode of Exploring AI in Oncology, expert faculty explain how AI is accelerating complex biostatistical workflows without compromising scientific rigor. They explore Ontada’s three-pillar framework for real-world data quality (relevance, reliability, and external validity), the role of generative AI in trial emulation, and why human oversight and regulatory transparency remain essential. Read the full accompanying article on Oncology Data Advisor: https://bit.ly/3SpSv9S What You’ll Learn in This Episode 🔹 Data Quality Before AI: Understanding why complete, traceable, and structured real-world data (RWD) is a prerequisite for generating trustworthy AI analyses. 🔹 Three Pillars of Reliable RWE: Analyzing relevance, reliability, and external validity using Ontada’s dataset of 4 million patients across 700 community oncology clinics. 🔹 Accelerating Trial Emulation: How generative AI assists biostatisticians in defining patient cohorts, writing statistical code, and building analytic frameworks. 🔹 Essential Human Oversight: Why progressive summaries, milestone checkpoints, and human expertise prevent AI "black box" decisions and manage missing EHR data. 🔹 Regulatory Transparency: Meeting FDA and EMA expectations through structured prompting, audit trails, and early bias detection to ensure reproducible findings. Chapter Timestamps About the Speakers Waqas Haque, MD, MPH, is a second-year Hematology/Oncology Fellow at the University of Chicago. He completed his Internal Medicine Residency at New York University (NYU) in a Clinical Investigator Track, with research focusing on innovative clinical trial design, value-based care delivery, and clinical investigation. Saamir Pasha, MPH, is a Senior Biostatistician and Data Scientist at Ontada. He specializes in real-world studies, study protocol preparation, and statistical analysis plans, bringing extensive experience in epidemiology, data quality monitoring, and health outcomes research. Stay Connected Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: High-Quality Real-World Evidence in Oncology</li><li>01:45 – Why Data Quality Must Come Before AI Implementation</li><li>04:10 – The Three Pillars: Relevance, Reliability, and External Validity</li><li>06:50 – Generative AI in Trial Emulation & Biostatistical Workflows</li><li>09:15 – Maintaining Human Oversight & Progressive Summaries</li><li>11:20 – Addressing Data Limitations and Reducing Research Bias</li><li>12:50 – Regulatory Transparency & The Future of AI in RWE</li></ul> 2026-08-11T19:32:03.822Z https://www.youtube.com/embed/gLzHEYcWvJY 892 https://oncdata.com/videos/when-should-you-stop-immunotherapy-resistance-iraes-retreatment-strategies 2026-11-11 https://i.ytimg.com/vi/afIZNzkhHaM/maxresdefault.jpg When Should You Stop Immunotherapy? Resistance, irAEs & Retreatment Strategies When should clinicians continue, pause, or permanently discontinue immunotherapy? In this episode of Oncology Unfiltered, Melissa Cutrona sits down with Matthew Hadfield, DO, Editor-in-Chief of Oncology Data Advisor, to discuss the complex clinical challenges of long-term checkpoint inhibitor management. Together, they explore subtle immune-related adverse events (irAEs), tumor microenvironment resistance mechanisms, optimal treatment duration, and the risk-benefit balance of retreatment. 🔗 Read the companion article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-immunotherapy-fatigue 🎙️ FEATURING: • Melissa Cutrona – Co-Founder & General Manager, i3 Health and Oncology Data Advisor • Matthew Hadfield, DO – Editor-in-Chief, Oncology Data Advisor 📌 CLINICAL HIGHLIGHTS: - Identifying non-specific irAEs (endocrine complications, fatigue, pneumonitis) - Tumor microenvironment evasion & resistance across cancer types - Evaluating complete response vs. stable disease for treatment stopping points - Safety & rationale of restarting immunotherapy after progression or toxicity - Incorporating shared decision-making, patient burden, and ctDNA surveillance ⏱️ CHAPTER TIMESTAMPS: 💬 DISCUSSION FOR CLINICIANS: How do you navigate the decision to pause or discontinue immunotherapy in patients with stable disease or low-grade toxicity? Let us know your clinical approach in the comments! Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 - Introduction: The Evolving Role of Immunotherapy</li><li>01:50 - Spotting Subtle & Variable Immune-Related Adverse Events</li><li>04:45 - How Tumors Evade Checkpoint Inhibitors</li><li>07:30 - Duration of Therapy: How Long Should Patients Remain on Treatment?</li><li>11:15 - Retreatment Considerations After Progression or Toxicity</li><li>14:30 - Balancing Clinical Benefit with Patient Burden & Quality of Life</li><li>17:15 - Supporting Patients During Treatment Breaks & ctDNA Monitoring</li><li>19:40 - Navigating Clinical Gray Areas in Immuno-Oncology</li></ul> 2026-08-06T14:54:45.717Z https://www.youtube.com/embed/afIZNzkhHaM 1266 https://oncdata.com/videos/asco-2026-prostate-cancer-updates-talapro-3-proteus-earlier-intervention 2026-11-11 https://i.ytimg.com/vi/nqitXbo4BtM/maxresdefault.jpg ASCO 2026 Prostate Cancer Updates: TALAPRO-3, PROTEUS, & Earlier Intervention The treatment paradigm for advanced prostate cancer is undergoing a major shift—bringing highly effective, targeted therapies into earlier disease settings to improve long-term outcomes while balancing long-term treatment burden. This discussion serves as a faculty follow-up to Dr. Freedland's i3 Health Virtual Tumor Board, Navigating Treatment Selection and Sequencing in Metastatic Prostate Cancer. Read the full accompanying article on Oncology Data Advisor: 👉 https://oncdata.com/prostate-cancer-faculty-follow-up In this interview, expert faculty discusses practice-changing updates presented at the 2026 ASCO Annual Meeting. Highlighting key results from the phase 3 TALAPRO-3 and PROTEUS trials, Dr. Freedland explores how PARP inhibition and perioperative androgen receptor pathway inhibitors (ARPIs) are expanding treatment options across both metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease. What You’ll Learn in This Episode: 🔹 TALAPRO-3 Trial Insights: How talazoparib plus enzalutamide demonstrated broad-based benefit in HRR-altered mHSPC, including unexpected activity in ATM-mutated tumors. 🔹 PROTEUS Trial Findings: Evaluating perioperative apalutamide plus ADT in high-risk localized prostate cancer to achieve a 20% reduction in metastasis/death risk and a 35% reduction in the need for subsequent salvage therapies. 🔹 Moving Effective Therapies Earlier: Exploring the defining clinical trend of shifting PARP inhibitors and ARPIs into earlier disease settings to achieve durable control through finite treatment. 🔹 The Role of Biomarkers & Imaging: Leveraging genomic testing and prostate-specific membrane antigen (PSMA) imaging to identify aggressive disease sooner and personalize shared decision-making. 🔹 Next-Generation Targets: A look ahead at emerging therapeutic modalities, including T-cell engagers and androgen receptor degraders. Chapter Timestamps: About the Speaker: Stephen Freedland, MD, is the Warschaw Robertson Law Families Chair in Prostate Cancer, Professor of Surgery (Urology), and Director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Medical Center in Los Angeles, California. He is an internationally recognized expert in urologic oncology, risk stratification, and personalized cancer management. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Key Prostate Cancer Highlights from ASCO 2026</li><li>02:15 – TALAPRO-3: Expanding PARP Inhibition in HRR-Altered mHSPC</li><li>04:45 – Broad-Based Benefit: Unexpected Activity in ATM Mutations</li><li>07:00 – PROTEUS Trial: Perioperative Apalutamide in High-Risk Localized Disease</li><li>09:30 – Shared Decision-Making: Balancing Treatment Trade-Offs & Salvage Radiation</li><li>11:45 – Paradigm Shift: Moving Effective Therapies into Earlier Disease Settings</li><li>13:20 – Future Horizons: PSMA Imaging, T-Cell Engagers, & AR Degraders</li></ul> 2026-07-29T16:51:34.804Z https://www.youtube.com/embed/nqitXbo4BtM 876 https://oncdata.com/videos/additional-advances-in-extrapulmonary-neuroendocrine-carcinomas 2026-11-11 https://i.ytimg.com/vi/_ll_ze8tZ1c/maxresdefault.jpg Additional Advances in Extrapulmonary Neuroendocrine Carcinomas Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies that present unique diagnostic and therapeutic challenges. While treatment has historically followed small cell lung cancer (SCLC) pathways, the rapid emergence of Delta-like ligand 3 (DLL3)–targeted therapies—particularly bispecific T-cell engagers—is poised to reshape the treatment landscape.In this discussion, Dr. Danielle Hutchings and Dr. Andrew Hendifar sit down to explore the critical importance of accurate pathologic classification, the biological rationale behind targeting DLL3, ongoing clinical trial updates, and the practical challenges surrounding immunohistochemistry (IHC) testing thresholds in routine practice.Read the full accompanying article on Oncology Data Advisor: oncdata.com/additional-advances-ep-necsWhat You’ll Learn in This Episode:● Pathologic Classification: Why distinguishing well-differentiated neuroendocrine tumors (NETs) from poorly differentiated neuroendocrine carcinomas (NECs) is essential for selecting correct treatment algorithms.● Targeting DLL3 in EP-NECs: How DLL3-directed T-cell engager therapies recruit T cells to attack tumor cells, and why lower heterogeneity in EP-NECs may yield impressive treatment responses.● Unresolved IHC Testing Thresholds: The ongoing debate surrounding optimal DLL3 positivity cutoffs (e.g., 1% vs. 50% vs. 75%) and overcoming send-out testing logistics.● Expanding Clinical Trials: Future outlook for single-agent T-cell engagers and chemotherapy combinations in both first-line and refractory settings.● Multidisciplinary Coordination: Why close communication between pathologists, medical oncologists, and radiologists is vital for navigating rare neuroendocrine neoplasms.Chapter Timestamps:00:00 – Introduction: Unmet Needs in Extrapulmonary Neuroendocrine Carcinomas01:20 – Pathologic Precision: NETs vs. Poorly Differentiated NECs02:50 – DLL3 as a Therapeutic Target: Leveraging SCLC Pathways04:15 – T-Cell Engager Therapies in EP-NECs and GU Subgroups05:45 – Unresolved Questions: IHC Testing Thresholds & Access07:15 – The Clinical Trial Pipeline: First-Line and Refractory Options08:35 – Key Takeaways: The Power of Multidisciplinary CareAbout the Speakers:Danielle Hutchings, MD, is an Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, specializing in tumor classification, diagnostic precision, and biomarker evaluation in complex neuroendocrine neoplasms.Andrew E. Hendifar, MD, is an Associate Professor of Medicine and Medical Director of Pancreatic Cancer at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, leading research into targeted therapeutics, T-cell engagers, and novel clinical trial design.Stay Connected:Subscribe for more deep dives into oncology research and practice.Website: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a>Follow us on X/Twitter: @OncData#Oncology #NeuroendocrineTumors #EPNEC #DLL3 #TCellEngagers #OncologyDataAdvisor #MedEd #CancerResearch #Pathology #ClinicalTrials 2026-07-23T15:23:51.364Z https://www.youtube.com/embed/_ll_ze8tZ1c 593 https://oncdata.com/videos/earlier-detection-better-outcomes-in-ovarian-cancer-diagnostic-gaps 2026-11-09 https://i.ytimg.com/vi/RaywBmnxp98/maxresdefault.jpg Earlier Detection, Better Outcomes in Ovarian Cancer | Diagnostic Gaps Ovarian cancer remains one of the deadliest gynecologic malignancies, largely because approximately 75% of cases are diagnosed at an advanced stage. A critical lack of reliable population-level screening methods, combined with highly nonspecific symptoms, makes early detection one of the greatest unmet needs in gynecologic oncology.Read the full accompanying article on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/earlier-detection-better-outcomes-ovarian-cancer">https://oncdata.com/earlier-detection-better-outcomes-ovarian-cancer</a>In this discussion, experts join Dr. Jasmin Hundal to explore the ongoing challenges of early diagnosis. They review recent therapeutic breakthroughs for platinum-resistant disease—including newly approved antibody-drug conjugates (ADCs) and novel immunotherapy combinations—and highlight the promise of precision medicine and investigational agents like KAD101 in bridging the diagnostic and therapeutic gaps.What You’ll Learn in This Episode:🔹 The Dilemma of Delayed Diagnosis: Understanding why the anatomical location and nonspecific symptoms of ovarian cancer lead to three-quarters of patients presenting with advanced, metastatic disease.🔹 Limitations of Current Diagnostics: Analyzing the clinical constraints of transvaginal ultrasound and serum CA-125 testing, and why they fail as reliable population-based screening tools.🔹 Expanding Options in Platinum-Resistant Disease: Reviewing newly approved therapies, including mirvetuximab soravtansine (folate receptor alpha ADC), pembrolizumab plus paclitaxel, and relacorilant plus nab-paclitaxel.🔹Targeting the Prolactin Receptor: Discussing the biological rationale and clinical pipeline for KAD101, an investigational antagonist targeting the prolactin pathway in recurrent ovarian cancer.🔹 The Role of Genomic Screening: Evaluating how rapid, cost-effective genomic sequencing and homologous recombination deficiency (HRD) status guide personalized treatment and PARP inhibitor selection. Chapter Timestamps:00:00 – Introduction: The Critical Challenge of Ovarian Cancer01:15 – Why Ovarian Cancer is Diagnosed Too Late: Nonspecific Symptoms03:00 – Limitations of Current Diagnostics: Ultrasound & CA-12504:45 – The Clinical Reality: Advanced Staging & Survival Stats06:30 – Therapeutic Innovation: New Approvals in Platinum-Resistant Disease08:15 – Next-Gen Targets: Exploring Prolactin Receptor & KAD10110:00 – Precision Medicine: Fast Genomic Screening and HRD Status11:15 – Key Takeaways: Raising the Bar for Early DetectionAbout the Speakers:George Peoples, MD, is a surgical oncologist with extensive experience in cancer research, clinical leadership, and oncology drug development. Formerly at @mdanderson , he has led multiple comprehensive cancer programs and currently serves as Chief Medical Officer of Kaida Biopharma, where he focuses on developing novel targeted therapies for platinum-resistant ovarian cancer and other solid tumors. Jasmin Hundal, MD, MS, MPH, is a third-year Hematology/Oncology Fellow at the @clevelandclinic in Cleveland, Ohio. Previously, she completed her Internal Medicine Residency at the University of Connecticut. Dr. Hundal’s main area of interest is the overlap between cardiometabolic health and cancer, particularly for breast cancer patients and survivors.Stay Connected:Subscribe for more deep dives into oncology research and practice.Website: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a>Follow us on X/Twitter: @OncData#ovariancancer #GynecologicOncology #EarlyDetection #CancerScreening #OncologyDataAdvisor #MedEd #MedicalEducation #Oncology #PlatinumResistant #CMEhttps://oncdata.com/earlier-detection-better-outcomes-ovarian-cancer 2026-07-16T13:56:43.747Z https://www.youtube.com/embed/RaywBmnxp98 864 https://oncdata.com/videos/information-overload-and-the-portal-patient 2026-11-11 https://i.ytimg.com/vi/UIGkbM0aJkY/maxresdefault.jpg Information Overload and the Portal Patient The way that patients receive medical information has changed dramatically, shifting the dynamics of communication and transparency across the entire oncology landscape.Read the full accompanying article on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/information-overload-and-the-portal-patient">https://oncdata.com/information-overload-and-the-portal-patient</a>What You’ll Learn in This Episode:● Instant Information Without Context: Understanding the communication gap that occurs when patients receive complex lab or radiology results before their physician can review them.● Frightening Jargon and Misinterpretation: Analyzing how routine clinical notes—such as a "nonspecific pulmonary nodule"—can spark panic and inaccurate self-diagnosis when researched online without guidance.● Setting Clinical Expectations Early: Proactive techniques for onboarding patients to their health portals and establishing clear workflows for how and when difficult results will be addressed.● Reinterpreting Reference Ranges: Managing the emotional distress caused by automated portal flags (like red exclamation points) on clinically insignificant laboratory variations.● Navigating the Digital Messaging Burden: Addressing the growing institutional challenges of secure messaging triage and managing the modern clinician's digital communication workload.Chapter Timestamps:00:00 – Introduction: The Patient Portal Era in Oncology02:15 – Instant Information Without Clinical Context04:30 – Misinterpreting Medical Language and Digital Panic06:45 – Navigating Significant and Difficult Results Before Visits09:15 – Contextualizing Data: Why More Data Isn't Always Better11:45 – Reassurance Workflows: Explaining Reference Ranges and Flags14:15 – Tailoring Care Transparency to Patient Preferences16:30 – Managing the Burgeoning Burden of Digital Messaging17:40 – Key Takeaways: Clear Communication and Proactive ExpectationsAbout the Speakers:Matthew Hadfield, DO, is the Editor in Chief of Oncology Data Advisor. He is a practicing oncology professional specializing in early-phase clinical trials, developmental therapeutics, and immunotherapy toxicities, dedicating his work to improving both clinician workflows and patient-centered survivorship care.Melissa Cutrona, MS, is the Co-Founder and General Manager of i3 Health and Oncology Data Advisor. She is committed to developing cutting-edge, evidence-based continuing medical education (CME/CE) programs and digital resources that optimize multi-professional collaboration and advance oncology care outcomes.Stay Connected:Subscribe for more deep dives into oncology research and practice.Website: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a>Follow us on X/Twitter: @OncData#PatientPortal #Oncology #DigitalHealth #HealthIT #OncologyDataAdvisor #PatientAnxiety #MedEd #CancerCare #PhysicianBurnout #SharedDecisionMaking #MedEd #MedicalEducation #Education #OncData #OncEd #DigitalCommunication 2026-07-09T14:09:45.620Z https://www.youtube.com/embed/UIGkbM0aJkY 1122 https://oncdata.com/videos/one-size-fits-one-personalizing-cancer-prevention-through-ai-enhanced-imaging 2026-11-11 https://i.ytimg.com/vi/VHy7NJcGbxM/maxresdefault.jpg One Size Fits One: Personalizing Cancer Prevention Through AI-Enhanced Imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging Expert faculty discuss how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while moving away from a uniform model toward a "one size fits one" preventive approach. What You’ll Learn in This Episode: 🔹 Combining Human Expertise and AI: How fellowship-trained radiologists use advanced clinical AI deployments at scale to achieve faster, more accurate early cancer detection. 🔹 Moving From Reactive to Preventive: Shifting away from symptom-driven medicine by using AI tools to analyze imaging findings alongside electronic medical records and patient histories before symptoms develop. 🔹 A "One Size Fits One" Screening Model: Integrating breast density, family history, and routine imaging findings to generate highly individualized risk assessments and screening recommendations. 🔹 Opportunistic Screening Advancements: Utilizing routine imaging encounters to uncover unrelated health markers, such as identifying breast arterial calcifications (BACs) on mammograms to evaluate cardiovascular risk. 🔹 Closing the Patient-Provider Gap: How the AI-powered ClearPath platform translates complex radiology findings into accessible, highly engaging educational summaries to prevent patient confusion over incidental findings. Chapter Timestamps: About the Speakers: Sean Raj, MD, MBA, is the Chief Medical Officer and Chief Innovation Officer at SimonMed. As a board-certified radiologist, he leads the evaluation, acquisition, integration, and implementation of new clinical technologies into SimonMed’s infrastructure, directing patient-centered research focused on incorporating AI technologies into clinical practice. Waqas Haque, MD, MPH, is a second-year Hematology/Oncology Fellow at the University of Chicago. He completed his Internal Medicine Residency at NYU on a Clinical Investigator Track, and his research focuses on innovative clinical trial design, value-based care delivery to cancer patients, and clinical investigation. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Shifting to Proactive Cancer Prevention</li><li>02:15 – AI Deployments in Modern Outpatient Radiology</li><li>05:00 – Transitioning Healthcare from Reactive to Preventive Care</li><li>08:30 – Implementing a "One Size Fits One" Screening Approach</li><li>11:15 – Opportunistic Screening: Detecting Cardiovascular Risk on Mammograms</li><li>14:00 – Bridging the Communication Gap with ClearPath AI Reports</li><li>16:45 – Managing Incidental Findings and Coordinating Follow-Up</li><li>18:50 – Key Takeaways: The Future of AI Across Preventive Health</li></ul> 2026-07-01T12:41:01.165Z https://www.youtube.com/embed/VHy7NJcGbxM 1233 https://oncdata.com/videos/the-silent-side-effect-addressing-ototoxicity-in-germ-cell-tumor-treatment 2026-11-11 https://i.ytimg.com/vi/6AHT0gQ2_44/maxresdefault.jpg The Silent Side Effect: Addressing Ototoxicity in Germ Cell Tumor Treatment Long-term survivorship and quality of life remain paramount considerations in oncology, particularly for highly curable malignancies like metastatic germ cell tumors. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/silent-side-effect-ototoxicity-germ-cell-tumor-treatment In this interview, Dr. Koral Shah discusses her team's open and enrolling randomized trial testing whether sodium thiosulfate can successfully mitigate cisplatin-induced ototoxicity in adult patients. She breaks down the pathophysiology of permanent high-frequency hearing loss, outlines the critical timing required when administering protective agents, and shares actionable insights into making audiology a proactive metric of comprehensive survivorship care. What You’ll Learn in This Episode: 🔹 Understanding Ototoxicity: Exploring how cisplatin damages the outer hair cells within the cochlea, leading to high-frequency hearing loss and permanent tinnitus in up to 75% of germ cell tumor patients. 🔹 Protective Interventions & Rationale: Examining the mechanism of sodium thiosulfate (PEDMARK®) in binding reactive platinum species and why it must be given exactly six hours post-chemotherapy to maintain anti-cancer efficacy. 🔹 Evaluating Trial Design: Deconstructing City of Hope's randomized trial comparing physician-choice cisplatin-based chemotherapy alone versus chemotherapy followed by sodium thiosulfate. 🔹 Clinical Trial Accrual & Scaling: Reviewing the primary and secondary endpoints—including ASHA criteria ototoxicity and progression-free survival—and plans for satellite site expansion. 🔹 Redefining Care Benchmarks: Practical strategies for oncology teams to proactively implement baseline audiology assessments, patient counseling, and multidisciplinary supportive care. Chapter Timestamps: About the Speaker: Dr. Koral Shah, MD, is a Hematology/Oncology Fellow at @cityofhope. She is passionate about clinical trial design, therapeutic optimization, and improving long-term supportive care outcomes and quality of life for cancer survivors. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Addressing Ototoxicity in Germ Cell Tumor Care</li><li>01:30 – What is Ototoxicity? Cisplatin and Cochlear Damage</li><li>03:15 – The Protective Mechanism of Sodium Thiosulfate</li><li>05:00 – Trial Design: City of Hope's Randomized Comparison</li><li>06:45 – Accrual and Expanding Access to Satellite Sites</li><li>08:15 – Clinical Workflows: Prioritizing Audiology in Survivorship</li><li>09:30 – Key Takeaways: Quality of Life Beyond the Cure</li></ul> 2026-06-29T15:14:06.983Z https://www.youtube.com/embed/6AHT0gQ2_44 644 https://oncdata.com/videos/equity-in-preventive-oncology-practices-that-respect-identity-and-anatomy 2026-11-10 https://i.ytimg.com/vi/a_Bkz9IRsP4/maxresdefault.jpg Equity in Preventive Oncology: Practices That Respect Identity and Anatomy As oncology care continues to evolve toward more personalized and patient-centered approaches, addressing the unique needs of LGBTQ+ individuals remains an important component of equitable care delivery.Read the full accompanying article on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/equity-preventive-oncology-identity-anatomy">https://oncdata.com/equity-preventive-oncology-identity-anatomy</a>In this interview, expert faculty discusses key considerations for clinicians caring for LGBTQ+ patients across the cancer continuum. He highlights the clinical importance of adopting an anatomy-based approach to cancer screenings, recognizing the vital role of "chosen families" in caregiving networks, and implementing culturally competent communication strategies to bridge historic healthcare disparities and build inclusive environments.What You’ll Learn in This Episode:🔹 Recognizing the Chosen Family: Understanding how support networks often extend beyond biological relatives to provide critical caregiving and emotional backing throughout cancer treatment.🔹 Anatomy-Based Cancer Screening: Ensuring that preventive screening recommendations are strictly guided by the specific organs and tissues present rather than assumptions about sex or gender identity.🔹 Addressing Disparities Through Communication: Overcoming historical screening and care avoidance within the LGBTQ+ community through clear, transparent, and compassionate patient education.🔹 Diverse Caregiving Structures: Honoring meaningful relationships outside of legal or biological frameworks to coordinate effective, inclusive care and end-of-life planning.🔹 Creating Inclusive Environments: Actionable steps for healthcare systems to train clinical staff, build institutional trust, and establish affirming healthcare environments.Chapter Timestamps:00:00 – Introduction: Fostering Equity in Preventive Oncology01:30 – Redefining Care Networks: The Concept of Chosen Family03:00 – Clinical Frameworks: Anatomy-Based Cancer Screening Protocols04:45 – Bridging Gaps: Culturally Competent Patient Communication06:15 – Honoring Relationships in Caregiving and End-of-Life Planning07:45 – Systemic Inclusivity: Training Staff and Finding Affirming Care08:45 – Key Takeaways: Tools for Equitable PreventionAbout the Speaker: Dr. Justin Schweitzer, DO, is a family medicine physician and the Medical Director of LGBTQ+ Health and Primary Care at Cooper University Health Care. He is dedicated to improving healthcare accessibility for underrepresented populations, focusing on identity-affirming primary care, gender-affirming hormone therapy, and expanding training programs in cultural competency for medical professionals. Stay Connected:Subscribe for more deep dives into oncology research and <a target="_blank" rel="noopener noreferrer nofollow" href="http://practice.Website">practice.Website</a>: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a>Follow us on X/Twitter: @OncData#lgbtqhealth #HealthEquity #PreventiveOncology #CancerScreening #PrimaryCare #OncologyDataAdvisor #MedEd #MedicalEducation #InclusionInHealthcare #CulturallyCompetentCare 2026-06-25T14:32:24.247Z https://www.youtube.com/embed/a_Bkz9IRsP4 576 https://oncdata.com/videos/is-racial-and-ethnic-representation-in-oncology-clinical-trials-improving 2026-11-11 https://i.ytimg.com/vi/qPVPkh1mPIg/maxresdefault.jpg Is Racial and Ethnic Representation in Oncology Clinical Trials Improving? Health equity remains a critical priority in oncology, particularly ensuring that clinical trial enrollment accurately reflects the diverse populations impacted by cancer. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/racial-ethnic-representation-oncology-clinical-trials What You’ll Learn in This Episode: 🔹 AI Meets Trial Data: Understanding how multimodal large language models (LLMs) were utilized to automatically extract and evaluate three decades of demographic metrics from thousands of publication PDFs. 🔹 Exposing Enrollment Disparities: Analyzing why a dramatic tripling of trial demographic reporting has failed to translate into actual increased representation for Black and Hispanic communities in the US. 🔹 The Illusion of Global Progress: Exploring how international trial expansion, particularly in Asia, drives overall non-White participation data while domestic minority enrollment remains low or declines. 🔹 Structural Barriers to Participation: Evaluating the real-world operational and economic constraints—such as rigid follow-up schedules, travel distances, and dense language barriers—that hinder diverse patient accrual. 🔹 Fostering Equitable Research Environments: Actionable advice for investigators on leveraging pragmatic AI tools, like simplified consent language and patient-facing Q&A systems, to improve trial accessibility and trust. Chapter Timestamps: About the Speakers: Jiasheng Wang, MD, is an Assistant Professor of Hematology at The @OSUCCC_James – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He specializes in the treatment of blood cancers with a holistic approach that considers each patient’s physical, mental, and social well-being. Waqas Haque, MD, MPH, is a second-year Hematology/Oncology Fellow at the@UChicago. His research focuses on innovative clinical trial design, value-based care delivery to cancer patients, and clinical investigation. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Diversity and Representation in Oncology Trials</li><li>01:15 – AI Meets Trial Data: Processing 30 Years of Research</li><li>02:50 – Key Findings: The Rise in Reporting vs. Actual Inclusion</li><li>04:30 – Global Trends vs. US Minority Underrepresentation</li><li>06:10 – Operational Obstacles and Structural Barriers to Enrollment</li><li>07:50 – Pragmatic AI Applications: Simplifying the Patient Consent Process</li><li>09:25 – Key Takeaways: Building an Equitable Oncology Research Landscape</li></ul> 2026-06-24T17:04:11.145Z https://www.youtube.com/embed/qPVPkh1mPIg 723 https://oncdata.com/videos/join-the-discussion-translating-ndmm-trial-data-into-real-world-workflows 2026-11-11 https://i.ytimg.com/vi/BMoTpeJsYoc/maxresdefault.jpg Precision Decisions in NDMM: A Live Virtual Rounds Preview The therapeutic landscape for newly diagnosed multiple myeloma (NDMM) is expanding rapidly, offering better outcomes alongside distinct management challenges. In this Live Virtual Rounds previews, expert faculty shares critical insights into the modern multidisciplinary approach to NDMM. Learn more about the Live Virtual Rounds here: https://oncdata.com/ndmm-live-virtual-rounds-preview Session 1 - July 8 at 6:00 pm EST: https://bit.ly/3QWrgD5 Session 2 - July 28 at 7:00 pm EST: https://bit.ly/4ahPmi5 What You’ll Learn in This Episode: 🔹 Nuanced Treatment Selection: How disease-related features and patient logs dictate modern frontline choices over a "one-size-fits-all" model. 🔹 Proactive Patient Care: Essential strategies to stay ahead of insurance barriers, steroid side effects, and adherence issues during induction. 🔹 Sustainable Treatment Goals: Recognizing why delivering a sustainable, tolerated dose is often more clinically effective than chasing maximum trial-level doses in real-world settings. Chapter Timestamps: About the Speaker: Ashley Chen, PharmD, BCOP, is a Clinical Pharmacist in Malignant Hematology/Oncology at Fred Hutchinson Cancer Center and the University of Washington. She is deeply involved in clinical research, safe medication use practices, and the development of institutional clinical practice guidelines. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Navigating NDMM Therapeutic Advances</li><li>00:55 – Interview: Dr. Ashley Chen on the Evolving Pharmacist Role</li><li>02:00 – Managing Nuances: Quadruplets and Shifting Transplant Landscapes</li><li>03:15 – Solving Medication Burden and Steroid Toxicities in Induction</li><li>04:30 – Case for Individualized, Sustainable Dosing for Frail Patients</li><li>05:40 – What to Expect from i3 Health's Upcoming Live Virtual Rounds</li><li>06:35 – Wrap-up & Links to Full Coverage</li></ul> 2026-06-22T19:14:50.020Z https://www.youtube.com/embed/BMoTpeJsYoc 416 https://oncdata.com/videos/lgbtq-health-equity-lessons-from-a-three-time-cancer-survivor 2026-11-11 https://i.ytimg.com/vi/OAC0I0GSMoI/maxresdefault.jpg LGBTQ+ Health Equity: Lessons from a Three-Time Cancer Survivor In recognition of Pride Month, three-time cancer survivor and long-term HIV advocate Steve Drayton shares his powerful journey navigating the intersection of chronic illness and oncology care. Discover the critical steps clinicians and communities can take to dismantle biases and build a truly inclusive healthcare landscape.Read the full accompanying article on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://bit.ly/4xCXcgd">https://bit.ly/4xCXcgd</a>Key Takeaways🔹 Overcoming Barriers: LGBTQ+ patients frequently encounter diagnostic delays and systemic care barriers that directly impact clinical outcomes.🔹 The Impact of Bias: Stigma and provider discomfort continue to contribute to significant delays in proper medical evaluations and life-saving treatments.🔹 Cultural Competency: Delivering high-quality, inclusive care requires clinicians to foster trust, engage in open dialogue, and strictly follow evidence-based protocols regardless of patient identity.🔹 Community & Empowerment: Grassroots advocacy and patient self-empowerment are vital catalysts for improving healthcare access and equity.Video Chapters00:00 – Introduction: LGBTQ+ Health Equity in Oncology01:15 – A Complex Clinical Journey: HIV & Cancer Survivorship02:30 – Disparities in Care Delivery & Diagnostic Delays04:00 – Addressing Systemic Bias and Stigma in Healthcare05:15 – The Power of Grassroots Advocacy & Community Connection06:45 – Clinician Lessons: Creating Inclusive Care Environments08:00 – Patient Empowerment & Self-Advocacy09:20 – Key Takeaways: Building an Equitable Oncology LandscapeSpeaker OverviewSteve Drayton is a resilient three-time cancer survivor, a long-term HIV survivor (diagnosed in 1994), and a dedicated LGBTQ+ health advocate. Partnering with organizations like the American Cancer Society, Steve leverages his personal healthcare journey to champion grassroots initiatives, promote local health fairs, and educate medical professionals on cultural competency and inclusive clinical practices.Stay Connected:Subscribe for more deep dives into oncology research and practice.Website: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a>Follow us on X/Twitter: @OncData#HealthEquity #Oncology #LGBTQHealth #CancerSurvivor #HIVSurvivor #PrideMonth #PatientAdvocacy #InclusiveCare 2026-06-22T13:58:32.505Z https://www.youtube.com/embed/OAC0I0GSMoI 631 https://oncdata.com/videos/no-one-is-invincible-a-call-for-proactive-skin-cancer-screening 2026-11-11 https://i.ytimg.com/vi/zJ_HSVGZ6JQ/maxresdefault.jpg No One Is Invincible: A Call for Proactive Skin Cancer Screening No one is too young, too healthy, or too invincible to take skin cancer screening seriously. Diagnosed at age 38 with a lesion on his thigh that he initially dismissed as a bug bite, CJ details how his sense of invincibility was shattered when the cancer rapidly progressed and spread to his lymph nodes. Sitting down to discuss the critical intersections of oncology, masculinity, and LGBTQ+ health, he outlines why proactive dermatological care is an essential act of self-care and community survival. Read the full accompanying article on Oncology Data Advisor: What You’ll Learn in This Episode: 🔹 Shattering the Invincibility Myth: Recognizing that physical fitness and healthy lifestyles do not immunize younger adults against aggressive skin malignancies. 🔹 The Rapid Progression of Melanoma: Understanding how a minor skin spot can transform into a life-threatening diagnosis within just a few months. 🔹 Navigating LGBTQ+ Healthcare Barriers: Confronting the systemic stigma, lack of trust, and unique pressures that discourage gay men and LGBTQ+ individuals from seeking medical providers. 🔹 The Long Shadow of Survival: Unpacking the heavy physical scars, permanent emotional anxiety of cancer surveillance, and debilitating financial toxicities that persist long after active therapy ends. 🔹 The Vital Role of Peer Support: Utilizing community networks and proactive peer advocacy to look out for loved ones and encourage early screening. Chapter Timestamps: About the Speaker: CJ Weiss is a melanoma survivor, husband, father, fitness coach, and health advocate who is deeply passionate about sharing the message that cancer does not discriminate by age, appearance, or lifestyle. After being diagnosed with stage IV melanoma at age 38, he underwent emergency surgery, immunotherapy, and five years of intensive clinical surveillance. Today, he partners with the American Cancer Society and campaigns like Philadelphia’s Real Men Wear Pink to challenge medical taboos and encourage annual skin checks across underrepresented communities. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: The Myth of Invincibility in Skin Cancer</li><li>01:45 – A Diagnosis That Changed Everything: From Bug Bite to Melanoma</li><li>04:20 – Narrow Windows: Missing a Vacation to Save a Life</li><li>06:50 – The Long Shadow of Cancer: Physical, Emotional, and Financial Tolls</li><li>09:15 – Cancer, Masculinity, and Addressing LGBTQ+ Healthcare Gaps</li><li>11:40 – Community Systems: The Power of Support and Survivor Advocacy</li><li>13:55 – Key Takeaways: A Lifesaving Pride Month Reminder</li></ul> 2026-06-17T18:55:58.924Z https://www.youtube.com/embed/zJ_HSVGZ6JQ 1091 https://oncdata.com/videos/partners-in-care-the-community-role-in-men-s-cancer-prevention-and-treatment 2026-11-11 https://i.ytimg.com/vi/Vxfb6S91JdI/maxresdefault.jpg Partners in Care: The Community Role in Men’s Cancer Prevention and Treatment 2026-06-16T17:24:09.802Z https://www.youtube.com/embed/Vxfb6S91JdI 849 https://oncdata.com/videos/building-patient-trust-in-oncology-overcoming-clinical-trial-mistrust 2026-11-11 https://i.ytimg.com/vi/agzV0jPdQXs/maxresdefault.jpg Building Patient Trust in Oncology: Overcoming Clinical Trial Mistrust Increasing clinical trial diversity requires far more than expanding access—it demands a foundation of authentic, hard-earned patient trust.Read the full accompanying article on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/asco-voices-patient-trust">https://oncdata.com/asco-voices-patient-trust</a>At the ASCO Annual Meeting, breast cancer survivor and advocate Megan-Claire Chase took the stage for the prestigious ASCO Voices program to share her personal evolution from a complete clinical trial skeptic to a passionate advocate. In this episode, she sits down with Dr. Jasmin Hundal to discuss how healthcare professionals can improve diversity and health equity in oncology. Together, they outline how to address the deep-rooted historical trauma and community memory behind medical mistrust, dismantle confusing clinical jargon, debunk the oncology placebo myth, and prioritize cultural competency to build genuine patient rapport.What You’ll Learn in This Episode:🔹 Understanding the Roots of Mistrust: Recognizing how historical medical exploitation continues to shape perceptions of research within minoritized communities.🔹 Ditch the Clinical Jargon: Replacing complex terms like "standard of care" and "randomization" with clear, accessible language that resonates with patients.🔹 Dismantling the Placebo Myth: Reassuring patients that modern oncology clinical trials do not utilize placebos in place of active cancer therapy.🔹 Prioritizing Patient Autonomy: Empowering individuals by reinforcing that they are always "in the driver's seat" regarding their own care.🔹 The Impact of Authenticity: Cultivating cultural competency and leveraging patient-centered storytelling to drive systemic change across healthcare networks.Chapter Timestamps:00:00 – Introduction: The Power of Patient Trust at ASCO01:45 – From Skeptic to Speaker: Megan-Claire's ASCO Voices Debut04:10 – Facing the Stain on History: Unpacking the Roots of Medical Mistrust07:15 – Demystifying Trial Jargon: Standard of Care and Randomization09:50 – The Placebo Misconception: Clarifying Active Treatment Safeguards12:10 – Cultural Competency: Honoring Representation and Community Memory14:35 – Key Takeaways: Relational Trust and Achieving Health EquityAbout the Speakers:Megan-Claire Chase: A patient advocate, Breast Cancer Program Director for SHARE Cancer Support, and a 10-year survivor of invasive lobular breast cancer. Representing Advocates for Collaborative Education (ACE) at ASCO, her work has been widely documented in her blog, "Life on the Cancer Train," and featured across major national media outlets.Jasmin Hundal, MD, MS, MPH: A Hematology/Oncology Fellow at the @clevelandclinic specializing in the intersection of cardiometabolic health and comprehensive care for breast cancer patients and survivors.Stay Connected:Subscribe for more deep dives into oncology research and practice.Website: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a>Follow us on X/Twitter: @OncData#ASCO #Oncology #ClinicalTrials #PatientAdvocacy #HealthEquity #MedicalMistrust #BreastCancer #OncologyDataAdvisor #MedEd #MedicalEducation #CulturalCompetency #CancerCare 2026-06-12T18:00:16.734Z https://www.youtube.com/embed/agzV0jPdQXs 1195 https://oncdata.com/videos/why-human-expertise-still-matters-in-healthcare-ai 2026-11-11 https://i.ytimg.com/vi/3hTibwjKcjY/maxresdefault.jpg Why Human Expertise Still Matters in Healthcare AI Artificial Intelligence can pull structured data from a medical chart in seconds—but can it understand the "why" behind an oncology patient's changing treatment plan? True data quality will always require an experienced human in the loop. In this episode of Exploring AI in Oncology, we bust the myth that AI can completely automate clinical registries and reveal why data abstraction is actually a critical patient safety issue where a single missed data point can lead to dangerous over-radiation.Read the full accompanying article on Oncology Data Advisor:To dive into this massive paradigm shift, our host Dr. Waqas Haque sits down with Erin Tobaison, Senior Clinical Data Abstraction Manager at Carta Healthcare. Together, they discuss how AI is reshaping registry workflows while reinforcing the critical need for strong clinical judgment, specialty expertise, and institutional support.🔹 The Safety Link: Why faulty data abstraction isn't just a compliance issue, but a direct threat to downstream clinical decision-making and patient safety.🔹 Where AI Wins: How AI-assisted workflows cut down abstraction times from 30 minutes to 15 minutes for simple cases, and save hours on complex charts.🔹 The Hybrid Model: Why expert human oversight is indispensable for interpreting ambiguous language, conflicting documentation, and nuanced pathology reports.🔹 The Specialty Myth: Why abstractors are not interchangeable, and why moving an expert from oncology to a cardiovascular registry makes them a "novice" again.🔹 The Learning Health Cycle: How monthly audits and investing in ongoing provider education ensure AI acts as an accelerator, not a replacement for clinical judgment.Chapter Timestamps[00:00:00] - Introduction: Balancing AI Scale with Clinical Expertise[00:02:15] - Frontline Clinical Experience as a Foundation for Data Quality[00:04:40] - Why Data Abstraction Is a Critical Patient Safety Issue[00:07:10] - Where AI Adds Immediate Operational Value in Registries[00:09:35] - The Hybrid Approach: Why Human Oversight Remains Essential[00:11:50] - Operational Challenges: Specialty Nuance and Productivity Benchmarks[00:13:45] - Conclusion: Investing in People to Strengthen Data TeamsAbout the SpeakersErin Tobaison is the Senior Clinical Data Abstraction Manager at Carta Healthcare, with extensive experience spanning oncology, cardiovascular, and surgical registries. Having previously worked as a radiation therapist for 15 years, she brings vital frontline clinical insight to her leadership role in tumor registry operations, data quality, and abstraction management.Waqas Haque, MD, MPH, is a second-year Hematology/Oncology Fellow at the @UChicagoMedicine He completed his Internal Medicine Residency at New York University (NYU) in the Clinical Investigator Track. Dr. Haque balances direct patient care with clinical investigations into innovative trial design and value-based care delivery.Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData 2026-06-11T13:00:41.894Z https://www.youtube.com/embed/3hTibwjKcjY 954 https://oncdata.com/videos/a-new-door-in-lung-cancer-targeting-met-amplification-as-a-primary-driver 2026-11-11 https://i.ytimg.com/vi/LekWx8loP_o/maxresdefault.jpg A New Door in Lung Cancer: Targeting MET Amplification as a Primary Driver 2026-06-10T12:40:11.272Z https://www.youtube.com/embed/LekWx8loP_o 666 https://oncdata.com/videos/can-podcasts-help-improve-adoption-of-her2-low-therapies 2026-11-11 https://i.ytimg.com/vi/pRzWwVx9Vxs/maxresdefault.jpg Can Podcasts Help Improve Adoption of HER2-Low Therapies? At the 2026 ISPOR Annual Meeting, Dr. Jessica Paulus presented research on how targeted education can improve real-world adoption of HER2-low therapies for metastatic breast cancer. 2026-06-09T15:08:17.551Z https://www.youtube.com/embed/pRzWwVx9Vxs 843 https://oncdata.com/videos/only-the-first-chapter-reframing-cancer-survivorship 2026-11-11 https://i.ytimg.com/vi/1SKzM5UEO40/maxresdefault.jpg Only the First Chapter: Reframing Cancer Survivorship 2026-06-05T15:52:08.030Z https://www.youtube.com/embed/1SKzM5UEO40 1027 https://oncdata.com/videos/multidisciplinary-realities-tumor-board-vs-tuesday-afternoon 2026-11-11 https://i.ytimg.com/vi/G4ZZm6HlMQI/maxresdefault.jpg Multidisciplinary Realities: Tumor Board vs Tuesday Afternoon 2026-06-04T18:36:20.760Z https://www.youtube.com/embed/G4ZZm6HlMQI 1219 https://oncdata.com/videos/75-of-breast-cancers-have-no-family-history-the-dangerous-myth-you-need-to-know 2026-11-11 https://i.ytimg.com/vi/RXWe71Kfbq0/maxresdefault.jpg 75% of Breast Cancers Have NO Family History. The Dangerous Myth You Need to Know. 2026-06-02T19:02:17.876Z https://www.youtube.com/embed/RXWe71Kfbq0 517 https://oncdata.com/videos/targeting-ras-in-pancreatic-cancer-is-the-undruggable-era-finally-over 2026-11-11 https://i.ytimg.com/vi/8jSCedLPpNs/maxresdefault.jpg Targeting RAS in Pancreatic Cancer: Is the "Undruggable" Era Finally Over? For decades, targeting RAS in pancreatic cancer was deemed "undruggable"—until now. With groundbreaking Phase 3 RASOLUTE trial data shaking up the treatment landscape, are next-generation pan-RAS inhibitors finally delivering the breakthrough clinicians and patients have been waiting for?Read the full accompanying article on Oncology Data Advisor:Pancreatic cancer remains a profound clinical challenge, but a new class of targeted therapies is rewriting the treatment landscape. In this episode, Gastrointestinal Oncologist Dr. Christos Fountzilas and Hematology/Oncology Fellow Dr. Waqas Haque break down the emerging science, biomarker-driven strategies, and toxicity management behind the novel pan-RAS inhibitor, daraxonrasib. Discover how these biology-driven designs are moving past old limitations to expand options for advanced pancreatic cancer care.What You’ll Learn in This Episode:● From "Undruggable" to Opportunity: How broader strategies, like pan-RAS inhibitors, are expanding treatment options for more patients.● Clinical Trial Spotlight: Early signals from the phase 3 RASOLUTE trial evaluating the investigational pan-RAS inhibitor daraxonrasib.● Biomarker Testing & Patient Selection: Why comprehensive molecular profiling (somatic, liquid, and germline) is essential at advanced diagnosis.● Managing Toxicities: How to interpret preliminary data and proactively manage gastrointestinal and dermatologic side effects.● The Future of RAS Therapy: Why treatment strategies must remain grounded in tumor biology to build effective combination therapies.About the Speakers: Christos Fountzilas, MD, FACP: A Gastrointestinal Medical Oncologist and early-phase clinical trial investigator at @roswellparkofficial. Waqas Haque, MD, MPH: A Hematology/Oncology Fellow at the @UChicago specializing in innovative clinical trial design, value-based care delivery, and clinical investigation.Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: https://oncdata.com/ Follow us on X/Twitter: @OncData<h3>Timestamps</h3><ul><li>00:00 – Introduction: Shifting the Paradigm in Pancreatic Cancer</li><li>01:10 – Overcoming the "Undruggable" Barrier of RAS Mutations</li><li>03:25 – Phase 3 RASOLUTE Trial: Early Efficacy Data for Daraxonrasib</li><li>05:40 – Biomarker Strategies: Tissue-Based vs. Liquid Biopsies</li><li>07:55 – Toxicity Management: Navigating GI and Skin Adverse Events</li><li>10:15 – Clinical Trial Implementation and Real-World Considerations</li><li>12:30 – Future Outlook: Biology-Driven Design and Combination Therapies</li></ul> 2026-06-01T18:21:41.597Z https://www.youtube.com/embed/8jSCedLPpNs 1129 https://oncdata.com/videos/conquering-triple-negative-breast-cancer-why-clinical-care-isn-t-enough 2026-11-11 https://i.ytimg.com/vi/nL7kdGqnZGs/maxresdefault.jpg Strength in Community: Building Visibility in LGBTQ+ Cancer Care After being diagnosed with aggressive triple-negative breast cancer on Valentine’s Day 2022, Alix Shulman quickly learned that conquering cancer involves much more than medical expertise—it requires community. Today, she is cancer-free and turning her experience into action as an American Cancer Society ambassador for Portraits of Hope. In this interview for Pride Month, she sits down with Oncology Data Advisor to share how passion for advocating for early detection and breast cancer awareness, with a focus on ensuring that LGBTQ+ patients feel seen and supported in clinical settings. 2026-06-01T13:43:41.693Z https://www.youtube.com/embed/nL7kdGqnZGs 1109 https://oncdata.com/videos/can-exercise-lower-your-lung-cancer-risk 2026-11-11 https://i.ytimg.com/vi/sjwAq5RG2UI/maxresdefault.jpg Can Exercise Lower Your Lung Cancer Risk? At the American Association for Cancer Research (AACR) Annual Meeting, Dr. Marisa Bittoni of The Ohio State University Comprehensive Cancer Center shared interim findings from the <a target="_blank" rel="noopener noreferrer nofollow" href="https://aacrjournals.org/cancerres/article/86/7_Supplement/3635/779803/Abstract-3635-Interim-results-of-the-BEFIT?searchresult=1">BEFIT study,</a> a pilot exercise intervention for people at high risk for lung cancer. Rather than focusing on patients already diagnosed with disease, the study targets a vulnerable group—longtime smokers and former smokers eligible for lung cancer screening—to explore whether structured exercise can improve fitness, reduce body mass index, and potentially influence inflammation and the microbiome. 2026-05-29T15:23:25.702Z https://www.youtube.com/embed/sjwAq5RG2UI 1049 https://oncdata.com/videos/the-invisible-side-of-cancer-treatment 2026-11-10 https://i.ytimg.com/vi/sa_oFJj1j5E/maxresdefault.jpg The Invisible Side of Cancer Treatment This Mental Health Awareness Month, the conversation around cancer care is shifting. While oncology has traditionally focused on physical survival, the field is seeing an increasing shift towards a holistic approach that treats mental wellness as a core component of care. In this discussion, Dr. Joseph McCollom and Dr. Jasmin Hundal highlights a critical truth: a cancer diagnosis impacts not just the body, but the mental, emotional, and spiritual health of the patient. 2026-05-28T16:05:34.223Z https://www.youtube.com/embed/sa_oFJj1j5E 1625 https://oncdata.com/videos/the-immunotherapy-revolution-transforming-melanoma-survival 2026-11-11 https://i.ytimg.com/vi/zJ40DUeub0U/maxresdefault.jpg The Immunotherapy Revolution: Transforming Melanoma Survival May is Melanoma and Skin Cancer Awareness Month—a critical time to focus on a disease that is becoming increasingly manageable through early detection and groundbreaking new therapies. In this episode, we explore the evolving landscape of care, from the "ABCDs" of prevention to the immunotherapy revolution. Read the full accompanying article on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/melanoma-matters-recognizing-risk-acting-early-and-advancing-care/">https://oncdata.com/melanoma-matters-recognizing-risk-acting-early-and-advancing-care/</a> What You’ll Learn in This Episode: --The ABCDs of Detection: Why asymmetry, border, color, diameter, and evolving features are the keys to identifying suspicious moles. --Sun Safety Essentials: Why even small sunburns are dangerous and how to properly protect yourself from chronic UV radiation. --The Immunotherapy Revolution: How immune checkpoint inhibitors have shifted the median survival for metastatic melanoma from less than one year to nearly ten years. --The Future of Treatment: Insights into novel therapies like oncolytic viruses and bispecific T-cell engagers for treatment-resistant cases. Chapter Timestamps:00:00 – Introduction: Meet the Experts00:38 – Early Detection: Risk Factors and the ABCDs of Melanoma03:19 – Beyond the Skin: Common and Hidden Locations for Melanoma04:40 – Prevention Strategies: UV Protection and Sun Safety05:56 – The Treatment Shift: From Chemotherapy to Immunotherapy07:42 – Innovation: Emerging Therapies and Overcoming Resistance09:22 – Key Takeaways: Self-Advocacy and Monitoring ChangesAbout the Speakers: Jasmin Hundal, MD, MS, MPH: A Hematology/Oncology Fellow at the @clevelandclinic specializing in the intersection of cardiometabolic health and cancer for breast cancer patients and survivors. Matthew Hadfield, DO: A Medical Oncologist and Assistant Professor at @brownuniversity specializing in cutaneous malignancies and phase 1 clinical trials. Stay Connected: Subscribe for more deep dives into oncology research and practice. Website: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com/">https://oncdata.com/</a> Follow us on X/Twitter: @OncData 2026-05-15T18:23:16.813Z https://www.youtube.com/embed/zJ40DUeub0U 660 https://oncdata.com/videos/can-real-world-evidence-close-the-clinical-trial-gap 2026-11-11 https://i.ytimg.com/vi/_Vh1V7HUjmU/maxresdefault.jpg Can Real-World Evidence Close the Clinical Trial Gap? The full article for this interview is available on Oncology Data Advisor. Check it out here: https://bit.ly/48PRtJo Every oncologist knows the moment: you’re discussing guideline-based options with a patient—and realize they wouldn’t have qualified for the pivotal trial behind the recommendation. In this episode of Oncology Unfiltered, Melissa Cutrona, MS, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, to examine one of oncology’s most persistent challenges: the widening gap between curated clinical trial populations and complex real-world patients. Dr. Hadfield breaks down why eligibility criteria often select for the “healthiest” oncology patients, how some criteria may be rooted in older chemotherapy-era assumptions, and what it means when guidelines meet patients with comorbidities, organ transplants, or other factors that excluded them from landmark studies. The conversation also explores the evolving role of phase 1 trials, why earlier trial enrollment is becoming more common, and how disparities in access and representation continue to shape who benefits from trial-driven advances. Finally, they discuss how real-world evidence—case series, retrospective studies, and institutional experience—can help clinicians fill the gaps when gold-standard randomized data doesn’t exist for the patient in front of them. 2026-05-07T13:10:27.360Z https://www.youtube.com/embed/_Vh1V7HUjmU 1220 https://oncdata.com/videos/ai-in-pancreatic-cancer-moving-from-promise-to-practical-application 2026-11-10 https://i.ytimg.com/vi/MYNNEiIHK_8/maxresdefault.jpg AI in Pancreatic Cancer: Moving From Promise to Practical Application The full article for this interview is available on Oncology Data Advisor. Check it out here: https://bit.ly/4n5aU6K Artificial intelligence is generating excitement in oncology, but its real-world clinical impact remains inconsistent. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, shares his AACR presentation on AI-driven pathological subtyping in pancreatic cancer. Dr. Manne discusses how his team is moving AI from theoretical promise to practical application by using digital pathology to classify pancreatic tumors into classical and basal subtypes—categories with significant therapeutic implications. He explains how this accessible approach could democratize precision medicine globally, reducing reliance on expensive genomic testing. The conversation also addresses the barriers to AI adoption in clinical decision-making, including the "black box" problem of trust and transparency, and why current AI applications are primarily focused on workflow optimization. Dr. Manne advocates for a physician-led, specialty-specific approach to model development to ensure AI meets the real-world needs of clinicians and patients. 2026-05-04T13:16:31.205Z https://www.youtube.com/embed/MYNNEiIHK_8 810 https://oncdata.com/videos/asco-genitourinary-cancers-symposium-2026-prostate-cancer-recap 2026-11-11 https://oncdata.com/videos/patient-experience-week-how-small-moments-make-a-big-impact 2026-11-11 https://oncdata.com/videos/measuring-clinical-trial-representation-in-the-era-of-precision-medicine 2026-10-26 https://oncdata.com/videos/a-guide-to-egg-and-embryo-cryopreservation-in-oncofertility-care 2026-10-26 https://oncdata.com/videos/national-minority-health-month-equity-begins-with-access 2026-11-10 https://i.ytimg.com/vi/UBX1rN-5MSQ/maxresdefault.jpg National Minority Health Month: Equity Begins With Access In recognition of National Minority Health Month, OncData Editorial Board members Dr. Jasmin Hundal, Hematology/Oncology Fellow at the Cleveland Clinic, and Megan-Claire Chase, 10-year breast cancer survivor and patient advocate, came together for a candid conversation about the systemic barriers—from transportation and food access to implicit bias and communication failures—that continue to drive health disparities in minoritized communities. Drawing on personal experiences from both sides of the exam room, they confront the reality that awareness alone has never been enough, making a call for cultural competence, shared decision making, and community-level collaboration to close these gaps. 2026-04-16T12:40:25.438Z https://www.youtube.com/embed/UBX1rN-5MSQ 1142 https://oncdata.com/videos/expanding-early-detection-of-hepatocellular-carcinoma-with-helioliver 2026-11-11 https://i.ytimg.com/vi/G9xz7FRpIfQ/maxresdefault.jpg Expanding Early Detection of Hepatocellular Carcinoma With HelioLiver Patients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/playlist?list=PLP9_nE1bb7vfc-XYxDDRGt2jHd_JmaFQI">Exploring AI in Oncology</a>, Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company’s AI-powered blood test, <a target="_blank" rel="noopener noreferrer nofollow" href="https://heliogenomics.com/products">HelioLiver</a>, and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption. 2026-04-15T15:04:08.554Z https://www.youtube.com/embed/G9xz7FRpIfQ 1010 https://oncdata.com/videos/the-power-of-community-for-women-in-science-and-research 2026-11-10 https://i.ytimg.com/vi/08RW7IMONTw/maxresdefault.jpg The Power of Community for Women in Science and Research At a recent symposium hosted by Oregon Health & Science University (OHSU) and the Lustgarten Foundation for Pancreatic Cancer Research in honor of International Women’s Day, Dr. Katelyn Byrne, Assistant Professor of Cell, Developmental & Cancer Biology at OHSU Knight Cancer Institute, shared insights spanning pancreatic cancer immunotherapy and the power of community for women in science leadership positions. Afterwards, she sat down with Oncology Data Advisor to share more about her work investigating immune responses to better target pancreatic cancer and perspectives highlighting how culture and mentorship directly influence innovation. 2026-04-13T13:54:09.031Z https://www.youtube.com/embed/08RW7IMONTw 435 https://oncdata.com/videos/exercise-for-older-cancer-survivors-dispelling-the-myths-and-creating-guidance 2026-11-11 https://i.ytimg.com/vi/3bIgA8DDek0/maxresdefault.jpg Exercise for Older Cancer Survivors: Dispelling the Myths and Creating Guidance For older adults who have survived cancer, exercise guidance is often constrained by over-cautiousness, limited age-specific evidence, and uncertainty about how to tailor programs to comorbidities and functional limitations. In this interview Dr. Kerri Winters-Stone, an Exercise Scientist and the Penny and Phil Knight endowed professor in Cancer Research Innovation at Oregon Health & Science University (OHSU), outlined why clinicians should treat exercise like a clinical intervention for older patients, how a multidisciplinary expert panel developed consensus recommendations, and what matters most: safety, functional independence, and quality of life. 2026-04-09T19:23:29.914Z https://www.youtube.com/embed/3bIgA8DDek0 868 https://oncdata.com/videos/aya-cancer-awareness-the-unique-challenges-of-patients-under-40 2026-11-11 https://i.ytimg.com/vi/W16JYLqM8yo/maxresdefault.jpg AYA Cancer Awareness: The Unique Challenges of Patients Under 40 Watch the full interview on Oncology Data Advisor: <a target="_blank" rel="noopener noreferrer nofollow" href="https://oncdata.com">https://oncdata.com</a>Adolescent and Young Adult (AYA) Cancer Awareness Week serves as a critical reminder that patients diagnosed under the age of 40 represent a distinct population with unique biological, psychological, and social needs. In this discussion, Editorial Board members Jasmin Hundal, MD, MS, MPH, a Hematology/Oncology Fellow at the Cleveland Clinic, and Megan-Claire Chase, a 10-year breast cancer survivor and advocate, explore the evolving landscape of AYA oncology.Dr. Hundal explains the rising incidence of cancer in younger adults and why these cases are often more aggressive and resistant to traditional therapies, necessitating a precision medicine approach. Ms. Chase shares the lived experience of "rapid aging" caused by toxic treatments and the long-term emotional toll of PTSD, grief, and overlooked sexual health issues in survivorship.The conversation covers the "quarterback" role of the physician in coordinating multidisciplinary care—from fertility preservation to workplace accommodations—and the urgent need for more diverse genetic databases to ensure equitable care for people of color. By treating the "whole person" rather than just the disease, the medical community can better support AYA patients through diagnosis and the lifelong phase of survivorship. 2026-04-07T16:12:59.233Z https://www.youtube.com/embed/W16JYLqM8yo 1766 https://oncdata.com/videos/additional-advances-in-esophagogastric-cancer-research-and-clinical-trials 2026-11-11 https://i.ytimg.com/vi/_DukKHI0xXA/maxresdefault.jpg Additional Advances in Esophagogastric Cancer Research and Clinical Trials Complete the full activity here: https://bit.ly/45606Oq Watch Module 1: https://www.youtube.com/watch?v=LmTWPr7GSc0&t=2s Watch Module 2: https://www.youtube.com/watch?v=3zWERGHtUu8 Watch Module 3: https://www.youtube.com/watch?v=g5ABcgmRS8o Watch the full interview on Oncology Data Advisor: https://oncdata.com The treatment of esophagogastric cancer has undergone a profound transformation, moving away from the "nihilism" of the early 2000s toward a redefined strategy of immune priming and molecular precision. In this edition of Additional Advances, Yelena Janjigian, MD, Chief of the GI Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the latest clinical breakthroughs and the critical importance of multidisciplinary care. Dr. Janjigian explores the paradigm shift toward perioperative chemoimmunotherapy, highlighting how initiating treatment before surgery can "educate" the immune system and lead to pathologic complete responses with near-100% cure rates. She addresses the dangers of clinical understaging and explains why a "belt and suspenders" approach—incorporating PET, CT, laparoscopy, and cytology—is essential for accurate treatment planning. The conversation also emphasizes the non-negotiable need for universal biomarker testing (MSI, PD-L1, HER2, and CLDN18.2) for all adenocarcinoma patients and the vital role of medical oncology input before any surgical intervention. With landmark data emerging from trials like MATTERHORN and CheckMate 649, Dr. Janjigian shares a message of significant optimism for achieving long-term survival in esophagogastric cancer. Follow us here: Facebook https://www.facebook.com/i3Health Instagram https://www.instagram.com/i3health Soundcloud https://soundcloud.com/i3-health X https://twitter.com/i3health 2026-04-06T19:46:15.313Z https://www.youtube.com/embed/_DukKHI0xXA 495 https://oncdata.com/videos/her2-mutant-nsclc-update-expanded-approval-of-zongertinib 2026-11-11 https://i.ytimg.com/vi/phD8jt8maAI/maxresdefault.jpg HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences. 2026-04-03T13:43:32.152Z https://www.youtube.com/embed/phD8jt8maAI 379 https://oncdata.com/videos/choosing-not-to-treat-how-do-you-know-when-the-best-treatment-is-no-treatment 2026-11-10 https://i.ytimg.com/vi/IJoa95A3t3I/maxresdefault.jpg Choosing Not to Treat: How Do You Know When the Best Treatment is No Treatment? Watch the full episode of Oncology Unfiltered: https://oncdata.com/oncology-unfiltered-choosing-not-to-treat In oncology, progress is often measured by how effectively we can treat disease. But what happens when the best course of action is no treatment at all? In this episode of Oncology Unfiltered, Melissa Cutrona, MS, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, speaks with Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, about the nuanced, evidence-based decision to forgo systemic therapy. Dr. Hadfield discusses how modern targeted therapies and immunotherapy have changed the calculus of risk and benefit, and why quality of life must remain central when expected benefit is small and treatment burden is high. The conversation explores performance status, comorbidities, and prognostic uncertainty, along with practical ways clinicians can communicate transparently with patients and families during high stakes decisions. They also reframe the misconception that declining treatment means giving up. Instead, choosing not to treat can be an intentional, patient centered decision to prioritize meaningful time, symptom control, and personal goals. The episode concludes with an important discussion on the role of palliative care as supportive care and why early involvement can improve symptom management and even survival. 2026-04-02T12:51:12.289Z https://www.youtube.com/embed/IJoa95A3t3I 1240 https://oncdata.com/videos/mrd-and-complete-response-end-points-new-guidance-for-multiple-myeloma-trials 2026-11-11 https://oncdata.com/videos/national-doctors-day-upholding-the-human-connection-with-jasmin-hundal-md-and-matthew-hadfield-do 2026-11-10 https://i.ytimg.com/vi/WqZ46W9SPas/maxresdefault.jpg National Doctors Day: Upholding the Human Connection With Jasmin Hundal, MD and Matthew Hadfield, DO View the full article at: https://oncdata.com/national-doctors-day-2026 In this conversation honoring National Doctors’ Day, Dr. Jasmin Hundal, Hematology/Oncology Fellow at the Cleveland Clinic, and OncData Editor in Chief Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University, sat down to discuss their journeys in the world of medicine. From the personal motivations that led them to oncology to the rapid-fire pace of innovation throughout their careers, they explore the humbling privilege of walking alongside patients during their most vulnerable moments. 2026-03-30T13:21:39.943Z https://www.youtube.com/embed/WqZ46W9SPas 1029 https://oncdata.com/videos/additional-advances-in-hemophilia-research-and-clinical-trials-with-robert-f-sidonio-jr-md-msc 2026-11-10 https://i.ytimg.com/vi/mrkmIQkHz5o/maxresdefault.jpg Additional Advances in Hemophilia Research and Clinical Trials With Robert F. Sidonio, Jr., MD, MSc View the full article on Oncology Data Advisor: https://bit.ly/48b8AVo Start the full CME activity here: https://www.youtube.com/watch?v=cJ0klW_mNzI&feature=youtu.be View and download the slide deck here: https://www.slideshare.net/slideshow/raising-the-bar-for-hemophilia-management-47c1/282931071 In this edition of Additional Advances, Robert F. Sidonio, Jr., MD, MSc, Professor of Pediatrics and Medical Director of Hemophilia at the Georgia Center for Bleeding and Clotting Disorders, Children’s Healthcare of Atlanta, shares the latest clinical trial and real-world insights shaping hemophilia care. As co-chair of i3 Health’s symposium and online activity, Raising the Bar for Hemophilia Management, Dr. Sidonio discusses how ongoing experience with newer therapies continues to refine patient selection, dosing, and day-to-day implementation. He reviews key considerations for rebalancing agents and the importance of guardrails in dosing and monitoring, along with emerging data related to inhibitor risk mitigation, including findings from a study of rurioctocog alfa. Dr. Sidonio also discusses the Atlanta Protocol, an institutional approach that combines emicizumab with factor VIII to support immune tolerance, and why higher factor VIII dosing may be more effective than lower doses for inducing tolerance. The conversation highlights the expanding hemophilia treatment toolkit, including bispecific antibodies, extended half-life factors, anti TFPI agents, and siRNA therapies, as well as the evolving role of gene therapy. In recognition of Bleeding Disorders Awareness Month, Dr. Sidonio also emphasizes the need to broaden awareness beyond the most severe phenotypes and to include women and girls with hemophilia. 2026-03-27T14:08:40.875Z https://www.youtube.com/embed/mrkmIQkHz5o 580 https://oncdata.com/videos/perioperative-chemoimmunotherapy-in-nsclc-from-clinical-trials-to-practice 2026-11-11 https://i.ytimg.com/vi/TYnzeRK8EsA/maxresdefault.jpg Perioperative Chemoimmunotherapy in NSCLC: From Clinical Trials to Practice Watch the full conversation on Oncology Data Advisor: https://oncdata.com/perioperative-chemoimmunotherapy-nsclc-meir-aung Perioperative chemoimmunotherapy has rapidly moved from clinical trials into practice for patients with resectable non–small cell lung cancer (NSCLC), yet real-world implementation remains a challenge. In this discussion, Wint Yan (Arthur) Aung, MD, and Juliet Meir, MD, Hematology/Oncology Fellows at Northwell Health, explore how to optimize these strategies to improve patient outcomes. Dr. Meir outlines the clinical rationale for perioperative care, including improved major pathologic response rates and overall survival. She addresses common clinical concerns, such as treatment-related fibrosis and the risk of delayed or missed surgery, while emphasizing how multidisciplinary coordination between thoracic surgeons, medical oncologists, and pulmonologists can mitigate these risks. The conversation also highlights Northwell Health’s quality improvement initiative to increase referral rates and the importance of nuanced patient selection, particularly for those with actionable driver mutations like EGFR or ALK. Looking ahead, the experts discuss the role of biomarkers and ctDNA in creating risk-adapted, personalized perioperative pathways that maintain the curative potential of surgery. 2026-03-26T17:15:02.437Z https://www.youtube.com/embed/TYnzeRK8EsA 369 https://oncdata.com/videos/fueling-survival-the-power-of-nutrition-in-breast-and-prostate-cancer 2026-11-11 https://i.ytimg.com/vi/fMEAzmHQnFM/maxresdefault.jpg Fueling Survival: The Power of Nutrition in Breast and Prostate Cancer The intersection of nutrition and oncology is a rapidly evolving pillar of comprehensive cancer care. In this discussion, Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center, and Dr. Jasmin Hundal, Hematology/Oncology Fellow at the Cleveland Clinic, explore how nutritional interventions and new metabolic therapies are reshaping outcomes in breast and prostate cancer. Their conversation highlights a critical shift in patient-centered care: treating the patient’s metabolic environment is as vital as treating the tumor itself. 2026-03-18T13:10:11.652Z https://www.youtube.com/embed/fMEAzmHQnFM 1211 https://oncdata.com/videos/ai-navigation-in-pancreatic-cancer-how-inav-speeds-diagnosis-and-treatment 2026-11-05 https://i.ytimg.com/vi/c6XgFcpc6Vs/maxresdefault.jpg AI Navigation in Pancreatic Cancer: How iNav Speeds Diagnosis and Treatment Watch the full episode of Exploring AI in Oncology: https://oncdata.com/inav-daniel-king Pancreatic cancer is fast-moving and often diagnosed after curative options have narrowed. In this episode, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Daniel King, MD, PhD, Gastrointestinal Medical Oncologist at Northwell Health and co-inventor of iNav, an AI-enabled navigation platform designed to speed diagnosis and treatment for patients with suspected pancreatic cancer. Dr. King explains how iNav uses natural language processing to scan radiology reports for language suggestive of pancreatic malignancy, flagging high-risk patients before they ever see an oncologist. A dedicated navigation team then connects those AI triggers to real-world action, expediting biopsies, oncology consults, and treatment starts. Early data show meaningful reductions in time from imaging to biopsy, consult, and therapy initiation, helping more patients reach surgery while their disease is still resectable. The conversation also covers balancing early detection with false-positive concerns, the importance of a human-in-the-loop workflow, and how clinician-innovators can leverage grants and health system support to bring AI tools like iNav into practice. 2026-03-16T15:47:19.403Z https://www.youtube.com/embed/c6XgFcpc6Vs 990 https://oncdata.com/videos/additional-advances-in-neuroendocrine-tumor-research-and-clinical-trials-with-aman-chauhan-md 2026-11-11 https://i.ytimg.com/vi/J9xB7Hocdjg/maxresdefault.jpg Additional Advances in Neuroendocrine Tumor Research and Clinical Trials With Aman Chauhan, MD The treatment landscape for neuroendocrine tumors (NETs) is undergoing a period of accelerated progress, with new epidemiologic insights, targeted therapies, and novel immunotherapeutic approaches reshaping clinical practice. Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), recently chaired i3 Health’s CME activity, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care. With several important developments emerging in recent months, Dr. Chauhan sat down again to share key updates that are influencing how clinicians approach the treatment of NETs. Click below to view the full activity and claim your free credit! Online Activity: https://i3health.com/course-information/optimizing-neuroendocrine-tumor-outcomes-closing-the-gaps-in-diagnosis-and-care Downloadable Infographic: https://www.slideshare.net/slideshow/infographic-optimizing-neuroendocrine-tumor-outcomes/283784320?utm_source=clipboard_share_button&utm_campaign=slideshare_make_sharing_viral_v2&utm_variation=control&utm_medium=share 2026-03-11T13:18:27.947Z https://www.youtube.com/embed/J9xB7Hocdjg 1090 https://oncdata.com/videos/international-women-s-day-sharing-knowledge-and-community-with-jasmin-hundal-and-megan-claire-chase 2026-11-05 https://i.ytimg.com/vi/ELLpStSprQQ/maxresdefault.jpg International Women’s Day: Sharing Knowledge and Community With Jasmin Hundal and Megan-Claire Chase International Women’s Day provides an opportunity to reflect not only on progress for women in medicine and research, but also on the lived experiences of women navigating cancer. In this conversation, Oncology Data Advisor Editorial Board members Dr. Jasmin Hundal, Hematology/Oncology Fellow at the Cleveland Clinic, and Megan-Claire Chase, breast cancer survivor and advocate, explore themes of community, vulnerability, mentorship, and representation for women on both sides of cancer care. 2026-03-09T13:00:41.782Z https://www.youtube.com/embed/ELLpStSprQQ 1281 https://oncdata.com/videos/molecular-testing-chaos-are-we-over-testing-under-testing-or-testing-at-the-wrong-time 2026-11-11 https://oncdata.com/videos/oncofertility-bridging-reproductive-medicine-and-cancer-care-with-meaghan-delaney-md-ma 2026-11-11 https://i.ytimg.com/vi/uXT89_9bXJs/maxresdefault.jpg Oncofertility: Bridging Reproductive Medicine and Cancer Care With Meaghan Delaney, MD, MA Fertility preservation is an essential component of comprehensive cancer care for patients of reproductive age. As treatment regimens grow more complex—and survivorship expands—oncology clinicians increasingly play a pivotal role in helping patients navigate how cancer therapy may impact their ability to build a family in the future. In this discussion, Dr. Meaghan Delaney, Co‑Director of the Oncofertility Program at Boston IVF, shares insights on the program’s approach, the options available, and how clinicians can better support patients through these conversations. 2026-03-02T16:58:26.455Z https://www.youtube.com/embed/uXT89_9bXJs 661 https://oncdata.com/videos/rare-disease-day-2026-the-hidden-burden-of-rare-cancers-with-claire-saxton 2026-11-11 https://i.ytimg.com/vi/O3NMjH-5UWM/maxresdefault.jpg Rare Disease Day 2026: The Hidden Burden of Rare Cancers With Claire Saxton In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Claire Saxton, MBA, Executive Vice President for Insights and Impact at Support Community (CSC). In this interview, Ms. Saxton explores the hidden psychosocial burden carried by patients with rare cancers, the diagnostic challenges of "zebra" diseases like neuroendocrine tumors (NETs), and the crucial role of multidisciplinary teams in supporting patients through active surveillance and beyond. Ms. Saxton discusses how precision medicine is redefining "rare" as common cancers are divided into small molecular subsets, why patients with ultra-rare malignancies often feel invisible, and how delayed or missed diagnoses fuel isolation, anxiety, and depression. She also explains why CSC prefers the term "active surveillance" over "watch and wait," and offers practical strategies (lifestyle changes, mindfulness, and peer support) to help patients cope when immediate treatment is not indicated. Finally, she highlights the importance of connecting patients and caregivers with advocacy organizations and support communities, not only to combat isolation but also to empower them as storytellers and policy advocates who can drive meaningful change in research and health care. For more information about Cancer Support Community, visit https://www.cancersupportcommunity.org/ or call the helpline at 888-793-9355. 2026-02-27T14:39:32.748Z https://www.youtube.com/embed/O3NMjH-5UWM 1265 https://oncdata.com/videos/cholangiocarcinoma-awareness-month-with-kannan-thanikachalam-md 2026-11-10 https://i.ytimg.com/vi/hHSfMKCQmiM/maxresdefault.jpg Cholangiocarcinoma Awareness Month With Kannan Thanikachalam, MD Cholangiocarcinoma has historically been a challenging malignancy to treat, marked by limited therapeutic options and poor outcomes. In this interview honoring Cholangiocarcinoma Awareness Month, Kannan Thanikachalam, MD, a Gastrointestinal Medical Oncologist at Roswell Park Comprehensive Cancer Center, discusses how the treatment landscape has evolved in recent years and highlights the growing roles of immunotherapy, molecular profiling, and clinical trial participation in improving patient care. 2026-02-23T14:31:00.585Z https://www.youtube.com/embed/hHSfMKCQmiM 453 https://oncdata.com/videos/national-caregivers-day-navigating-both-sides-of-the-journey-with-heather-badt-and-jasmin-hundal 2026-11-11 https://i.ytimg.com/vi/LyLjET4Chc4/maxresdefault.jpg National Caregivers Day: Navigating Both Sides of the Journey With Heather Badt and Jasmin Hundal National Caregivers Day, observed on February 20, is a day to honor the unsung heroes who provide care to individuals navigating a health journey. In this discussion, Heather Badt, Chief Operating Officer at Cancer Support Community, sits down with Dr. Jasmin Hundal to discuss her experience as both a patient and a caregiver, as well as how Cancer Support Community strives to support caregivers as they support their loved ones.  2026-02-20T13:44:05.129Z https://www.youtube.com/embed/LyLjET4Chc4 1158 https://oncdata.com/videos/additional-advances-in-biliary-tract-cancer-research-and-advocacy-with-melinda-bachini 2026-11-05 https://i.ytimg.com/vi/xXVyrAE-NVY/maxresdefault.jpg Additional Advances in Biliary Tract Cancer Research and Advocacy With Melinda Bachini Biliary tract cancers (BTCs), including cholangiocarcinoma, remain among the most complex and aggressive malignancies encountered in oncology practice. Melinda Bachini, the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 16‑year survivor of stage IV intrahepatic cholangiocarcinoma, recently served as a member of i3 Health’s Multidisciplinary Task Force activity, Challenges and Innovations in Biliary Tract Cancer: A Multidisciplinary Task Force Perspective. In this follow-up interview in honor of World Cholangiocarcinoma Day, she shared further insights into her experiences as a patient and advocate, the importance of clinical trials, and the power of advocacy in the cholangiocarcinoma community. 2026-02-19T14:23:36.107Z https://www.youtube.com/embed/xXVyrAE-NVY 718 https://oncdata.com/videos/working-with-cancer-insights-for-employer-support-with-hadly-clark-and-sabrina-spitaletta 2026-11-11 https://i.ytimg.com/vi/bQZzSxL3wSk/maxresdefault.jpg Working With Cancer: Insights for Employer Support With Hadly Clark and Sabrina Spitaletta As the landscape of oncology shifts, cancer clinics are increasingly seeing a demographic that defies traditional expectations: the younger, working-age adult. In this discussion, Hadly Clark and Sabrina Spitaletta of the Milken Institute discuss their recently published report, "Employers Mitigating Risk and Building Resilience: Responses to Early-Onset Cancer." Their findings offer crucial insights into the challenges that patients with cancer face in the workplace and what employers can do to help. 2026-02-17T17:13:01.372Z https://www.youtube.com/embed/bQZzSxL3wSk 1278 https://oncdata.com/videos/national-cancer-prevention-month-practical-strategies-for-melanoma-and-breast-cancer 2026-11-11 https://i.ytimg.com/vi/GTY0f-kXUjc/maxresdefault.jpg National Cancer Prevention Month: Practical Strategies for Melanoma and Breast Cancer In honor of National Cancer Prevention Month, Jasmin Hundal, MD, MS, MPH, and Matthew Hadfield, DO, discuss practical strategies for cancer prevention and early detection. Their conversation highlights the importance of evidence-based screening, risk factor modification, and the interpretation of emerging diagnostics. Dr. Hadfield reviews the ABCDE criteria for melanoma and the necessity of sun safety, while Dr. Hundal discusses updated breast cancer screening guidelines and supplemental imaging for dense breast tissue. They also explore the rise of young-onset cancers, the impact of high-fiber diets on immunotherapy efficacy, and the future of blood-based early detection and MRD testing. Together, they emphasize that shared decision making and data-driven counseling remain essential for improving patient outcomes. 2026-02-12T15:34:25.112Z https://www.youtube.com/embed/GTY0f-kXUjc 1099 https://oncdata.com/videos/oncology-unfiltered-if-a-patient-can-t-afford-the-prescription-is-it-really-a-treatment-option 2026-11-11 https://i.ytimg.com/vi/i1iEiAoAaOQ/maxresdefault.jpg Oncology Unfiltered: If a Patient Can’t Afford the Prescription, Is It Really a Treatment Option? In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, explore financial and geographic toxicities in oncology and how they are really clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option? 2026-02-05T13:55:36.848Z https://www.youtube.com/embed/i1iEiAoAaOQ 1507 https://oncdata.com/videos/world-cancer-day-united-by-uniqueness-with-jasmin-hundal-md-ms-mph-and-sally-werner-rn-bsn 2026-11-11 https://i.ytimg.com/vi/73nMBP1M3Ro/maxresdefault.jpg World Cancer Day: United by Uniqueness With Jasmin Hundal, MD, MS, MPH, and Sally Werner, RN, BSN On World Cancer Day, breakthroughs in treatment often take center stage, but the psychosocial experience of patients and caregivers is equally vital. In this discussion, Jasmin Hundal, MD, MS, MPH, speaks with Sally Werner, RN, BSN, MSHA, CEO of Cancer Support Community (CSC), about how person-centered support improves oncology outcomes. Ms. Werner outlines CSC’s model of proactive navigation, which screens for social and emotional stressors and ensures patients successfully connect with resources. They discuss the Cancer Experience Registry—a unique dataset capturing both patient and caregiver perspectives—and explore World Cancer Day priorities including multicancer early detection (MCED), rising cancer rates in young adults, and the importance of culturally adapted care. Aligned with the theme "United by Uniqueness," this conversation highlights why psychosocial and logistical support must be treated as core components of high-quality cancer care. 2026-02-04T15:31:50.769Z https://www.youtube.com/embed/73nMBP1M3Ro 773 https://oncdata.com/videos/how-ai-can-empower-community-oncologists-with-kristin-ashcraft-and-waqas-haque-md-mph 2026-11-11 https://oncdata.com/videos/anitocabtagene-autoleucel-in-rrmm-efficacy-safety-and-improving-access-with-krina-patel-md-msc 2026-11-11 https://i.ytimg.com/vi/Qj9QWkpX1ko/maxresdefault.jpg Anitocabtagene Autoleucel in RRMM: Efficacy, Safety, and Improving Access With Krina Patel, MD, MSc Watch the full interview on Oncology Data Advisor: https://oncdata.com/anitocabtagene-autoleucel-krina-patel-md-msc BCMA‑directed CAR T‑cell therapy continues to transform expectations for relapsed/refractory multiple myeloma (RRMM). In this conversation, Krina Patel, MD, MSc, Section Chief for Multiple Myeloma and Director of Myeloma Clinical Research at the University of Texas MD Anderson Cancer Center, discusses new data for anitocabtagene autoleucel (anito‑cel) from the phase 2 IMAGINE‑1 study presented at ASH—highlighting deep, durable responses, a favorable safety profile, and what these findings could mean for expanding access, including outpatient CAR T delivery. Dr. Patel explains how anito‑cel’s unique D‑domain binding design may improve CAR T transfection, reduce inflammation through a fast off‑rate, and support a lower administered dose enriched for CAR‑positive T cells. She reviews IMAGINE‑1 results demonstrating a 96% overall response rate, 74% CR/sCR, high levels of MRD negativity at 10⁻⁵, and sustained MRD in the majority of reassessed patients. Safety signals remain reassuring, with minimal CRS/ICANS and no delayed neurotoxicities such as Parkinsonianism, cranial nerve palsies, or Guillain‑Barré syndrome. The discussion also puts anito‑cel in context with other BCMA‑directed CAR Ts, underscoring why quality of life and freedom from continuous therapy remain major advantages for patients. Dr. Patel shares insights into outpatient feasibility—where 9% of patients in IMAGINE‑1 were infused safely outside the hospital—and how strategies such as prophylactic tocilizumab may further support wider, community‑based CAR T access. 2026-01-30T17:29:40.586Z https://www.youtube.com/embed/Qj9QWkpX1ko 544 https://oncdata.com/videos/additional-advances-in-melanoma-research-and-clinical-trials-with-michael-a-davies-md-phd 2026-10-26 https://i.ytimg.com/vi/zsJ9f6z-rjk/maxresdefault.jpg Additional Advances in Melanoma Research and Clinical Trials With Michael A. Davies, MD, PhD Claim your CME and NCPD here: https://bit.ly/4iJnCEq Watch Module 1: https://www.youtube.com/watch?v=GxpkIupgTgY&feature=youtu.be Watch Module 2: https://www.youtube.com/watch?v=jnwCEDsViwE&feature=youtu.be View and download the slide deck here: https://www.slideshare.net/slideshow/melanoma-in-minutes-evidence-driven-care-for-improved-patient-outcomes-module-1/283120169 The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. Follow us here: Facebook https://www.facebook.com/i3Health Instagram https://www.instagram.com/i3health Linkedin https://www.linkedin.com/company/i3health Soundcloud https://soundcloud.com/i3-health X https://twitter.com/i3health 2026-01-28T17:38:09.160Z https://www.youtube.com/embed/zsJ9f6z-rjk 400 https://oncdata.com/videos/unlock-cancer-treatment-why-molecular-testing-is-a-game-changer 2026-01-27 https://i.ytimg.com/vi/AggcoS5pSas/mqdefault.jpg Unlock Cancer Treatment: Why Molecular Testing is a Game Changer Prostate cancer is the most common cancer in men and the second most common cause of cancer death in men, accounting for 30% of new cancer diagnoses and 11% of cancer deaths in males. When diagnosed in early stages, 5- and 10-year survival rates are high; however, 5-year survival remains under 50% if disease is first detected when metastatic (Siegel et al, 2024). The last 15 years have seen significant advances in systemic therapeutic options for prostate cancer, rendering molecular testing necessary for selecting optimal therapy. Improving outcomes for patients relies on collaboration amongst the care team; pathologists have the crucial expertise for interpreting test results, while nurses play a critical role in connecting patients with support and preventing and managing adverse events. In this Virtual Tumor Board Challenge, Stephen Freedland, MD, Professor of Urology at Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center; Andrés Matoso, MD, Professor of Pathology, Urology, and Oncology at Johns Hopkins School of Medicine; and Jennifer Sutton, RN, BS, CCRC, Director of Nursing and Study Operations at START Carolinas, the START Center for Cancer Research, will navigate treatment selection and sequencing in metastatic prostate cancer through patient case studies. 2026-01-27T15:58:32.000Z https://www.youtube.com/embed/AggcoS5pSas 41 https://oncdata.com/videos/new-cancer-drug-approved-rova-t-vs-darlatamab-explained 2026-11-11 https://i.ytimg.com/vi/RTbSmoj99B8/mqdefault.jpg New Cancer Drug Approved! Rova T vs Darlatamab Explained Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. 2026-01-27T14:45:04.000Z https://www.youtube.com/embed/RTbSmoj99B8 59 https://oncdata.com/videos/cancer-meds-side-effects-i-want-to-live-now 2026-11-11 https://i.ytimg.com/vi/DHKQBqh4sk0/mqdefault.jpg Cancer Meds Side Effects: I Want to LIVE NOW! Read the full conversation on Oncology Data Advisor: https://oncdata.com/sabcs-2025-chase-hundal At the 2025 San Antonio Breast Cancer Symposium (SABCS), Editorial Board member Jasmin Hundal, MD, MS, MPH, and breast cancer survivor and advocate Megan‑Claire “Warrior Megsie” Chase reflect on how research, clinical care, and lived experience come together to shape the future of breast cancer care. They discuss what it means to attend SABCS as a 10‑year invasive lobular breast cancer survivor, the emotional reality of fear of recurrence, and the power of seeing patient advocates leading posters, panels, and conversations. Ms. Chase shares her journey from communications and theater into research collaboration and co‑authorship, including her poster on real‑world patient and caregiver experiences with fear of recurrence, while Dr. Hundal highlights why language around “non‑adherence” often obscures the true burden of long‑term endocrine side effects and why quality of life must be treated as a primary outcome. The conversation also explores digital health and wearables in breast cancer survivorship, balancing the promise of earlier detection of issues through technology with concerns about equity, inclusion of older adults, and preserving human connection. Together, they underscore that patient experience is a form of expertise—and that survivors’ voices are essential to driving meaningful, patient‑centered research. #SABCS2025 #BreastCancer #BreastCancerSurvivor #LobularBreastCancer #PatientAdvocacy #FearOfRecurrence #EndocrineTherapy #QualityOfLife #DigitalHealth #Wearables #OncologyFellow #CancerSurvivorship #OncologyDataAdvisor 2026-01-26T15:45:01.000Z https://www.youtube.com/embed/DHKQBqh4sk0 17 https://oncdata.com/videos/pet-scans-unlocking-the-secrets-of-neuroendocrine-tumors 2026-11-11 https://i.ytimg.com/vi/ba0P_aAzUyQ/mqdefault.jpg PET Scans: Unlocking the Secrets of Neuroendocrine Tumors Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. 2026-01-26T14:13:37.000Z https://www.youtube.com/embed/ba0P_aAzUyQ 26 https://oncdata.com/videos/cancer-survivors-need-more-support-acupuncture-costs-too-much 2026-11-11 https://i.ytimg.com/vi/x5cOBvE5zU4/mqdefault.jpg Cancer Survivors Need More Support: Acupuncture Costs Too Much! Read the full conversation on Oncology Data Advisor: https://oncdata.com/sabcs-2025-chase-hundal At the 2025 San Antonio Breast Cancer Symposium (SABCS), Editorial Board member Jasmin Hundal, MD, MS, MPH, and breast cancer survivor and advocate Megan‑Claire “Warrior Megsie” Chase reflect on how research, clinical care, and lived experience come together to shape the future of breast cancer care. They discuss what it means to attend SABCS as a 10‑year invasive lobular breast cancer survivor, the emotional reality of fear of recurrence, and the power of seeing patient advocates leading posters, panels, and conversations. Ms. Chase shares her journey from communications and theater into research collaboration and co‑authorship, including her poster on real‑world patient and caregiver experiences with fear of recurrence, while Dr. Hundal highlights why language around “non‑adherence” often obscures the true burden of long‑term endocrine side effects and why quality of life must be treated as a primary outcome. The conversation also explores digital health and wearables in breast cancer survivorship, balancing the promise of earlier detection of issues through technology with concerns about equity, inclusion of older adults, and preserving human connection. Together, they underscore that patient experience is a form of expertise—and that survivors’ voices are essential to driving meaningful, patient‑centered research. #SABCS2025 #BreastCancer #BreastCancerSurvivor #LobularBreastCancer #PatientAdvocacy #FearOfRecurrence #EndocrineTherapy #QualityOfLife #DigitalHealth #Wearables #OncologyFellow #CancerSurvivorship #OncologyDataAdvisor 2026-01-26T13:01:45.000Z https://www.youtube.com/embed/x5cOBvE5zU4 43 https://oncdata.com/videos/cancer-survivorship-what-s-missing-after-treatment 2026-11-11 https://i.ytimg.com/vi/dVYPxmmFnVE/mqdefault.jpg Cancer Survivorship: What's Missing After Treatment Read the full conversation on Oncology Data Advisor: https://oncdata.com/sabcs-2025-chase-hundal At the 2025 San Antonio Breast Cancer Symposium (SABCS), Editorial Board member Jasmin Hundal, MD, MS, MPH, and breast cancer survivor and advocate Megan‑Claire “Warrior Megsie” Chase reflect on how research, clinical care, and lived experience come together to shape the future of breast cancer care. They discuss what it means to attend SABCS as a 10‑year invasive lobular breast cancer survivor, the emotional reality of fear of recurrence, and the power of seeing patient advocates leading posters, panels, and conversations. Ms. Chase shares her journey from communications and theater into research collaboration and co‑authorship, including her poster on real‑world patient and caregiver experiences with fear of recurrence, while Dr. Hundal highlights why language around “non‑adherence” often obscures the true burden of long‑term endocrine side effects and why quality of life must be treated as a primary outcome. The conversation also explores digital health and wearables in breast cancer survivorship, balancing the promise of earlier detection of issues through technology with concerns about equity, inclusion of older adults, and preserving human connection. Together, they underscore that patient experience is a form of expertise—and that survivors’ voices are essential to driving meaningful, patient‑centered research. #SABCS2025 #BreastCancer #BreastCancerSurvivor #LobularBreastCancer #PatientAdvocacy #FearOfRecurrence #EndocrineTherapy #QualityOfLife #DigitalHealth #Wearables #OncologyFellow #CancerSurvivorship #OncologyDataAdvisor 2026-01-25T14:15:05.000Z https://www.youtube.com/embed/dVYPxmmFnVE 45 https://oncdata.com/videos/why-do-treatments-have-different-side-effects-let-s-find-out 2026-11-11 https://i.ytimg.com/vi/z49TFadaTbw/mqdefault.jpg Why Do Treatments Have Different Side Effects: Let's Find Out! Read the full conversation on Oncology Data Advisor: https://oncdata.com/sabcs-2025-chase-hundal At the 2025 San Antonio Breast Cancer Symposium (SABCS), Editorial Board member Jasmin Hundal, MD, MS, MPH, and breast cancer survivor and advocate Megan‑Claire “Warrior Megsie” Chase reflect on how research, clinical care, and lived experience come together to shape the future of breast cancer care. They discuss what it means to attend SABCS as a 10‑year invasive lobular breast cancer survivor, the emotional reality of fear of recurrence, and the power of seeing patient advocates leading posters, panels, and conversations. Ms. Chase shares her journey from communications and theater into research collaboration and co‑authorship, including her poster on real‑world patient and caregiver experiences with fear of recurrence, while Dr. Hundal highlights why language around “non‑adherence” often obscures the true burden of long‑term endocrine side effects and why quality of life must be treated as a primary outcome. The conversation also explores digital health and wearables in breast cancer survivorship, balancing the promise of earlier detection of issues through technology with concerns about equity, inclusion of older adults, and preserving human connection. Together, they underscore that patient experience is a form of expertise—and that survivors’ voices are essential to driving meaningful, patient‑centered research. #SABCS2025 #BreastCancer #BreastCancerSurvivor #LobularBreastCancer #PatientAdvocacy #FearOfRecurrence #EndocrineTherapy #QualityOfLife #DigitalHealth #Wearables #OncologyFellow #CancerSurvivorship #OncologyDataAdvisor 2026-01-24T17:01:35.000Z https://www.youtube.com/embed/z49TFadaTbw 32 https://oncdata.com/videos/cancer-diagnoses-plummet-early-signs-of-hope 2026-11-11 https://i.ytimg.com/vi/-iNPrWoh5ks/mqdefault.jpg Cancer Diagnoses Plummet: Early Signs of Hope! Watch the full conversation on Oncology Data Advisor: https://oncdata.com/breast-cancer-screening-welman-hundal Federally qualified health centers (FQHCs) play a critical role in cancer prevention for underserved communities, yet structural barriers often delay diagnosis and contribute to later-stage breast cancer presentation. In this discussion, Martha Welman, MD, Chief Medical Officer of Neighborhood Health, joins Jasmin Hundal, MD, MS, MPH, to share how a structured breast cancer screening navigation program dramatically shortened time to diagnosis and showed early signals of reducing late-stage disease. They explore how post–COVID-19 disruptions led to more advanced presentations, particularly among younger women, and how patient navigation emerged as the most impactful intervention. Dr. Welman details how dedicated navigators, standing orders, strengthened imaging partnerships, and mobile mammography helped reduce average time from screening order to diagnostic resolution from nearly four months to less than three—while also addressing literacy, language, transportation, and digital access barriers common in FQHC populations. The conversation highlights why human-centered navigation is essential for translating screening guidelines into real-world impact, the emotional and logistical obstacles patients face along the diagnostic pathway, and what oncology clinicians can learn about partnering with community practices to improve equity, outcomes, and continuity of care across the breast cancer continuum. #BreastCancerScreening #HealthEquity #CommunityOncology #FQHC #PatientNavigation #CancerPrevention #EarlyDetection #BreastCancerCare #UnderservedPopulations #PublicHealth #OncologyDataAdvisor 2026-01-22T16:49:11.000Z https://www.youtube.com/embed/-iNPrWoh5ks 32 https://oncdata.com/videos/cancer-early-detection-patient-navigators-make-it-possible 2026-11-11 https://i.ytimg.com/vi/px51bqaxeJM/mqdefault.jpg Cancer Early Detection: Patient Navigators Make It Possible! Watch the full conversation on Oncology Data Advisor: https://oncdata.com/breast-cancer-screening-welman-hundal Federally qualified health centers (FQHCs) play a critical role in cancer prevention for underserved communities, yet structural barriers often delay diagnosis and contribute to later-stage breast cancer presentation. In this discussion, Martha Welman, MD, Chief Medical Officer of Neighborhood Health, joins Jasmin Hundal, MD, MS, MPH, to share how a structured breast cancer screening navigation program dramatically shortened time to diagnosis and showed early signals of reducing late-stage disease. They explore how post–COVID-19 disruptions led to more advanced presentations, particularly among younger women, and how patient navigation emerged as the most impactful intervention. Dr. Welman details how dedicated navigators, standing orders, strengthened imaging partnerships, and mobile mammography helped reduce average time from screening order to diagnostic resolution from nearly four months to less than three—while also addressing literacy, language, transportation, and digital access barriers common in FQHC populations. The conversation highlights why human-centered navigation is essential for translating screening guidelines into real-world impact, the emotional and logistical obstacles patients face along the diagnostic pathway, and what oncology clinicians can learn about partnering with community practices to improve equity, outcomes, and continuity of care across the breast cancer continuum. #BreastCancerScreening #HealthEquity #CommunityOncology #FQHC #PatientNavigation #CancerPrevention #EarlyDetection #BreastCancerCare #UnderservedPopulations #PublicHealth #OncologyDataAdvisor 2026-01-22T16:48:38.000Z https://www.youtube.com/embed/px51bqaxeJM 49 https://oncdata.com/videos/human-touch-the-secret-to-mammogram-success-cancer-prevention 2026-11-11 https://i.ytimg.com/vi/L4z5TT_splM/mqdefault.jpg Human Touch: The Secret to Mammogram Success & Cancer Prevention Watch the full conversation on Oncology Data Advisor: https://oncdata.com/breast-cancer-screening-welman-hundal Federally qualified health centers (FQHCs) play a critical role in cancer prevention for underserved communities, yet structural barriers often delay diagnosis and contribute to later-stage breast cancer presentation. In this discussion, Martha Welman, MD, Chief Medical Officer of Neighborhood Health, joins Jasmin Hundal, MD, MS, MPH, to share how a structured breast cancer screening navigation program dramatically shortened time to diagnosis and showed early signals of reducing late-stage disease. They explore how post–COVID-19 disruptions led to more advanced presentations, particularly among younger women, and how patient navigation emerged as the most impactful intervention. Dr. Welman details how dedicated navigators, standing orders, strengthened imaging partnerships, and mobile mammography helped reduce average time from screening order to diagnostic resolution from nearly four months to less than three—while also addressing literacy, language, transportation, and digital access barriers common in FQHC populations. The conversation highlights why human-centered navigation is essential for translating screening guidelines into real-world impact, the emotional and logistical obstacles patients face along the diagnostic pathway, and what oncology clinicians can learn about partnering with community practices to improve equity, outcomes, and continuity of care across the breast cancer continuum. #BreastCancerScreening #HealthEquity #CommunityOncology #FQHC #PatientNavigation #CancerPrevention #EarlyDetection #BreastCancerCare #UnderservedPopulations #PublicHealth #OncologyDataAdvisor 2026-01-22T16:48:06.000Z https://www.youtube.com/embed/L4z5TT_splM 32 https://oncdata.com/videos/post-covid-why-more-young-women-face-advanced-breast-cancer 2026-11-11 https://i.ytimg.com/vi/w2Qo0CwMYFk/mqdefault.jpg Post COVID: Why More Young Women Face Advanced Breast Cancer Watch the full conversation on Oncology Data Advisor: https://oncdata.com/breast-cancer-screening-welman-hundal Federally qualified health centers (FQHCs) play a critical role in cancer prevention for underserved communities, yet structural barriers often delay diagnosis and contribute to later-stage breast cancer presentation. In this discussion, Martha Welman, MD, Chief Medical Officer of Neighborhood Health, joins Jasmin Hundal, MD, MS, MPH, to share how a structured breast cancer screening navigation program dramatically shortened time to diagnosis and showed early signals of reducing late-stage disease. They explore how post–COVID-19 disruptions led to more advanced presentations, particularly among younger women, and how patient navigation emerged as the most impactful intervention. Dr. Welman details how dedicated navigators, standing orders, strengthened imaging partnerships, and mobile mammography helped reduce average time from screening order to diagnostic resolution from nearly four months to less than three—while also addressing literacy, language, transportation, and digital access barriers common in FQHC populations. The conversation highlights why human-centered navigation is essential for translating screening guidelines into real-world impact, the emotional and logistical obstacles patients face along the diagnostic pathway, and what oncology clinicians can learn about partnering with community practices to improve equity, outcomes, and continuity of care across the breast cancer continuum. #BreastCancerScreening #HealthEquity #CommunityOncology #FQHC #PatientNavigation #CancerPrevention #EarlyDetection #BreastCancerCare #UnderservedPopulations #PublicHealth #OncologyDataAdvisor 2026-01-22T16:47:36.000Z https://www.youtube.com/embed/w2Qo0CwMYFk 25 https://oncdata.com/videos/her2-lung-cancer-rare-but-affects-10-000-us-patients-annually 2026-11-11 https://i.ytimg.com/vi/EOaNZSeWx4Q/mqdefault.jpg HER2 Lung Cancer Rare but Affects 10,000 US Patients Annually! Lung cancer remains the leading cause of cancer-related deaths, with an estimated 226,650 new cases diagnosed and 124,730 deaths in the United Stated in 2025 (Siegel et al, 2025). Non–small cell lung cancer (NSCLC) is a biologically heterogenous type of lung cancer associated with a range of molecular alterations, including human epidermal growth factor 2 (HER2) mutations in approximately 4% of cases. HER2 represents a promising therapeutic target, with National Comprehensive Cancer Network (NCCN) 2026 guidelines now recommending testing for rare oncogenic driver alterations, including HER2 mutations, to personalize therapeutic decision making. While biomarker testing is critical to improving outcomes for patients with NSCLC, challenges such as cost, time, access, and awareness pose barriers to its implementation, particularly in the community setting where resources may be limited (Salazar et al, 2025; Ismail et al, 2025). Multidisciplinary collaboration between oncologists, pathologists, nurses, and other members of the care team is crucial to streamline biomarker testing, select the optimal treatment for individual patients, and manage treatment-related toxicities. In this Virtual Tumor Board, Tejas Patil, MD, Assistant Professor of Thoracic Oncology and Associate Director of Clinical Affairs at the University of Colorado Cancer Center; Beth Sandy, MSN, CRNP, FAPO, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of the University of Pennsylvania; and Maureen F. Zakowski, MD, JD, Thoracic Pathologist and Chief of the Cytopathology Service at Mount Sinai Medical Center, will explore the application of advances and best practices in HER2-mutant NSCLC in the community setting. #treatment #NSCLC #Cancer #Lungcancer #oncologyeducation #patientoutcomes #immunotherapy #oncologyinnovation #cancercare #cancerresearch 2026-01-12T17:07:13.000Z https://www.youtube.com/embed/EOaNZSeWx4Q 34 https://oncdata.com/videos/new-cancer-drug-shows-promise-but-watch-for-lung-side-effects 2026-01-27 https://i.ytimg.com/vi/8gTdxnmOW90/mqdefault.jpg New Cancer Drug Shows Promise, But Watch For Lung Side Effects! Lung cancer remains the leading cause of cancer-related deaths, with an estimated 226,650 new cases diagnosed and 124,730 deaths in the United Stated in 2025 (Siegel et al, 2025). Non–small cell lung cancer (NSCLC) is a biologically heterogenous type of lung cancer associated with a range of molecular alterations, including human epidermal growth factor 2 (HER2) mutations in approximately 4% of cases. HER2 represents a promising therapeutic target, with National Comprehensive Cancer Network (NCCN) 2026 guidelines now recommending testing for rare oncogenic driver alterations, including HER2 mutations, to personalize therapeutic decision making. While biomarker testing is critical to improving outcomes for patients with NSCLC, challenges such as cost, time, access, and awareness pose barriers to its implementation, particularly in the community setting where resources may be limited (Salazar et al, 2025; Ismail et al, 2025). Multidisciplinary collaboration between oncologists, pathologists, nurses, and other members of the care team is crucial to streamline biomarker testing, select the optimal treatment for individual patients, and manage treatment-related toxicities. In this Virtual Tumor Board, Tejas Patil, MD, Assistant Professor of Thoracic Oncology and Associate Director of Clinical Affairs at the University of Colorado Cancer Center; Beth Sandy, MSN, CRNP, FAPO, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of the University of Pennsylvania; and Maureen F. Zakowski, MD, JD, Thoracic Pathologist and Chief of the Cytopathology Service at Mount Sinai Medical Center, will explore the application of advances and best practices in HER2-mutant NSCLC in the community setting. #treatment #NSCLC #Cancer #Lungcancer #oncologyeducation #patientoutcomes #immunotherapy #oncologyinnovation #cancercare #cancerresearch 2026-01-12T17:06:56.000Z https://www.youtube.com/embed/8gTdxnmOW90 29 https://oncdata.com/videos/pathology-s-new-role-guiding-cancer-treatment-with-molecular-insights 2026-11-11 https://i.ytimg.com/vi/nDawDBWei44/mqdefault.jpg Pathology's New Role: Guiding Cancer Treatment with Molecular Insights Lung cancer remains the leading cause of cancer-related deaths, with an estimated 226,650 new cases diagnosed and 124,730 deaths in the United Stated in 2025 (Siegel et al, 2025). Non–small cell lung cancer (NSCLC) is a biologically heterogenous type of lung cancer associated with a range of molecular alterations, including human epidermal growth factor 2 (HER2) mutations in approximately 4% of cases. HER2 represents a promising therapeutic target, with National Comprehensive Cancer Network (NCCN) 2026 guidelines now recommending testing for rare oncogenic driver alterations, including HER2 mutations, to personalize therapeutic decision making. While biomarker testing is critical to improving outcomes for patients with NSCLC, challenges such as cost, time, access, and awareness pose barriers to its implementation, particularly in the community setting where resources may be limited (Salazar et al, 2025; Ismail et al, 2025). Multidisciplinary collaboration between oncologists, pathologists, nurses, and other members of the care team is crucial to streamline biomarker testing, select the optimal treatment for individual patients, and manage treatment-related toxicities. In this Virtual Tumor Board, Tejas Patil, MD, Assistant Professor of Thoracic Oncology and Associate Director of Clinical Affairs at the University of Colorado Cancer Center; Beth Sandy, MSN, CRNP, FAPO, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of the University of Pennsylvania; and Maureen F. Zakowski, MD, JD, Thoracic Pathologist and Chief of the Cytopathology Service at Mount Sinai Medical Center, will explore the application of advances and best practices in HER2-mutant NSCLC in the community setting. #treatment #NSCLC #Cancer #Lungcancer #oncologyeducation #patientoutcomes #immunotherapy #oncologyinnovation #cancercare #cancerresearch 2026-01-12T17:06:07.000Z https://www.youtube.com/embed/nDawDBWei44 21 https://oncdata.com/videos/targeted-cancer-drugs-how-antibodies-deliver-deadly-payloads 2026-11-11 https://i.ytimg.com/vi/Sv_MMOhL0PM/mqdefault.jpg Targeted #Cancer Drugs: How Antibodies Deliver Deadly Payloads Lung cancer remains the leading cause of cancer-related deaths, with an estimated 226,650 new cases diagnosed and 124,730 deaths in the United Stated in 2025 (Siegel et al, 2025). Non–small cell lung cancer (NSCLC) is a biologically heterogenous type of lung cancer associated with a range of molecular alterations, including human epidermal growth factor 2 (HER2) mutations in approximately 4% of cases. HER2 represents a promising therapeutic target, with National Comprehensive Cancer Network (NCCN) 2026 guidelines now recommending testing for rare oncogenic driver alterations, including HER2 mutations, to personalize therapeutic decision making. While biomarker testing is critical to improving outcomes for patients with NSCLC, challenges such as cost, time, access, and awareness pose barriers to its implementation, particularly in the community setting where resources may be limited (Salazar et al, 2025; Ismail et al, 2025). Multidisciplinary collaboration between oncologists, pathologists, nurses, and other members of the care team is crucial to streamline biomarker testing, select the optimal treatment for individual patients, and manage treatment-related toxicities. In this Virtual Tumor Board, Tejas Patil, MD, Assistant Professor of Thoracic Oncology and Associate Director of Clinical Affairs at the University of Colorado Cancer Center; Beth Sandy, MSN, CRNP, FAPO, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of the University of Pennsylvania; and Maureen F. Zakowski, MD, JD, Thoracic Pathologist and Chief of the Cytopathology Service at Mount Sinai Medical Center, will explore the application of advances and best practices in HER2-mutant NSCLC in the community setting. #treatment #NSCLC #Cancer #Lungcancer #oncologyeducation #patientoutcomes #immunotherapy #oncologyinnovation #cancercare #cancerresearch 2026-01-12T17:05:01.000Z https://www.youtube.com/embed/Sv_MMOhL0PM 21 https://oncdata.com/videos/bringing-breast-cancer-screening-to-the-neighborhood-martha-welman-md-and-jasmin-hundal-md 2026-11-11 https://i.ytimg.com/vi/7N2nQgn-nZg/mqdefault.jpg Bringing Breast Cancer Screening to the Neighborhood: Martha Welman, MD, and Jasmin Hundal, MD Watch the full conversation on Oncology Data Advisor: https://oncdata.com/breast-cancer-screening-welman-hundal Federally qualified health centers (FQHCs) play a critical role in cancer prevention for underserved communities, yet structural barriers often delay diagnosis and contribute to later-stage breast cancer presentation. In this discussion, Martha Welman, MD, Chief Medical Officer of Neighborhood Health, joins Jasmin Hundal, MD, MS, MPH, to share how a structured breast cancer screening navigation program dramatically shortened time to diagnosis and showed early signals of reducing late-stage disease. They explore how post–COVID-19 disruptions led to more advanced presentations, particularly among younger women, and how patient navigation emerged as the most impactful intervention. Dr. Welman details how dedicated navigators, standing orders, strengthened imaging partnerships, and mobile mammography helped reduce average time from screening order to diagnostic resolution from nearly four months to less than three—while also addressing literacy, language, transportation, and digital access barriers common in FQHC populations. The conversation highlights why human-centered navigation is essential for translating screening guidelines into real-world impact, the emotional and logistical obstacles patients face along the diagnostic pathway, and what oncology clinicians can learn about partnering with community practices to improve equity, outcomes, and continuity of care across the breast cancer continuum. #BreastCancerScreening #HealthEquity #CommunityOncology #FQHC #PatientNavigation #CancerPrevention #EarlyDetection #BreastCancerCare #UnderservedPopulations #PublicHealth #OncologyDataAdvisor 2026-01-12T13:00:16.000Z https://www.youtube.com/embed/7N2nQgn-nZg 771 https://oncdata.com/videos/advocacy-and-innovation-at-sabcs-2025-with-megan-claire-chase-and-jasmin-hundal-md-ms-mph 2026-11-11 https://i.ytimg.com/vi/RzOsBaZN0MM/mqdefault.jpg Advocacy and Innovation at SABCS 2025 With Megan-Claire Chase and Jasmin Hundal, MD, MS, MPH Read the full conversation on Oncology Data Advisor: https://oncdata.com/sabcs-2025-chase-hundal At the 2025 San Antonio Breast Cancer Symposium (SABCS), Editorial Board member Jasmin Hundal, MD, MS, MPH, and breast cancer survivor and advocate Megan‑Claire “Warrior Megsie” Chase reflect on how research, clinical care, and lived experience come together to shape the future of breast cancer care. They discuss what it means to attend SABCS as a 10‑year invasive lobular breast cancer survivor, the emotional reality of fear of recurrence, and the power of seeing patient advocates leading posters, panels, and conversations. Ms. Chase shares her journey from communications and theater into research collaboration and co‑authorship, including her poster on real‑world patient and caregiver experiences with fear of recurrence, while Dr. Hundal highlights why language around “non‑adherence” often obscures the true burden of long‑term endocrine side effects and why quality of life must be treated as a primary outcome. The conversation also explores digital health and wearables in breast cancer survivorship, balancing the promise of earlier detection of issues through technology with concerns about equity, inclusion of older adults, and preserving human connection. Together, they underscore that patient experience is a form of expertise—and that survivors’ voices are essential to driving meaningful, patient‑centered research. #SABCS2025 #BreastCancer #BreastCancerSurvivor #LobularBreastCancer #PatientAdvocacy #FearOfRecurrence #EndocrineTherapy #QualityOfLife #DigitalHealth #Wearables #OncologyFellow #CancerSurvivorship #OncologyDataAdvisor 2026-01-08T13:00:55.000Z https://www.youtube.com/embed/RzOsBaZN0MM 1558 https://oncdata.com/videos/navigating-mrd-as-an-end-point-in-hematologic-malignancies-with-rahul-banerjee-nicholas-richardson 2026-11-11 https://i.ytimg.com/vi/1x-Pu5DWQCc/mqdefault.jpg Navigating MRD as an End Point in Hematologic Malignancies With Rahul Banerjee & Nicholas Richardson Read the full interview on Oncology Data Advisor: https://oncdata.com/navigating-mrd-as-an-end-point-banerjee-richardson Measurable residual disease (MRD) has quickly shifted from an exploratory biomarker to a central focus of clinical trial design and regulatory debate in hematologic malignancies. In this interview, Editorial Board member Rahul Banerjee, MD, FACP, speaks with Nicholas Richardson, DO, MPH, Vice President of Clinical Development at Precision for Medicine and former Deputy Director for the Division of Hematologic Malignancies 2 at the FDA, about how clinicians should interpret MRD assays, what “FDA‑cleared” actually means, and how the 2024 FDA Oncologic Drugs Advisory Committee (ODAC) on MRD in multiple myeloma is likely to shape future drug development. Dr. Richardson explains the distinction between FDA‑cleared MRD assays such as clonoSEQ and FDA‑approved devices, clarifies why MRD does not yet meet strict Prentice criteria as a true surrogate for overall survival, and describes its current role as a candidate surrogate or intermediate clinical endpoint. They review the 2024 ODAC’s unanimous decision that MRD data are sufficient to support future accelerated approvals in myeloma, discuss why standardized thresholds (such as 10⁻⁵ in multiple myeloma) and assay‑agnostic validation are critical, and outline what trialists, sponsors, and practicing hematologist–oncologists should keep in mind as MRD and ctDNA are integrated into studies and regulatory pathways. #MRD #MeasurableResidualDisease #MultipleMyeloma #CLL #HematologicMalignancies #clonoSEQ #FDA #ODAC #SurrogateEndpoints #ClinicalTrials #PrecisionOncology #HematologyOncology 2026-01-06T13:00:06.000Z https://www.youtube.com/embed/1x-Pu5DWQCc 1017 https://oncdata.com/videos/live-webinar-preview-navigating-her2-mutant-nsclc-pathology-and-management 2026-11-10 https://i.ytimg.com/vi/w_TQmEW6pTo/mqdefault.jpg Live Webinar Preview: Navigating HER2-Mutant NSCLC Pathology and Management Register for the webinar below! January 8, 2026 @ 5:00 pm ET: https://bit.ly/4iZxnA0 January 26, 2026 @ 5:00 pm ET: https://bit.ly/4qALw9J You are invited to join i3 Health for a live webinar, HER2–Mutant NSCLC: Closing the Gap Between Detection and Optimal Treatment. Helena A. Yu, MD, Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Anatomic and Clinical Pathologist and the Director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center, will explore how to optimize HER2 testing and integrate emerging HER2-directed therapies into routine care for patients with non–small cell lung cancer (NSCLC). The webinar will be held on two days: Wednesday, January 8th at 5:00 pm ET and Monday, January 26th at 5:00 pm ET. #NSCLC #Oncology #LungCancer #OncologyEducation #LungHealth #HER2 #SmallCellLungCancer 2025-12-19T15:31:07.000Z https://www.youtube.com/embed/w_TQmEW6pTo 427 https://oncdata.com/videos/discovering-systemic-mastocytosis-in-practice-a-webinar-preview-with-lauren-m-madigan-md 2026-11-11 https://i.ytimg.com/vi/3xhXatFGjDM/mqdefault.jpg Discovering Systemic Mastocytosis in Practice: A Webinar Preview With Lauren M. Madigan, MD Read the full interview and learn more on Oncology Data Advisor: https://oncdata.com/systemic-mastocytosis-webinar-preview Register for the webinars today! January 13th: https://bit.ly/4p7HRil February 2nd: https://bit.ly/495gnEd Systemic mastocytosis is a multisystem disease that often goes unrecognized for years, despite causing significant symptoms and morbidity. In this preview of the live CME webinar “Beyond the Skin: Uncovering Systemic Mastocytosis in Dermatology Practice,” Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, shares why diagnosis is frequently delayed, how cutaneous findings can be a crucial gateway to recognition, and how new targeted therapies are changing what clinicians can offer patients. Dr. Madigan discusses practical tips for spotting characteristic skin lesions, the importance of early diagnosis to prevent complications such as recurrent anaphylaxis and osteoporosis, and the critical role of multidisciplinary collaboration among dermatology, hematology/oncology, allergy/immunology, gastroenterology, and endocrinology. She also previews the rapidly evolving treatment landscape, including FDA‑approved and emerging targeted agents for both indolent and advanced systemic mastocytosis. #SystemicMastocytosis #Mastocytosis #Dermatology #HematologyOncology #AllergyImmunology #TargetedTherapy #RareDisease #Anaphylaxis #Osteoporosis #MultidisciplinaryCare #OncologyEducation #CME 2025-12-18T16:56:38.000Z https://www.youtube.com/embed/3xhXatFGjDM 324 https://oncdata.com/videos/car-t-cell-unleash-your-immune-system-against-cancer 2026-11-11 https://i.ytimg.com/vi/kmXuZfJIufU/mqdefault.jpg CAR T Cell: Unleash Your Immune System Against Cancer! Read the full interview on Oncology Data Advisor: https://oncdata.com/car-t-in-practice-ehsan-malek CAR T-cell therapy has gone from experimental to a real-world option in multiple myeloma and lymphoma, but questions remain about durability, resistance, access, and value. In this interview, Ehsan Malek, MD, Associate Professor of Oncology and Director of Translational Research for Multiple Myeloma at Roswell Park Comprehensive Cancer Center, explains how CAR T, bispecifics, and checkpoint inhibitors have reshaped the immunotherapy landscape and what this means for everyday practice. Dr. Malek discusses efforts to improve CAR T-cell persistence, overcome the immunosuppressive tumor microenvironment with “armored” CARs, and integrate CAR T alongside bispecifics without exhausting T cells. He highlights national survey data showing that many patients now prefer CAR T over continuous chemotherapy, underscoring the need for early referral, value-focused conversations, and hub-and-spoke models that expand access beyond academic centers. Looking ahead, he outlines how off‑the‑shelf allogeneic CAR T and rational combinations may further transform outcomes in the coming years. #CARTCellTherapy #MultipleMyeloma #Lymphoma #Immunotherapy #BispecificAntibodies #TranslationalResearch #HematologicMalignancies #QualityOfLife #ValueBasedCare #OncologyEducation 2025-12-15T16:16:47.000Z https://www.youtube.com/embed/kmXuZfJIufU 29 https://oncdata.com/videos/car-t-cells-the-ultimate-cancer-warriors-that-conquer-without-chemo 2026-01-27 https://i.ytimg.com/vi/fd315MuGcpA/mqdefault.jpg CAR T Cells: The Ultimate Cancer Warriors That Conquer Without Chemo! Read the full interview on Oncology Data Advisor: https://oncdata.com/car-t-in-practice-ehsan-malek CAR T-cell therapy has gone from experimental to a real-world option in multiple myeloma and lymphoma, but questions remain about durability, resistance, access, and value. In this interview, Ehsan Malek, MD, Associate Professor of Oncology and Director of Translational Research for Multiple Myeloma at Roswell Park Comprehensive Cancer Center, explains how CAR T, bispecifics, and checkpoint inhibitors have reshaped the immunotherapy landscape and what this means for everyday practice. Dr. Malek discusses efforts to improve CAR T-cell persistence, overcome the immunosuppressive tumor microenvironment with “armored” CARs, and integrate CAR T alongside bispecifics without exhausting T cells. He highlights national survey data showing that many patients now prefer CAR T over continuous chemotherapy, underscoring the need for early referral, value-focused conversations, and hub-and-spoke models that expand access beyond academic centers. Looking ahead, he outlines how off‑the‑shelf allogeneic CAR T and rational combinations may further transform outcomes in the coming years. #CARTCellTherapy #MultipleMyeloma #Lymphoma #Immunotherapy #BispecificAntibodies #TranslationalResearch #HematologicMalignancies #QualityOfLife #ValueBasedCare #OncologyEducation 2025-12-15T16:16:27.000Z https://www.youtube.com/embed/fd315MuGcpA 22 https://oncdata.com/videos/t-cells-the-cancer-fighters-reengineered-to-kill 2026-01-27 https://i.ytimg.com/vi/xbVLjaFikAg/mqdefault.jpg T Cells: The Cancer Fighters REENGINEERED to Kill! Read the full interview on Oncology Data Advisor: https://oncdata.com/car-t-in-practice-ehsan-malek CAR T-cell therapy has gone from experimental to a real-world option in multiple myeloma and lymphoma, but questions remain about durability, resistance, access, and value. In this interview, Ehsan Malek, MD, Associate Professor of Oncology and Director of Translational Research for Multiple Myeloma at Roswell Park Comprehensive Cancer Center, explains how CAR T, bispecifics, and checkpoint inhibitors have reshaped the immunotherapy landscape and what this means for everyday practice. Dr. Malek discusses efforts to improve CAR T-cell persistence, overcome the immunosuppressive tumor microenvironment with “armored” CARs, and integrate CAR T alongside bispecifics without exhausting T cells. He highlights national survey data showing that many patients now prefer CAR T over continuous chemotherapy, underscoring the need for early referral, value-focused conversations, and hub-and-spoke models that expand access beyond academic centers. Looking ahead, he outlines how off‑the‑shelf allogeneic CAR T and rational combinations may further transform outcomes in the coming years. #CARTCellTherapy #MultipleMyeloma #Lymphoma #Immunotherapy #BispecificAntibodies #TranslationalResearch #HematologicMalignancies #QualityOfLife #ValueBasedCare #OncologyEducation 2025-12-15T16:14:54.000Z https://www.youtube.com/embed/xbVLjaFikAg 30 https://oncdata.com/videos/car-t-cell-therapy-breakthrough-curing-myeloma-with-new-innovations 2026-01-27 https://i.ytimg.com/vi/rei6vYgioec/mqdefault.jpg CAR T Cell Therapy Breakthrough: Curing Myeloma with New Innovations! Read the full interview on Oncology Data Advisor: https://oncdata.com/car-t-in-practice-ehsan-malek CAR T-cell therapy has gone from experimental to a real-world option in multiple myeloma and lymphoma, but questions remain about durability, resistance, access, and value. In this interview, Ehsan Malek, MD, Associate Professor of Oncology and Director of Translational Research for Multiple Myeloma at Roswell Park Comprehensive Cancer Center, explains how CAR T, bispecifics, and checkpoint inhibitors have reshaped the immunotherapy landscape and what this means for everyday practice. Dr. Malek discusses efforts to improve CAR T-cell persistence, overcome the immunosuppressive tumor microenvironment with “armored” CARs, and integrate CAR T alongside bispecifics without exhausting T cells. He highlights national survey data showing that many patients now prefer CAR T over continuous chemotherapy, underscoring the need for early referral, value-focused conversations, and hub-and-spoke models that expand access beyond academic centers. Looking ahead, he outlines how off‑the‑shelf allogeneic CAR T and rational combinations may further transform outcomes in the coming years. #CARTCellTherapy #MultipleMyeloma #Lymphoma #Immunotherapy #BispecificAntibodies #TranslationalResearch #HematologicMalignancies #QualityOfLife #ValueBasedCare #OncologyEducation 2025-12-15T16:14:24.000Z https://www.youtube.com/embed/rei6vYgioec 44 https://oncdata.com/videos/exploring-breast-cancer-research-at-esmo-2025-with-jasmin-hundal-md-ms-mph 2026-11-11 https://i.ytimg.com/vi/eWrbeNtRe90/mqdefault.jpg Exploring Breast Cancer Research at ESMO 2025 With Jasmin Hundal, MD, MS, MPH Read the full interview on Oncology Data Advisor: https://oncdata.com/jasmin-hundal-esmo-breast-cancer At ESMO 2025, new data across early, metastatic, and HER2 positive breast cancer signaled important shifts in standards of care. In this interview, Editorial Board Member Jasmin Hundal, MD, MS, MPH, Hematology/Oncology Fellow at Cleveland Clinic, breaks down the most impactful trials and what they mean for real patients. Dr. Hundal reviews how monarchE and NATALEE are solidifying CDK4/6 inhibition in early HR positive disease, highlights emerging endocrine strategies such as giredestrant plus everolimus in ESR1 mutated metastatic tumors, and explains how DESTINY Breast trials are redefining the role of trastuzumab deruxtecan (T‑DXd) in HER2 positive cancer. She also emphasizes the importance of clear, patient centered communication when new data emerge before regulatory approval, helping patients understand that they received the best available options at the time while reassuring them that the treatment landscape is rapidly expanding. #BreastCancer #ESMO2025 #CDK46Inhibitors #monarchE #NATALEE #ESR1Mutations #SERDs #Giredestrant #HER2Positive #TDXd #DESTINYBreast #OncologyFellow #PrecisionOncology #OncologyDataAdvisor 2025-12-11T13:01:20.000Z https://www.youtube.com/embed/eWrbeNtRe90 422 https://oncdata.com/videos/car-t-in-practice-what-oncologists-need-to-know-with-ehsan-malek-md 2026-11-11 https://i.ytimg.com/vi/gfgux9Z_L0w/mqdefault.jpg CAR T in Practice: What Oncologists Need to Know With Ehsan Malek, MD Read the full interview on Oncology Data Advisor: https://oncdata.com/car-t-in-practice-ehsan-malek CAR T-cell therapy has gone from experimental to a real-world option in multiple myeloma and lymphoma, but questions remain about durability, resistance, access, and value. In this interview, Ehsan Malek, MD, Associate Professor of Oncology and Director of Translational Research for Multiple Myeloma at Roswell Park Comprehensive Cancer Center, explains how CAR T, bispecifics, and checkpoint inhibitors have reshaped the immunotherapy landscape and what this means for everyday practice. Dr. Malek discusses efforts to improve CAR T-cell persistence, overcome the immunosuppressive tumor microenvironment with “armored” CARs, and integrate CAR T alongside bispecifics without exhausting T cells. He highlights national survey data showing that many patients now prefer CAR T over continuous chemotherapy, underscoring the need for early referral, value-focused conversations, and hub-and-spoke models that expand access beyond academic centers. Looking ahead, he outlines how off‑the‑shelf allogeneic CAR T and rational combinations may further transform outcomes in the coming years. #CARTCellTherapy #MultipleMyeloma #Lymphoma #Immunotherapy #BispecificAntibodies #TranslationalResearch #HematologicMalignancies #QualityOfLife #ValueBasedCare #OncologyEducation 2025-12-08T13:01:26.000Z https://www.youtube.com/embed/gfgux9Z_L0w 1341 https://oncdata.com/videos/advancing-community-oncology-in-an-era-of-uncertainty-with-matthew-hadfield-do-and-jason-hammonds 2026-11-11 https://i.ytimg.com/vi/zckF171xoAg/mqdefault.jpg Advancing Community Oncology in an Era of Uncertainty With Matthew Hadfield, DO, and Jason Hammonds Read the full interview on Oncology Data Advisor: https://oncdata.com/advancing-community-oncology-hadfield-hammonds As cancer care becomes more complex, most patients are still treated close to home in community practices that are under growing economic and regulatory pressure. In this interview, Oncology Data Advisor Editor in Chief Matthew Hadfield, DO, talks with Jason Hammonds, President of Oncology and Multispecialty at McKesson, about how to preserve access to state-of-the-art care outside academic centers. They discuss the paradox of progress in oncology—rapid advances in targeted therapies, next-generation sequencing (NGS), and clinical trials alongside mounting administrative burden and reimbursement uncertainty. Mr. Hammonds outlines how McKesson is working to make precision oncology and trial enrollment feasible in busy community settings by integrating molecular testing, clinical decision support, and trial-matching tools directly into practice workflows, while also advocating for policies that sustain community oncology. Hashtags #CommunityOncology #PrecisionOncology #NGSTesting #ClinicalTrials #OncologyPolicy #CancerCareCloseToHome #HealthEquity #OncologyPractice #OncologyLeadership #OncologyDataAdvisor 2025-12-04T13:02:08.000Z https://www.youtube.com/embed/zckF171xoAg 871 https://oncdata.com/videos/manta-cares-making-cancer-care-personal-with-samira-daswani-and-waqas-haque-md-mph 2026-11-11 https://i.ytimg.com/vi/g5cTPRld05w/mqdefault.jpg Manta Cares: Making Cancer Care Personal With Samira Daswani and Waqas Haque, MD, MPH Read the full interview on Oncology Data Advisor: https://oncdata.com/manta-cares-samira-daswani Cancer care may look routine on the clinic schedule, but for patients and families it can feel like a disorienting full-time job. In this interview, breast cancer survivor and Manta Cares founder Samira Daswani talks with Waqas Haque, MD, MPH, about her own experience navigating 100+ appointments, multiple specialists, and constant uncertainty—and how it led her to redesign tools that center the patient-lived journey. They discuss how the Manta Cares planner evolved from a personal coping tool into a scalable platform, why designing for real-world health literacy and digital behaviors matters, and how small changes in clinic visits and post-visit guidance can make care feel more humane and navigable. The conversation offers practical ideas for clinicians who want to better recognize and support the invisible workload of cancer. #CancerSurvivorship #PatientExperience #MantaCares #OncologyNursing #CancerCare #HealthLiteracy #PatientCenteredCare #Caregivers #OncologyInnovation #WaqasHaque 2025-12-01T13:01:26.000Z https://www.youtube.com/embed/g5cTPRld05w 987 https://oncdata.com/videos/evolving-standards-in-prostate-cancer-lessons-from-esmo-2025 2026-11-11 https://i.ytimg.com/vi/N9bk2GHXL6M/mqdefault.jpg Evolving Standards in Prostate Cancer: Lessons From ESMO 2025 Read the full interview on Oncology Data Advisor: https://oncdata.com/stephen-freedland-murilo-luz-esmo-2025 At ESMO 2025, new data challenged and refined treatment standards in prostate cancer. In this interview, Stephen Freedland, MD, and Murilo Luz, MD, discuss why the Enza A trial failed to show benefit for adding enzalutamide to ADT plus radiation in high-risk localized disease, highlighting the impact of very low event rates and “wrong population” rather than a “bad drug.” They then review the evolving triplet landscape in metastatic castration-sensitive prostate cancer, including PARP inhibitor–based regimens such as AMPLITUDE and the PSMA Addition trial of lutetium PSMA plus ADT and an AR pathway inhibitor, and what these results mean for selecting patients rather than intensifying therapy for everyone. Finally, they touch on CAPItello and capivasertib in PTEN-deficient disease as a signal of where biomarker-driven triplets are headed. #ProstateCancer #ESMO2025 #EnzaA #PSMAAddition #AMPLITUDE #CAPItello #LutetiumPSMA #PARPInhibitors #PTENLoss #PrecisionOncology 2025-11-24T13:00:43.000Z https://www.youtube.com/embed/N9bk2GHXL6M 1305 https://oncdata.com/videos/cancer-breakthrough-tarlatumab-shows-huge-survival-improvement 2026-11-11 https://i.ytimg.com/vi/j3e6KM-wZks/mqdefault.jpg Cancer Breakthrough Tarlatumab Shows Huge Survival Improvement! Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-22T18:30:41.000Z https://www.youtube.com/embed/j3e6KM-wZks 29 https://oncdata.com/videos/doctors-discuss-diagnostic-pitfalls-and-collaboration-in-medical-field 2026-11-11 https://i.ytimg.com/vi/nIsxM8sw2vs/mqdefault.jpg Doctors Discuss Diagnostic Pitfalls and Collaboration in Medical Field Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-22T18:30:18.000Z https://www.youtube.com/embed/nIsxM8sw2vs 28 https://oncdata.com/videos/medical-conference-decoding-extrapulmonary-necs-diagnostic-criteria 2026-11-11 https://i.ytimg.com/vi/qCQF9ut0HmQ/mqdefault.jpg Medical Conference Decoding Extrapulmonary NECs Diagnostic Criteria Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-22T18:30:06.000Z https://www.youtube.com/embed/qCQF9ut0HmQ 22 https://oncdata.com/videos/neuroendocrine-carcinoma-quick-guide-for-beginners 2026-11-11 https://i.ytimg.com/vi/y2Wy6w2M910/mqdefault.jpg Neuroendocrine Carcinoma: Quick Guide for Beginners Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-22T18:28:52.000Z https://www.youtube.com/embed/y2Wy6w2M910 24 https://oncdata.com/videos/neuroendocrine-carcinomas-first-line-treatment-explained-simply 2026-11-11 https://i.ytimg.com/vi/t_a1OmC8RhU/mqdefault.jpg Neuroendocrine Carcinomas: First Line Treatment Explained Simply! Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-22T18:28:36.000Z https://www.youtube.com/embed/t_a1OmC8RhU 25 https://oncdata.com/videos/setting-new-standards-in-prostate-cancer-management-with-embark-with-stephen-freedland-md 2026-11-10 https://i.ytimg.com/vi/TR4hXNWgivU/mqdefault.jpg Setting New Standards in Prostate Cancer Management With EMBARK With Stephen Freedland, MD Read the full interview on Oncology Data Advisor: https://oncdata.com/embark-esmo-stephen-freedland At ESMO, the EMBARK trial delivered practice-changing overall survival data for men with high-risk biochemically recurrent (BCR) prostate cancer after surgery or radiation. In this interview, Stephen Freedland, MD, reviews how EMBARK was designed, the newest OS results, and what they mean for everyday practice. Learn how androgen deprivation therapy (ADT) plus enzalutamide achieved an unprecedented greater than 40% relative reduction in risk of death in high-risk BCR disease; when to use combination therapy versus enzalutamide monotherapy; and how PSA doubling time should guide treatment selection. Dr. Freedland also shares practical tips for managing toxicities such as fatigue, falls, hot flashes, seizures, and gynecomastia, while preserving quality of life. He explains how treatment suspension after response was incorporated into the trial and how ongoing analyses may further refine on/off strategies over time. #ProstateCancer #EMBARKTrial #Enzalutamide #BiochemicalRecurrence #ESMO2025 #AndrogenDeprivationTherapy #ADT #PSADoublingTime #UrologicOncology #PrecisionOncology #HormoneTherapy #ClinicalTrials #OncologyEducation #PatientOutcomes 2025-11-20T13:01:05.000Z https://www.youtube.com/embed/TR4hXNWgivU 827 https://oncdata.com/videos/neuroendocrine-neoplasms-understanding-tumor-grades-and-proliferation 2026-11-11 https://i.ytimg.com/vi/RUSmnw-oUbs/mqdefault.jpg Neuroendocrine Neoplasms Understanding Tumor Grades and Proliferation Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-18T17:00:50.000Z https://www.youtube.com/embed/RUSmnw-oUbs 30 https://oncdata.com/videos/neuroendocrine-neoplasms-treatment-sequencing-diagnosis-explained 2026-11-11 https://i.ytimg.com/vi/FOSRDoEs_6k/mqdefault.jpg Neuroendocrine Neoplasms Treatment: Sequencing & Diagnosis Explained! Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-18T13:45:02.000Z https://www.youtube.com/embed/FOSRDoEs_6k 35 https://oncdata.com/videos/adaptive-intelligence-in-prostate-cancer-radiation-with-dr-christopher-iannuzzi 2026-11-11 https://i.ytimg.com/vi/1P5xS4sU0sg/mqdefault.jpg Adaptive Intelligence in Prostate Cancer Radiation With Dr. Christopher Iannuzzi Read the full interview on Oncology Data Advisor: https://oncdata.com/adaptive-intelligence-prostate-cancer-radiation Hartford HealthCare’s Fairfield Cancer Center—an MSK Care Partner—is pioneering adaptive radiation for prostate cancer using the Varian Ethos Radiation Therapy System. In this interview, Dr. Christopher Iannuzzi, Medical Director of Radiation Oncology and Chair of Oncology at St. Vincent’s Medical Center, explains how adaptive intelligence personalizes radiation plans in real time to improve precision, outcomes, and patient experience. Learn how daily imaging, auto-contouring, and on-the-fly plan optimization enable safer stereotactic body radiation therapy (SBRT), especially when tumors sit near mobile organs like the bladder and rectum, and how this approach fits into holistic, guideline-informed, shared decision-making for prostate cancer care. #ProstateCancer #RadiationTherapy #AdaptiveRadiation #AIinOncology #VarianEthos #SBRT #MSKCarePartner #PrecisionRadiation #CancerTechnology #OncologyInnovation #PatientCenteredCare #SharedDecisionMaking #QualityOfLife #RadiationOncology 2025-11-18T13:00:08.000Z https://www.youtube.com/embed/1P5xS4sU0sg 302 https://oncdata.com/videos/complex-surgeries-teamwork-challenges-and-post-op-care-explained 2026-11-11 https://i.ytimg.com/vi/_LE3oLvw3h8/mqdefault.jpg Complex Surgeries: Teamwork, Challenges, and Post Op Care Explained! Watch the recording of this YouTube panel on dedifferentiated liposarcoma. This discussion brought together a multidisciplinary task force of expert faculty members, representing medical oncology, radiation oncology, surgical oncology, and pathology, who shared their insights and provide a consensus opinion on the optimal diagnosis, treatment, and management of soft tissue sarcoma for improving patient outcomes. During this discussion hear perspectives on: -Clinical presentation of dedifferentiated liposarcoma (DDLPS) -Role of oncogenes in the pathogenesis of DDPLS and their significance on prognosis -Diagnostic approach to dedifferentiated liposarcoma, including pathology, molecular genetics, and their related challenges and limitations -Multidisciplinary team management of disease, highlighting the roles of surgery, radiation, and systemic therapy Faculty: Richard F. Riedel, MD Associate Professor Division of Medical Oncology Duke University Medical Center Candace L. Haddox, MD Physician, Dana-Farber Cancer Institute Instructor in Medicine, Harvard Medical School Elizabeth H Baldini, MD, MPH, FASTRO Professor of Radiation Oncology Brigham and Women’s Hospital and Dana-Farber Cancer Institute Harvard Medical School Jason L. Hornick, MD, PhD Professor, Pathology Brigham and Women's Hospital Harvard Medical School Vicki L. Keedy, MD, MSCI Associate Professor of Medicine Clinical Director, Sarcoma Vanderbilt-Ingram Cancer Center Christina L. Roland, MD, MS, FACS Associate Professor Department of Surgical Oncology MD Anderson Cancer Center 2025-11-17T18:34:44.000Z https://www.youtube.com/embed/_LE3oLvw3h8 23 https://oncdata.com/videos/sharing-all-information-with-your-doctor-can-save-your-life 2026-11-11 https://i.ytimg.com/vi/Z49NLYpCu8A/mqdefault.jpg Sharing all Information with Your Doctor Can Save Your Life! Watch the recording of this YouTube panel on dedifferentiated liposarcoma. This discussion brought together a multidisciplinary task force of expert faculty members, representing medical oncology, radiation oncology, surgical oncology, and pathology, who shared their insights and provide a consensus opinion on the optimal diagnosis, treatment, and management of soft tissue sarcoma for improving patient outcomes. During this discussion hear perspectives on: -Clinical presentation of dedifferentiated liposarcoma (DDLPS) -Role of oncogenes in the pathogenesis of DDPLS and their significance on prognosis -Diagnostic approach to dedifferentiated liposarcoma, including pathology, molecular genetics, and their related challenges and limitations -Multidisciplinary team management of disease, highlighting the roles of surgery, radiation, and systemic therapy Faculty: Richard F. Riedel, MD Associate Professor Division of Medical Oncology Duke University Medical Center Candace L. Haddox, MD Physician, Dana-Farber Cancer Institute Instructor in Medicine, Harvard Medical School Elizabeth H Baldini, MD, MPH, FASTRO Professor of Radiation Oncology Brigham and Women’s Hospital and Dana-Farber Cancer Institute Harvard Medical School Jason L. Hornick, MD, PhD Professor, Pathology Brigham and Women's Hospital Harvard Medical School Vicki L. Keedy, MD, MSCI Associate Professor of Medicine Clinical Director, Sarcoma Vanderbilt-Ingram Cancer Center Christina L. Roland, MD, MS, FACS Associate Professor Department of Surgical Oncology MD Anderson Cancer Center 2025-11-17T18:34:15.000Z https://www.youtube.com/embed/Z49NLYpCu8A 12 https://oncdata.com/videos/neuroendocrine-tumors-radiology-reveals-distinct-features 2026-11-11 https://i.ytimg.com/vi/1ofVHClTlt8/mqdefault.jpg Neuroendocrine Tumors: Radiology Reveals Distinct Features! Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-17T18:28:41.000Z https://www.youtube.com/embed/1ofVHClTlt8 23 https://oncdata.com/videos/tumor-types-what-do-gallium68-and-fdg-positivity-mean 2026-01-27 https://i.ytimg.com/vi/IrMU_fK5Ttc/mqdefault.jpg Tumor Types: What Do Gallium68 and FDG Positivity Mean Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare and aggressive tumors with limited evidence to guide treatment. This enduring activity explores the latest advances—including targeted therapies, immunotherapy, and radionuclide approaches—while emphasizing the importance of multidisciplinary strategies to improve outcomes. Strengthen your knowledge with cutting-edge insights into EP-NEC management. STATEMENT OF NEED Neuroendocrine carcinomas (NECs) are a rare and highly aggressive group of tumors that can arise from neuroendocrine cells anywhere in the body. While the lung is the most common site of origin, approximately 9% are classified as extrapulmonary NECs (EP-NECs), which arise most commonly in the gastroenteropancreatic tract, followed by the genitourinary and gynecologic tracts (Stumpo et al, 2023; Dasari et al, 2017). Diagnosis of EP-NECs is complicated by their diverse clinical presentations, and there is suboptimal evidence for guiding treatment recommendations. Ongoing trials evaluating targeted therapies, immune checkpoint inhibitors, and radionuclide therapy are showing promise in the treatment of EP-NECs, and remaining up to date on emerging evidence and multidisciplinary strategies is essential to improving patient outcomes (Stumpo et al, 2023). In this Video Viewpoint Strategy Session, Andrew E. Hendifar, MD, Associate Professor of Medicine and Medical Director of Pancreatic Cancer at Samuel Oschin Comprehensive Cancer Center of Cedars-Sinai Medical Center, and Danielle Hutchings, MD, Assistant Professor of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, will provide expert insights on diagnosis, treatment, and emerging targets in EP-NECs. TARGET AUDIENCE Oncologists, gynecologic oncologists, pathologists, oncology advanced practice providers, pharmacists, and other healthcare professionals involved in the treatment of patients with neuroendocrine carcinomas (NECs). DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ACPE that require everyone in a position to control the content of a CME/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/CPE activity. CME/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Andrew E. Hendifar, MD, discloses that he has served on an advisory board or panel for Alcresta, Exelixis, Merck, and Pfizer. Danielle Hutchings, MD, has no relevant financial relationships to disclose. i3 Health has mitigated all relevant financial relationships. #NeuroendocrineCarcinomas #EPNECs #CancerCare #OncologyInnovation #TargetedTherapies #Immunotherapy #RadionuclideTherapy #OncologyEducation #CancerResearch #PatientOutcomes 2025-11-17T18:28:22.000Z https://www.youtube.com/embed/IrMU_fK5Ttc 23 https://oncdata.com/videos/navigating-new-frontiers-in-oncology-what-s-next-at-oncology-data-advisor 2026-11-11 https://i.ytimg.com/vi/pB5zr1Bs4e8/mqdefault.jpg Navigating New Frontiers in Oncology: What's Next at Oncology Data Advisor Read the full interview on Oncology Data Advisor: https://oncdata.com/navigating-new-frontiers-in-oncology-editor-in-chief As Oncology Data Advisor welcomes new editorial leadership, outgoing Editor in Chief Dr. Rahul Banerjee and incoming Editor in Chief Dr. Matthew Hadfield reflect on the evolving landscape of oncology collaboration, education, and innovation. They discuss key topics shaping the next era of cancer care—from scaling access to genomic testing and measurable residual disease (MRD) assessment, to expanding immunotherapy use, addressing telehealth barriers, and fostering mentorship for the next generation of oncologists. Hear their perspectives on bridging academic and community care, breaking down complex trial design concepts for trainees, and shaping Oncology Data Advisor’s future as a hub for collaboration, education, and equitable cancer care. #OncologyLeadership #CancerCareInnovation #PrecisionOncology #MRD #GenomicTesting #Immunotherapy #HealthPolicy #Telehealth #OncologyEducation #ProfessionalMentorship #OncoData #OncologyCommunity #CancerResearch #PatientOutcomes 2025-11-13T13:01:46.000Z https://www.youtube.com/embed/pB5zr1Bs4e8 936 https://oncdata.com/videos/improving-early-and-equitable-lung-cancer-detection-with-sybil-ai-mary-pasquinelli-and-waqas-haque 2026-11-11 https://i.ytimg.com/vi/UjK0gjx1gFc/mqdefault.jpg Improving Early and Equitable Lung Cancer Detection With Sybil AI: Mary Pasquinelli and Waqas Haque The full article for this interview is available on Oncology Data Advisor. Check it out here: https://oncdata.com/mary-pasquinelli-sybil-ai Mary Pasquinelli, DNP (UI Health), joins Dr. Waqas Haque to discuss how AI risk prediction (Sybil), low-dose CT, and ctDNA can improve early lung cancer detection and equity. Hear validation results of Sybil in a diverse cohort (AUC 0.94 at 1 year; 0.79 at 6 years), program design that boosted adherence 85%, and practical strategies for community and academic settings. #LungCancerScreening #SybilAI #AIinOncology #ctDNA #LowDoseCT #HealthEquity #LungCancerDetection #RiskPrediction #OncologyInformatics #PopulationHealth #WCLC #USPSTF #IASLC #EarlyDetection #PatientOutcomes 2025-11-10T13:15:05.000Z https://www.youtube.com/embed/UjK0gjx1gFc 1110 https://oncdata.com/videos/supporting-patients-throughout-their-treatment-podcast 2026-11-11 https://i.ytimg.com/vi/7p4egSB2R4M/mqdefault.jpg Supporting Patients Throughout Their Treatment #podcast Watch the recording of this YouTube panel on challenges and innovations in biliary tract cancer (BTC)! This in-depth discussion brought together an interprofessional Task Force of expert faculty members who shared their insights and provide a consensus opinion on optimizing diagnosis and treatment of BTC. During this discussion hear perspectives on: - Signs and symptoms of BTC and strategies for early diagnosis - The role of molecular testing in BTC and the implication of results for treatment selection - The importance of personalized medicine in BTC and factors considered when choosing initial and subsequent therapies - Novel treatment approaches for advanced disease, such as targeting the MDM2-p53 pathway - Future directions, including redefining curative transplantation and locoregional therapy in unresectable disease - Insights into BTC management from physician, nurse, patient advocate, and pathologist perspectives - And more! 2025-11-10T07:25:19.000Z https://www.youtube.com/embed/7p4egSB2R4M 21 https://oncdata.com/videos/ethical-trials-your-health-comes-first-oncology 2026-11-11 https://i.ytimg.com/vi/GqG8r-M-O-k/mqdefault.jpg Ethical Trials: Your Health Comes First! #oncology Watch the recording of this YouTube panel on challenges and innovations in biliary tract cancer (BTC)! This in-depth discussion brought together an interprofessional Task Force of expert faculty members who shared their insights and provide a consensus opinion on optimizing diagnosis and treatment of BTC. During this discussion hear perspectives on: - Signs and symptoms of BTC and strategies for early diagnosis - The role of molecular testing in BTC and the implication of results for treatment selection - The importance of personalized medicine in BTC and factors considered when choosing initial and subsequent therapies - Novel treatment approaches for advanced disease, such as targeting the MDM2-p53 pathway - Future directions, including redefining curative transplantation and locoregional therapy in unresectable disease - Insights into BTC management from physician, nurse, patient advocate, and pathologist perspectives - And more! 2025-11-10T07:25:08.000Z https://www.youtube.com/embed/GqG8r-M-O-k 32 https://oncdata.com/videos/empowering-the-patient-the-power-of-support-podcast-oncology 2026-11-11 https://i.ytimg.com/vi/gWCiZxIASvQ/mqdefault.jpg Empowering The Patient: The Power of Support #podcast #oncology Watch the recording of this YouTube panel on challenges and innovations in biliary tract cancer (BTC)! This in-depth discussion brought together an interprofessional Task Force of expert faculty members who shared their insights and provide a consensus opinion on optimizing diagnosis and treatment of BTC. During this discussion hear perspectives on: - Signs and symptoms of BTC and strategies for early diagnosis - The role of molecular testing in BTC and the implication of results for treatment selection - The importance of personalized medicine in BTC and factors considered when choosing initial and subsequent therapies - Novel treatment approaches for advanced disease, such as targeting the MDM2-p53 pathway - Future directions, including redefining curative transplantation and locoregional therapy in unresectable disease - Insights into BTC management from physician, nurse, patient advocate, and pathologist perspectives - And more! 2025-11-10T07:24:58.000Z https://www.youtube.com/embed/gWCiZxIASvQ 17 https://oncdata.com/videos/empowering-support-navigating-health-challenges-with-truth-guidance 2026-10-13 https://i.ytimg.com/vi/kiWg5pZCeZo/mqdefault.jpg Empowering Support: Navigating Health Challenges with Truth & Guidance Watch the recording of this YouTube panel on challenges and innovations in biliary tract cancer (BTC)! This in-depth discussion brought together an interprofessional Task Force of expert faculty members who shared their insights and provide a consensus opinion on optimizing diagnosis and treatment of BTC. During this discussion hear perspectives on: - Signs and symptoms of BTC and strategies for early diagnosis - The role of molecular testing in BTC and the implication of results for treatment selection - The importance of personalized medicine in BTC and factors considered when choosing initial and subsequent therapies - Novel treatment approaches for advanced disease, such as targeting the MDM2-p53 pathway - Future directions, including redefining curative transplantation and locoregional therapy in unresectable disease - Insights into BTC management from physician, nurse, patient advocate, and pathologist perspectives - And more! 2025-11-10T07:24:42.000Z https://www.youtube.com/embed/kiWg5pZCeZo 31 https://oncdata.com/how-clinical-intuition-and-genomic-ai-solved-a-cancer-misdiagnosis-mystery 2026-11-05 https://oncdata.com/ai-discovered-drugs-are-reaching-the-clinic-but-are-they-reaching-patients 2026-11-03 https://oncdata.com/closing-the-gap-in-colorectal-cancer-screening-adherence 2026-10-29 https://oncdata.com/oncology-unfiltered-the-documentation-burden 2026-10-22 https://oncdata.com/glp-1-receptor-agonists-in-breast-cancer 2026-10-15 https://oncdata.com/operationalizing-quality-frameworks-in-oncology-real-world-data 2026-10-08 https://oncdata.com/new-milestone-for-ai-powered-cancer-vaccine 2026-10-06 https://oncdata.com/reimagining-oncology-education-with-ai 2026-10-01 https://oncdata.com/bringing-bispecific-antibodies-into-community-myeloma-care 2026-09-22 https://oncdata.com/beyond-the-headlines-ai-in-breast-oncology 2026-09-15 https://oncdata.com/personalizing-surgical-risk-assessment-in-lung-cancer 2026-09-10 https://oncdata.com/oncology-unfiltered-clinical-trial-enrollment-barriers 2026-09-03 https://oncdata.com/simulation-modeling-reducing-oncology-clinic-wait-times 2026-08-25 https://oncdata.com/making-the-match-how-ai-improves-clinical-trial-matching 2026-08-21 https://oncdata.com/new-paths-forward-in-cutaneous-t-cell-lymphoma 2026-08-18 https://oncdata.com/real-world-evidence-ai-in-oncology 2026-08-11 https://oncdata.com/oncology-unfiltered-immunotherapy-fatigue 2026-08-06 https://oncdata.com/prostate-cancer-faculty-follow-up 2026-07-29 https://oncdata.com/additional-advances-ep-necs 2026-07-23 https://oncdata.com/earlier-detection-better-outcomes-ovarian-cancer 2026-07-16 https://oncdata.com/tailoring-diagnostic-treatment-strategies-systemic-mastocytosis 2026-07-13 https://oncdata.com/information-overload-and-the-portal-patient 2026-07-09 https://oncdata.com/how-a-multi-llm-ensemble-accelerates-drug-repurposing 2026-07-06 https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging 2026-07-01 https://oncdata.com/silent-side-effect-ototoxicity-germ-cell-tumor-treatment 2026-06-29 https://oncdata.com/equity-preventive-oncology-identity-anatomy 2026-06-25 https://oncdata.com/racial-ethnic-representation-oncology-clinical-trials 2026-06-24 https://oncdata.com/from-curiosity-to-contribution-how-oncologists-can-engage-in-ai-and-innovation 2026-06-23 https://oncdata.com/ndmm-live-virtual-rounds-preview 2026-06-22 https://oncdata.com/lgbtq-health-equity-lessons-from-a-three-time-survivor 2026-06-22 https://oncdata.com/no-one-is-invincible-proactive-skin-cancer-screening 2026-06-17 https://oncdata.com/partners-in-care-community-mens-health 2026-06-16 https://oncdata.com/asco-voices-patient-trust 2026-06-12 https://oncdata.com/human-expertise-matters-age-of-ai 2026-06-11 https://oncdata.com/new-door-in-lung-cancer-targeting-met-amplification 2026-06-10 https://oncdata.com/can-podcasts-help-improve-adoption-of-her2-low-therapies 2026-06-09 https://oncdata.com/national-cancer-survivors-day-2026 2026-06-05 https://oncdata.com/oncology-unfiltered-tumor-board-vs-tuesday-afternoon 2026-06-04 https://oncdata.com/debunking-myths-in-breast-cancer-screening 2026-06-02 https://oncdata.com/targeting-ras-in-pancreatic-cancer-emerging-clinical-evidence-and-the-promise-of-next-generation-inhibitors 2026-06-01 https://oncdata.com/strength-in-community-alix-shulman 2026-06-01 https://oncdata.com/can-exercise-lower-lung-cancer-risk 2026-05-29 https://oncdata.com/mental-health-awareness-month-2026 2026-05-28 https://oncdata.com/melanoma-matters-recognizing-risk-acting-early-and-advancing-care 2026-05-12 https://oncdata.com/vepdegestrant-approved-for-her2-negative-advanced-or-metastatic-breast-cancer 2026-05-11 https://oncdata.com/oncology-unfiltered-the-real-world-vs-the-trial-patient 2026-05-07 https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne 2026-05-04 https://oncdata.com/asco-gu-2026 2026-04-29 https://oncdata.com/patient-experience-week 2026-04-27 https://oncdata.com/clinical-trial-representation-cha-friedson 2026-04-23 https://oncdata.com/egg-and-embryo-cryopreservation-meaghan-delaney 2026-04-20 https://oncdata.com/national-minority-health-month-2026 2026-04-16 https://oncdata.com/exploring-ai-helioliver 2026-04-15 https://oncdata.com/power-of-community-for-women-in-science-and-research 2026-04-13 https://oncdata.com/exercise-for-older-cancer-survivors-dispelling-the-myths-and-creating-guidance-with-kerri-winters-stone-phd 2026-04-09 https://oncdata.com/aya-cancer-awareness-addressing-biological-distinctiveness-survivorship-and-the-whole-person-approach 2026-04-07 https://oncdata.com/additional-advances-in-esophagogastric-cancer-research-and-clinical-trials 2026-04-06 https://oncdata.com/her2-mutant-nsclc-zongertinib-approval 2026-04-03 https://oncdata.com/oncology-unfiltered-choosing-not-to-treat 2026-04-02 https://oncdata.com/mrd-complete-response-end-points-banerjee-richardson 2026-03-31 https://oncdata.com/national-doctors-day-2026 2026-03-30 https://oncdata.com/hemophilia-additional-advances-sidonio 2026-03-27 https://oncdata.com/perioperative-chemoimmunotherapy-nsclc-meir-aung 2026-03-26 https://oncdata.com/nivolumab-plus-chemotherapy-approved-for-previously-untreated-hodgkin-lymphoma 2026-03-25 https://oncdata.com/the-octavia-problem-optimizing-cancer-care-in-the-era-of-ai 2026-03-20 https://oncdata.com/national-nutrition-month-2026 2026-03-18 https://oncdata.com/inav-daniel-king 2026-03-16 https://oncdata.com/neuroendocrine-tumor-additional-advances 2026-03-11 https://oncdata.com/teclistamab-approved-for-relapsed-or-refractory-multiple-myeloma 2026-03-09 https://oncdata.com/international-womens-day-sharing-knowledge-and-community-with-jasmin-hundal-and-megan-claire-chase 2026-03-09 https://oncdata.com/oncology-unfiltered-molecular-testing 2026-03-05 https://oncdata.com/oncofertility-meaghan-delaney 2026-03-02 https://oncdata.com/the-hidden-burden-of-rarity-navigating-the-rare-cancer-journey-with-claire-saxton-mba 2026-02-27 https://oncdata.com/acalabrutinib-with-venetoclax-approved-for-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma 2026-02-24 https://oncdata.com/cholangiocarcinoma-awareness-month-2026-kannan-thanikachalam-md 2026-02-23 https://oncdata.com/national-caregivers-day-badt-hundal 2026-02-20 https://oncdata.com/additional-advances-biliary-tract-cancer 2026-02-19 https://oncdata.com/working-with-cancer-employer-support-clark-spitaletta 2026-02-17 https://oncdata.com/prevention-in-practice-hadfield-hundal 2026-02-12 https://oncdata.com/multicancer-early-detection-understanding-the-science-and-promoting-practical-application 2026-02-11 https://oncdata.com/oncology-unfiltered-financial-toxicity 2026-02-05 https://oncdata.com/world-cancer-day-hundal-werner 2026-02-04 https://oncdata.com/how-ai-can-empower-community-oncologists-oncorx-insights 2026-02-02 https://oncdata.com/anitocabtagene-autoleucel-krina-patel-md-msc 2026-01-30 https://oncdata.com/daratumumab-and-hyaluronidase-fihj-plus-vrd-approved-for-transplant-ineligible-newly-diagnosed-multiple-myeloma 2026-01-30 https://oncdata.com/world-cancer-day-cancer-support-community 2026-01-29 https://oncdata.com/additional-advances-in-melanoma-research-and-clinical-trials-with-michael-davies-md-phd 2026-01-28 https://oncdata.com/cybersecurity-patient-safety-how-this-plays-out-in-oncology 2026-01-28 https://oncdata.com/optimizing-clinical-strategies-for-successful-stem-cell-mobilization-outcomes-in-multiple-myeloma 2026-01-28 https://oncdata.com/trastuzumab-deruxtecan-pertuzumab-approved-her2-positive-breast-cancer 2026-01-28 https://oncdata.com/nurse-led-telehealth-yolanda-vanriel 2026-01-28 https://oncdata.com/systemic-mastocytosis-webinar-preview 2026-01-28 https://oncdata.com/breast-cancer-screening-welman-hundal 2026-01-12 https://oncdata.com/sabcs-2025-chase-hundal 2026-01-08 https://oncdata.com/navigating-mrd-as-an-end-point-banerjee-richardson 2026-01-06 https://oncdata.com/rucaparib-approved-for-metastatic-castration-resistant-prostate-cancer 2025-12-30 https://oncdata.com/niraparib-aap-approved-brca2-mutated-metastatic-cspc 2025-12-22 https://oncdata.com/her2-mutant-nsclc-webinar-preview 2025-12-19 https://oncdata.com/lisocabtagene-maraleucel-approved-relapsed-refractory-marginal-zone-lymphoma 2025-12-18 https://oncdata.com/durvalumab-approved-gastric-or-gastroesophageal-junction-adenocarcinoma 2025-12-18 https://oncdata.com/how-ai-is-redefining-lung-cancer-screening-precision 2025-12-15 https://oncdata.com/jasmin-hundal-esmo-breast-cancer 2025-12-11 https://oncdata.com/pembrolizumab-enfortumab-vedotin-ejfv-combination-approved-for-muscle-invasive-bladder-cancer 2025-12-09 https://oncdata.com/tarlatamab-dlle-approved-for-relapsed-extensive-stage-small-cell-lung-cancer 2025-12-08 https://oncdata.com/car-t-in-practice-ehsan-malek 2025-12-08 https://oncdata.com/advancing-community-oncology-hadfield-hammonds 2025-12-03 https://oncdata.com/manta-cares-samira-daswani 2025-12-01 https://oncdata.com/stephen-freedland-murilo-luz-esmo-2025 2025-11-24 https://oncdata.com/sevabertinib-granted-accelerated-approval-for-non-squamous-nsclc 2025-11-24 https://oncdata.com/epcoritamab-bysp-approved-for-relapsed-refractory-follicular-lymphoma 2025-11-21 https://oncdata.com/embark-esmo-stephen-freedland 2025-11-20 https://oncdata.com/ziftomenib-approved-for-relapsed-refractory-aml-with-susceptible-npm1-mutation 2025-11-19 https://oncdata.com/adaptive-intelligence-prostate-cancer-radiation 2025-11-18 https://oncdata.com/oncdata-welcomes-editor-in-chief-matthew-hadfield 2025-11-13 https://oncdata.com/navigating-new-frontiers-in-oncology-editor-in-chief 2025-11-13 https://oncdata.com/daratumumab-and-hyaluronidase-fihj-approved-for-high-risk-smoldering-multiple-myeloma 2025-11-12 https://oncdata.com/mary-pasquinelli-sybil-ai 2025-11-10 https://oncdata.com/sean-collins-hydrogel-spacers-prostate-cancer 2025-11-06 https://oncdata.com/revumenib-approved-for-relapsed-refractory-aml-with-susceptible-npm1-mutation 2025-10-30 https://oncdata.com/mars-2-mesothelioma 2025-10-28 https://oncdata.com/improving-oncologic-and-genetic-management-of-von-hippel-lindau-disease 2025-10-27 https://oncdata.com/belantamab-mafodotin-blmf-combination-approved-for-relapsed-refractory-multiple-myeloma 2025-10-24 https://oncdata.com/breast-cancer-fear-of-recurrence 2025-10-23 https://oncdata.com/beyond-the-pink-breast-cancer-awareness-month 2025-10-16 https://oncdata.com/ai-co-scientist 2025-10-14 https://oncdata.com/cemiplimab-approved-for-adjuvant-treatment-of-high-risk-cscc 2025-10-13 https://oncdata.com/breast-cancer-awareness-month-kurian-hundal 2025-10-09 https://oncdata.com/travis-osterman-ai-informatics 2025-10-07 https://oncdata.com/lurbinectedin-plus-atezolizumab-approved-for-maintenance-treatment-in-es-sclc-after-induction-therapy 2025-10-06 https://oncdata.com/imlunestrant-breast-cancer-komal-jhaveri 2025-10-02 https://oncdata.com/pembrolizumab-plus-berahyaluronidase-alfa-pmph-approved-for-subcutaneous-administration-across-solid-tumor-indications 2025-09-29 https://oncdata.com/world-lung-day-advancing-equity-through-low-dose-lung-cancer-screening 2025-09-25 https://oncdata.com/national-womens-health-and-fitness-day-hundal 2025-09-24 https://oncdata.com/pain-awareness-month-mccollom-hundal 2025-09-22 https://oncdata.com/the-future-of-fda-guidance-trial-design-and-accelerated-approvals 2025-09-18 https://oncdata.com/ana-baramidze-cemiplimab 2025-09-16 https://oncdata.com/lessons-from-year-one-in-oncology-practice 2025-09-11 https://oncdata.com/selumetinibs-pediatric-approval-expanded-for-neurofibromatosis-type-1-with-symptomatic-inoperable-plexiform-neurofibromas 2025-09-11 https://oncdata.com/gemcitabine-intravesical-system-approved-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2025-09-10 https://oncdata.com/from-knowledge-to-practice-ai-in-oncology 2025-09-09 https://oncdata.com/ai-ascomind 2025-09-04 https://oncdata.com/tailoring-treatment-and-building-confidence-in-management-of-hemophilia 2025-08-29 https://oncdata.com/dordaviprone-approval-patrick-wen 2025-08-26 https://oncdata.com/summer-sun-safety-month-matthew-hadfield 2025-08-21 https://oncdata.com/https-oncdata-com-world-breast-cancer-research-day-connie-visovsky 2025-08-18 https://oncdata.com/zongertinib-granted-accelerated-approval-for-her2-tkd-mutated-non-squamous-nsclc 2025-08-15 https://oncdata.com/digital-and-social-technology-blog 2025-08-13 https://oncdata.com/dordaviprone-granted-accelerated-approval-for-h3-k27m-mutant-diffuse-midline-glioma 2025-08-12 https://oncdata.com/rp1-fda-hadfield-moser 2025-08-11 https://oncdata.com/genetic-counseling-additional-advances 2025-08-08 https://oncdata.com/jasmin-hundal-mascc-highlights 2025-08-04 https://oncdata.com/her2-nsclc-additional-advances 2025-08-01 https://oncdata.com/jasmin-hundal-asco-breast-cancer 2025-07-31 https://oncdata.com/multicancer-early-detection-fellows-perspective 2025-07-29 https://oncdata.com/hnscc-outcomes 2025-07-24 https://oncdata.com/letter-from-the-editor-challenge-trial 2025-07-23 https://oncdata.com/mced-additional-advances 2025-07-21 https://oncdata.com/dedifferentiated-liposarcoma-additional-insights 2025-07-17 https://oncdata.com/glioblastoma-awareness-day-ajay-abad 2025-07-16 https://oncdata.com/ai-at-asco 2025-07-14 https://oncdata.com/gayathri-namasivayam-asco 2025-07-11 https://oncdata.com/nets-webinar-preview 2025-07-10 https://oncdata.com/sunvozertinib-approved-for-egfr-exon-20-insertion-mutation-positive-nsclc 2025-07-08 https://oncdata.com/asco-exercise-freedland-gong 2025-07-07 https://oncdata.com/linvoseltamab-gcpt-approved-for-relapsed-or-refractory-multiple-myeloma 2025-07-03 https://oncdata.com/natural-disaster-asco-manali-patel 2025-06-30 https://oncdata.com/datopotamab-deruxtecan-dlnk-granted-accelerated-approval-for-egfr-mutated-nsclc 2025-06-25 https://oncdata.com/abigail-zamorano-caregivers 2025-06-24 https://oncdata.com/tafasitamab-cxix-approved-for-relapsed-or-refractory-follicular-lymphoma 2025-06-23 https://oncdata.com/world-kidney-cancer-day-david-maj 2025-06-19 https://oncdata.com/pride-month-lauren-ghazal-jasmin-hundal 2025-06-18 https://oncdata.com/pembrolizumab-approved-for-perioperative-treatment-of-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma 2025-06-18 https://oncdata.com/biliary-tract-cancer-position-statement 2025-06-17 https://oncdata.com/nursing-assistants-day-2025 2025-06-17 https://oncdata.com/national-cancer-survivors-month-darcy-burbage 2025-06-16 https://oncdata.com/mitomycin-intravesical-solution-approved-for-low-grade-non-muscle-invasive-bladder-cancer 2025-06-16 https://oncdata.com/taletrectinib-approved-for-ros1-positive-non-small-cell-lung-cancer 2025-06-13 https://oncdata.com/mens-health-week-stephen-freedland 2025-06-11 https://oncdata.com/social-determinants-of-health-amy-osullivan 2025-06-09 https://oncdata.com/brain-tumor-awareness-day-ourbrainbank 2025-06-08 https://oncdata.com/darolutamide-approved-for-metastatic-castration-sensitive-prostate-cancer 2025-06-05 https://oncdata.com/moving-beyond-tradition-roles-with-ai-in-the-era-of-precision-medicine 2025-06-05 https://oncdata.com/standard-model-biomedicine 2025-06-04 https://oncdata.com/tackling-cancer-stigma-gretchen-mcnally 2025-06-03 https://oncdata.com/employee-wellness-month-jeri-lowman 2025-06-02 https://oncdata.com/world-no-tobacco-day-maureen-obrien 2025-05-31 https://oncdata.com/older-americans-month-carolina-uranga 2025-05-29 https://oncdata.com/oncology-nursing-month-pinheiro 2025-05-27 https://oncdata.com/bladder-cancer-awareness-lisa-herms 2025-05-23 https://oncdata.com/brighter-horizons-in-neuro-oncology 2025-05-21 https://oncdata.com/reimagining-oncology-nursing-through-ai 2025-05-21 https://oncdata.com/oncology-nursing-month-gilanie-de-castro 2025-05-19 https://oncdata.com/retifanlimab-dlwr-approved-for-advanced-squamous-cell-carcinoma-of-the-anal-canal 2025-05-19 https://oncdata.com/womens-health-week-chi-chen-hong 2025-05-16 https://oncdata.com/telisotuzumab-vedotin-tllv-receives-accelerated-approval-for-high-c-met-non-squamous-nsclc 2025-05-16 https://oncdata.com/belzutifan-approved-for-advanced-pheochromocytoma-and-paraganglioma 2025-05-15 https://oncdata.com/womens-health-week-valerie-brutus 2025-05-15 https://oncdata.com/womens-health-week-connie-visovsky 2025-05-14 https://oncdata.com/womens-health-week-gretchen-mcnally 2025-05-13 https://oncdata.com/oncology-nursing-month-martin-michalowski 2025-05-12 https://oncdata.com/womens-health-week-jasmin-hundal 2025-05-09 https://oncdata.com/avutometinib-and-defactinib-granted-accelerated-approval-for-kras-mutated-low-grade-serous-ovarian-cancer 2025-05-08 https://oncdata.com/join-vhl-awareness-month 2025-05-08 https://oncdata.com/oncology-nursing-month-eileen-hacker 2025-05-06 https://oncdata.com/melanoma-monday-matthew-hadfield 2025-05-05 https://oncdata.com/what-the-oncology-field-can-learn-from-the-white-lotus 2025-04-30 https://oncdata.com/penpulimab-kcqx-approved-for-non-keratinizing-nasopharyngeal-carcinoma 2025-04-30 https://oncdata.com/join-world-health-day-2025 2025-04-28 https://oncdata.com/harnessing-ai-for-early-lung-cancer-detection-qure-ais-innovations-and-impact 2025-04-24 https://oncdata.com/national-minority-health-month-2025 2025-04-23 https://oncdata.com/aml-awareness-day-tristan-knight 2025-04-21 https://oncdata.com/testicular-cancer-awareness-month-eric-zack 2025-04-17 https://oncdata.com/theranostics-in-prostate-cancer 2025-04-16 https://oncdata.com/precisca-mohammad-jahanzeb 2025-04-15 https://oncdata.com/nivolumab-and-ipilimumab-approved-for-advanced-hepatocellular-carcinoma 2025-04-14 https://oncdata.com/head-and-neck-cancer-awareness-month-2025 2025-04-10 https://oncdata.com/nivolumab-and-ipilimumab-approved-for-msi-h-dmmr-colorectal-cancer 2025-04-09 https://oncdata.com/rrmm-task-force-additional-advances 2025-04-09 https://oncdata.com/esophageal-cancer-awareness-month-harry-yoon 2025-04-02 https://oncdata.com/durvalumab-approved-for-muscle-invasive-bladder-cancer 2025-04-01 https://oncdata.com/fda-expands-indication-for-lutetium-lu-177-vipivotide-tetraxetan-in-psma-positive-mcrpc 2025-03-31 https://oncdata.com/megan-herr-car-t-cell-scoring 2025-03-31 https://oncdata.com/fda-approves-cabozantinib-for-pancreatic-and-extra-pancreatic-neuroendocrine-tumors 2025-03-28 https://oncdata.com/national-doctors-day-2025 2025-03-26 https://oncdata.com/car-t-second-primary-malignancies-clinic-conversation 2025-03-25 https://oncdata.com/cultivating-proficiency-in-mrd-testing-for-the-management-of-hematologic-malignancies 2025-03-21 https://oncdata.com/pembrolizumab-approved-for-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma 2025-03-20 https://oncdata.com/transforming-clinical-trial-matching-with-ai 2025-03-19 https://oncdata.com/neoantigen-vaccines-rcc-clinic-conversation-of-the-week 2025-03-18 https://oncdata.com/rare-disease-day-2025 2025-03-17 https://oncdata.com/fellow-of-the-month-mehndi-dandwani 2025-03-17 https://oncdata.com/asct-mm-additional-advances 2025-03-12 https://oncdata.com/checkmate-8hw-clinic-converation-of-the-week 2025-03-11 https://oncdata.com/international-womens-day-2025 2025-03-07 https://oncdata.com/tumor-infiltrating-lymphocytes-technology-melanoma 2025-03-06 https://oncdata.com/datopotamab-clinic-conversation-of-the-week 2025-03-04 https://oncdata.com/rcc-additional-advances 2025-03-03 https://oncdata.com/fda-new-approval-guidance-harpreet-singh 2025-02-27 https://oncdata.com/talquetamab-teclistimab-clinic-conversation-of-the-week 2025-02-25 https://oncdata.com/vimseltinib-approved-for-symptomatic-tenosynovial-giant-cell-tumor 2025-02-19 https://oncdata.com/national-cancer-prevention-month-sally-werner 2025-02-19 https://oncdata.com/brentuximab-vedotin-in-combination-with-lenalidomide-and-rituximab-approved-for-relapsed-or-refractory-large-b-cell-lymphoma 2025-02-18 https://oncdata.com/roswell-park-gmp-engineering-and-cell-manufacturing-facility 2025-02-14 https://oncdata.com/treosulfan-plus-fludarabine-approved-as-allohsct-preparative-regimen-for-aml-and-mds 2025-02-12 https://oncdata.com/digital-pathology-osama-khan 2025-02-10 https://oncdata.com/fellow-of-the-month-wint-yan-arthur-aung 2025-02-07 https://oncdata.com/new-frontiers-in-2025-with-ai 2025-02-03 https://oncdata.com/additional-advances-in-hemophilia-treatment 2025-01-31 https://oncdata.com/amplifying-nursing-proficiency-for-the-management-of-immune-related-adverse-events 2025-01-23 https://oncdata.com/how-ai-is-revolutionizing-precision-oncology 2025-01-23 https://oncdata.com/ash-trainee-council-kaitlyn-dykes-maya-abdallah-2 2025-01-22 https://oncdata.com/acalabrutinib-plus-bendamustine-and-rituximab-approved-for-previously-untreated-mantle-cell-lymphoma 2025-01-20 https://oncdata.com/mendel-ai-with-kristin-maloney 2025-01-16 https://oncdata.com/imlunestrant-clinic-conversation-of-the-week 2025-01-14 https://oncdata.com/cancer-support-community-breast-cancer-tolerability-sabcs 2025-01-10 https://oncdata.com/understanding-the-role-of-social-determinants-in-multiple-myeloma-care 2025-01-09 https://oncdata.com/what-oncologists-and-mathletes-have-in-common-during-2025 2025-01-07 https://oncdata.com/ponsegromab-clinic-conversation-of-the-week 2025-01-07 https://oncdata.com/venetoclax-immune-function-chronic-lymphocytic-leukemia 2025-01-06 https://oncdata.com/cosibelimab-new-option-for-cutaneous-squamous-cell-carcinoma 2025-01-03 https://oncdata.com/nivolumab-and-hyaluronidase-nvhy-approved-for-subcutaneous-injection 2024-12-31 https://oncdata.com/ai-applications-in-thymoma-diagnosis-and-management 2024-12-30 https://oncdata.com/encorafenib-cetuximab-mfolfox6-approved-for-braf-v600e-crc 2024-12-27 https://oncdata.com/remestemcel-l-approved-for-pediatric-acute-gvhd 2024-12-26 https://oncdata.com/ensartinib-approved-for-alk-positive-nsclc 2024-12-26 https://oncdata.com/systems-based-hematology-richard-godby 2024-12-23 https://oncdata.com/cancer-support-community-treatment-tolerability-ash 2024-12-20 https://oncdata.com/ctdna-in-breast-cancer-sabcs 2024-12-19 https://oncdata.com/epcore-cll-1-an-advance-in-treating-relapsed-refractory-chronic-lymphocytic-leukemia 2024-12-19 https://oncdata.com/zenocutuzumab-clinic-conversation-of-the-week 2024-12-17 https://oncdata.com/cosibelimab-ipdl-approved-for-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma 2024-12-16 https://oncdata.com/strength-in-motion-resistance-training-in-multiple-myeloma-janine-joseph 2024-12-16 https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology 2024-12-12 https://oncdata.com/zanidatamab-biliary-tract-cancer-james-harding 2024-12-11 https://oncdata.com/aall1731-trial-clinic-conversation-of-the-week 2024-12-10 https://oncdata.com/durvalumab-approved-for-limited-stage-small-cell-lung-cancer 2024-12-05 https://oncdata.com/dedifferentiated-liposarcoma-position-statement-and-podcast 2024-12-04 https://oncdata.com/indigo-trial-clinic-conversation-of-the-week 2024-12-03 https://oncdata.com/american-diabetes-month-2024 2024-11-27 https://oncdata.com/lung-cancer-awareness-month-2024 2024-11-26 https://oncdata.com/fellow-of-the-month-nida-khan 2024-11-25 https://oncdata.com/national-family-caregivers-month-2024 2024-11-22 https://oncdata.com/ai-advances-in-cancer-research 2024-11-21 https://oncdata.com/advancing-clinical-expertise-in-the-oncologic-and-pathologic-management-of-triple-negative-breast-cancer 2024-11-20 https://oncdata.com/revumenib-approved-for-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation 2024-11-18 https://oncdata.com/carcinoid-cancer-awareness-month-2024 2024-11-15 https://oncdata.com/transgender-awareness-week-prostate-cancer 2024-11-14 https://oncdata.com/optimizing-clinical-strategies-for-effective-management-of-soft-tissue-sarcomas 2024-11-13 https://oncdata.com/benefit-trial-clinic-conversation-of-the-week 2024-11-12 https://oncdata.com/obecabtagene-autoleucel-approved-for-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-12 https://oncdata.com/elevating-clinician-competence-in-the-management-of-early-stage-non-small-cell-lung-cancer 2024-11-08 https://oncdata.com/artera-personalizing-treatment-decisions-in-prostate-cancer 2024-11-08 https://oncdata.com/inspirogene-revolutionizing-the-cell-and-gene-therapy-landscape 2024-11-04 https://oncdata.com/jimmy-carter-editors-column-october-2024 2024-10-31 https://oncdata.com/asciminib-accelerated-approval-newly-diagnosed-chronic-myeloid-leukemia 2024-10-31 https://oncdata.com/kras-story-in-lung-cancer-dosing-lessons-to-learn-from-sotorasib 2024-10-30 https://oncdata.com/opportunities-for-ai-in-health-equity-medical-education-and-beyond 2024-10-25 https://oncdata.com/nbcf-helping-women-now-douglas-feil-megan-claire-chase 2024-10-24 https://oncdata.com/national-healthcare-quality-week-matthew-hadfield-lauren-ghazal 2024-10-22 https://oncdata.com/zolbetuximab-clzb-approved-for-gastroesophageal-junction-adenocarcinoma-2 2024-10-22 https://oncdata.com/fellow-of-the-month-jasmin-hundal 2024-10-18 https://oncdata.com/revolutionizing-cancer-diagnostics-through-ai-powered-analysis 2024-10-17 https://oncdata.com/advancing-clinician-expertise-in-recurrent-and-metastatic-head-and-neck-cancer 2024-10-16 https://oncdata.com/lobular-breast-cancer-awareness-day-making-strides-in-research-with-jason-mouabbi 2024-10-15 https://oncdata.com/approval-of-inavolisib-a-leap-forward-in-precision-breast-cancer-therapy-jason-mouabbi 2024-10-14 https://oncdata.com/world-hospice-and-palliative-care-day-richa-thakur-nida-khan 2024-10-11 https://oncdata.com/inavolisib-plus-palbociclib-and-fulvestrant-approved-for-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-advanced-breast-cancer 2024-10-11 https://oncdata.com/world-mental-health-day-perspectives-from-both-patient-and-provider 2024-10-10 https://oncdata.com/improving-confidence-with-bcma-directed-therapies-in-relapsed-refractory-multiple-myeloma 2024-10-09 https://oncdata.com/additional-advances-in-head-and-neck-squamous-cell-carcinoma 2024-10-04 https://oncdata.com/nivolumab-approved-for-neoadjuvant-adjuvant-treatment-of-resectable-non-small-cell-lung-cancer 2024-10-03 https://oncdata.com/studying-rare-cancers-current-methodologies-and-future-opportunities 2024-10-02 https://oncdata.com/selpercatinib-approved-for-ret-fusion-positive-medullary-thyroid-cancer 2024-09-30 https://oncdata.com/osimertinib-approved-for-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer-following-chemoradiation-therapy 2024-09-26 https://oncdata.com/childhood-cancer-awareness-month-a-primer-on-pediatric-cancers 2024-09-26 https://oncdata.com/isatuximab-irfc-plus-bortezomib-lenalidomide-and-dexamethasone-approved-for-newly-diagnosed-multiple-myeloma 2024-09-25 https://oncdata.com/world-cancer-research-day-trends-for-the-future 2024-09-24 https://oncdata.com/pain-awareness-month-a-dual-perspective-on-navigating-cancer-pain 2024-09-23 https://oncdata.com/prostate-cancer-awareness-month-overcoming-disparities 2024-09-23 https://oncdata.com/impacts-of-ai-in-the-evolving-oncology-landscape 2024-09-23 https://oncdata.com/amivantamab-vmjw-plus-chemotherapy-approved-for-non-small-cell-lung-cancer-with-egfr-exon-19-deletions-or-l858r-mutations 2024-09-20 https://oncdata.com/blood-cancer-awareness-month-navigating-hereditary-hematologic-malignancy-genetics 2024-09-20 https://oncdata.com/lymphoma-awareness-month-nursing-and-patient-advocacy-perspectives 2024-09-19 https://oncdata.com/pembrolizumab-plus-chemotherapy-approved-for-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma 2024-09-19 https://oncdata.com/ribociclib-plus-aromatase-inhibitor-and-ribociclib-letrozole-co-pack-approved-for-early-high-risk-breast-cancer 2024-09-18 https://oncdata.com/take-a-loved-one-to-the-doctor-day 2024-09-17 https://oncdata.com/prostate-cancer-awareness-month 2024-09-12 https://oncdata.com/enhancing-knowledge-of-emerging-treatment-strategies-and-latest-advances-in-follicular-lymphoma-therapy 2024-09-11 https://oncdata.com/investigating-the-impact-of-multiple-pharmacy-use-and-medication-adherence-in-colorectal-cancer 2024-09-09 https://oncdata.com/additional-advances-in-immune-related-adverse-events-research-and-clinical-trials-beth-sandy 2024-09-06 https://oncdata.com/icad-creating-a-world-where-cancer-cant-hide 2024-09-05 https://oncdata.com/i3-health-and-oncology-data-advisor-publish-multiple-myeloma-task-force-position-statement-in-blood-cancer-journal-2 2024-09-05 https://oncdata.com/i3-health-and-oncology-data-advisor-publish-multiple-myeloma-task-force-position-statement-in-blood-cancer-journal 2024-09-05 https://oncdata.com/national-grief-awareness-day 2024-08-30 https://oncdata.com/international-overdose-awareness-day-erasing-the-stigma 2024-08-29 https://oncdata.com/ai-in-pathology-transforming-oncology-diagnosis-and-treatment 2024-08-28 https://oncdata.com/improving-understanding-of-evolved-treatment-concepts-and-new-data-in-advanced-prostate-cancer 2024-08-26 https://oncdata.com/palliative-care-and-oncology-partners-in-patient-care 2024-08-23 https://oncdata.com/lazertinib-plus-amivantamab-vmjw-approved-for-non-small-cell-lung-cancer 2024-08-22 https://oncdata.com/neoadjuvant-adjuvant-durvalumab-approved-for-resectable-non-small-cell-lung-cancer 2024-08-20 https://oncdata.com/navigating-the-fellowship-application-experience-with-jorge-avila-md 2024-08-20 https://oncdata.com/axatilimab-csfr-approved-for-chronic-graft-versus-host-disease 2024-08-19 https://oncdata.com/act-for-humanity-advocating-for-aid-workers-on-world-humanitarian-day 2024-08-19 https://oncdata.com/world-breast-cancer-research-day-making-strides-in-neuropathy-research 2024-08-16 https://oncdata.com/summer-sun-safety-month-tristan-knight-matthew-hadfield 2024-08-15 https://oncdata.com/enhancing-value-based-care-and-treatment-of-newly-diagnosed-multiple-myeloma 2024-08-14 https://oncdata.com/vorasidenib-approved-for-astrocytoma-or-oligodendroglioma 2024-08-09 https://oncdata.com/statistically-significant-knowledge-gains-for-esophagogastric-cancer-care 2024-08-09 https://oncdata.com/the-digital-fingerprint-accelerating-personalized-drug-discovery-and-development 2024-08-08 https://oncdata.com/optimizing-sacituzumab-govitecan-tolerability-in-early-tnbc-antonio-llombart-cussac 2024-08-05 https://oncdata.com/afamitresgene-autoleucel-granted-accelerated-approval-as-first-gene-therapy-for-synovial-sarcoma 2024-08-05 https://oncdata.com/dostarlimab-gxly-plus-chemotherapy-receives-expanded-approval-for-endometrial-cancer 2024-08-02 https://oncdata.com/interpreting-psa-values-in-transgender-women-for-optimal-prostate-cancer-screening 2024-08-02 https://oncdata.com/world-lung-cancer-day-2024 2024-08-01 https://oncdata.com/new-updates-on-the-evolving-landscape-of-ai-in-oncology 2024-07-31 https://oncdata.com/leading-transplantation-support-and-research-at-nmdp-and-cibmtr 2024-07-31 https://oncdata.com/daratumumab-and-hyaluronidase-fihj-approved-for-newly-diagnosed-multiple-myeloma 2024-07-31 https://oncdata.com/national-minority-mental-health-awareness-month 2024-07-30 https://oncdata.com/sarcoma-awareness-month-partnering-to-provide-optimal-outcomes 2024-07-29 https://oncdata.com/enhancing-knowledge-of-advanced-renal-cell-carcinoma-treatment-and-patient-care 2024-07-26 https://oncdata.com/caringbridge-ensuring-no-one-goes-through-a-health-journey-alone-tia-newcomer 2024-07-26 https://oncdata.com/reimagining-surgery-through-ai-and-computer-vision-technology-tamir-wolf 2024-07-25 https://oncdata.com/rahul-banerjee-editors-column-july-2024-2 2024-07-24 https://oncdata.com/rahul-banerjee-editors-column-july-2024 2024-07-24 https://oncdata.com/oncology-data-advisor-receives-apex-award-of-excellence-2024-2 2024-07-24 https://oncdata.com/oncology-data-advisor-receives-apex-award-of-excellence-2024 2024-07-24 https://oncdata.com/exploring-association-of-fgfr3-alterations-in-urothelial-cancer-arlene-siefker-radtke 2024-07-22 https://oncdata.com/biomarker-documentation-in-the-community-setting-improving-clinical-decision-support 2024-07-19 https://oncdata.com/community-oncology-pharmacists-their-crucial-role-and-clinical-impact-andrea-roman 2024-07-18 https://oncdata.com/investigating-axicabtagene-ciloleucel-for-relapsed-refractory-central-nervous-system-lymphoma 2024-07-17 https://oncdata.com/updated-results-from-spotlight-and-ev-302-with-ahsan-arozullah 2024-07-16 https://oncdata.com/wommen-trekking-peru-with-gurbakhash-kaur 2024-07-15 https://oncdata.com/cancer-and-careers-with-rebecca-nellis 2024-07-15 https://oncdata.com/worth-the-wait-supporting-young-adult-cancer-survivors-on-the-path-to-parenthood 2024-07-12 https://oncdata.com/the-latest-data-on-zanidatamab-for-her2-positive-biliary-tract-cancer 2024-07-11 https://oncdata.com/intuitively-designing-clinical-trials-to-empower-patients-with-ishwaria-subbiah 2024-07-10 https://oncdata.com/combating-health-disparities-through-more-equitable-screening 2024-07-09 https://oncdata.com/the-nadina-trial-with-matthew-hadfield 2024-07-08 https://oncdata.com/multicancer-early-detection-whats-your-opinion 2024-07-08 https://oncdata.com/an-innovative-wellness-and-professional-development-curriculum-for-fellows 2024-07-05 https://oncdata.com/best-of-asco-2024-what-patients-need-to-know-2 2024-07-05 https://oncdata.com/best-of-asco-2024-what-patients-need-to-know 2024-07-05 https://oncdata.com/highlights-of-multiple-myeloma-at-ash-urvi-shah 2024-07-05 https://oncdata.com/implementing-a-novel-research-methods-training-curriculum-for-fellows 2024-07-03 https://oncdata.com/thinking-globally-broadening-cancer-treatment-equity-around-the-world 2024-07-03 https://oncdata.com/the-fellow-on-call-and-fellowship-research-at-asco 2024-07-02 https://oncdata.com/representing-symptom-research-and-nursing-at-asco-with-natalie-jackson-carroll 2024-07-02 https://oncdata.com/piloting-palliative-care-education-for-fellows-2 2024-07-01 https://oncdata.com/piloting-palliative-care-education-for-fellows 2024-07-01 https://oncdata.com/sarcoma-foundation-of-american-with-brandi-felser-and-waqas-haque 2024-07-01 https://oncdata.com/epcoritamab-granted-accelerated-approval-for-relapsed-refractory-follicular-lymphoma 2024-06-28 https://oncdata.com/advocates-for-universal-dpd-dpyd-testing 2024-06-28 https://oncdata.com/enzalutamide-patient-reported-outcomes-embark-trial-stephen-freedland 2024-06-28 https://oncdata.com/effective-care-for-substance-use-disorders-in-cancer-the-advanced-practice-nurse-perspective 2024-06-27 https://oncdata.com/addressing-barriers-to-transplantation-accessibility 2024-06-26 https://oncdata.com/improving-long-term-survivorship-care-in-head-and-neck-cancer 2024-06-26 https://oncdata.com/oncology-data-advisor-at-asco-2024 2024-06-26 https://oncdata.com/adagrasib-plus-cetuximab-granted-accelerated-approval-for-kras-g12cl-mutated-colorectal-cancer 2024-06-25 https://oncdata.com/count-me-in-partnering-with-patients-to-accelerate-the-pace-of-cancer-research 2024-06-24 https://oncdata.com/qure-ai-with-ranjana-devi-and-waqas-haque 2024-06-24 https://oncdata.com/qure-ai-with-ranjana-devi-and-waqas-haque-2 2024-06-24 https://oncdata.com/developing-a-polygenic-risk-score-for-tnbc-risk-assessment-in-black-women 2024-06-21 https://oncdata.com/harnessing-the-power-of-ai-for-cancer-detection 2024-06-21 https://oncdata.com/blue-faery-improving-liver-cancer-care-through-education-and-research 2024-06-20 https://oncdata.com/pembrolizumab-with-chemotherapy-approved-for-primary-advanced-or-recurrent-endometrial-carcinoma 2024-06-19 https://oncdata.com/highlights-of-brain-tumor-and-cns-research-at-asco-morana-vojnic 2024-06-19 https://oncdata.com/blinatumomab-approved-as-consolidation-for-cd19-positive-philadelphia-chromosome-negative-b-cell-precursor-acute-lymphoblastic-leukemia 2024-06-18 https://oncdata.com/artful-oncology-psychosocial-oncology-curriculum-for-heme-onc-fellows-jafar-al-mondhiry 2024-06-18 https://oncdata.com/representing-fellows-in-evidence-based-wellness-interventions-andrew-hearn 2024-06-17 https://oncdata.com/durvalumab-with-chemotherapy-approved-for-mismatch-repair-deficient-primary-advanced-or-recurrent-endometrial-cancer 2024-06-17 https://oncdata.com/fellows-forum-live-from-asco-2024-2 2024-06-14 https://oncdata.com/join-the-fellows-forum 2024-06-14 https://oncdata.com/repotrectinib-granted-accelerated-approval-for-ntrk-gene-fusion-positive-solid-tumors-2 2024-06-14 https://oncdata.com/repotrectinib-granted-accelerated-approval-for-ntrk-gene-fusion-positive-solid-tumors 2024-06-14 https://oncdata.com/assessing-risk-of-myelosuppression-parp-inhibitors-karan-jatwani 2024-06-14 https://oncdata.com/selpercatinib-granted-traditional-approval-for-ret-fusion-positive-thyroid-cancer 2024-06-13 https://oncdata.com/understanding-cardiotoxicity-risk-btk-inhibitors-muhammad-salman-faisal 2024-06-13 https://oncdata.com/fellows-forum-at-asco-2024 2024-06-13 https://oncdata.com/predicting-immunotherapy-benefit-ofer-sharon 2024-06-12 https://oncdata.com/fellows-forum-at-asco-2024-2 2024-06-12 https://oncdata.com/highlights-of-sarcoma-research-at-asco-2024 2024-06-11 https://oncdata.com/exploring-tumor-microenvironment-invasive-lobular-carcinoma 2024-06-10 https://oncdata.com/imetelstat-approved-for-low-to-intermediate-1-risk-myelodysplastic-syndromes 2024-06-07 https://oncdata.com/precision-health-approach-to-post-treatment-comorbid-diabetes-in-cancer 2024-06-06 https://oncdata.com/supporting-nurses-returning-to-work-after-cancer-diagnosis 2024-06-05 https://oncdata.com/live-webinar-vhl-2 2024-06-05 https://oncdata.com/food-for-thought-nutrition-in-vulnerable-cancer-populations 2024-06-04 https://oncdata.com/starting-the-conversation-end-of-life-communication-in-oncology-nursing 2024-06-03 https://oncdata.com/lisocabtagene-maraleucel-approved-relapsed-refractory-mantel-cell-lymphoma 2024-05-31 https://oncdata.com/mitigating-financial-toxicity-experienced-by-cancer-survivors 2024-05-31 https://oncdata.com/selpercatinib-granted-accelerated-approval-for-pediatric-patients-ret-mutations 2024-05-30 https://oncdata.com/our-brain-bank-creating-change-in-glioblastoma-treatment 2024-05-30 https://oncdata.com/championing-policy-advocacy-in-cancer 2024-05-29 https://oncdata.com/speed-dating-bridging-gap-between-dnp-phd-nurses 2024-05-28 https://oncdata.com/climate-change-and-healthcare-what-we-can-do-to-help 2024-05-28 https://oncdata.com/lisocabtagene-maraleucel-granted-accelerated-approval-follicular-lymphoma-2 2024-05-28 https://oncdata.com/lisocabtagene-maraleucel-granted-accelerated-approval-follicular-lymphoma 2024-05-24 https://oncdata.com/the-way-ahead-may-2024-2 2024-05-24 https://oncdata.com/the-way-ahead-may-2024 2024-05-24 https://oncdata.com/ons-lifetime-achievement-award-margaret-barton-burke 2024-05-24 https://oncdata.com/incorporating-patient-reported-outcomes-in-oncology-research 2024-05-24 https://oncdata.com/brain-tumor-awareness-month-2024-2 2024-05-23 https://oncdata.com/brain-tumor-awareness-month-2024 2024-05-23 https://oncdata.com/igniting-the-extraordinary-ons-congres-lauren-ghazal 2024-05-22 https://oncdata.com/approval-tarlatamab-subsequent-line-treatment-extensive-stage-small-cell-lung-cancer 2024-05-22 https://oncdata.com/power-of-persistence-and-perspective-kelsey-tainsh 2024-05-21 https://oncdata.com/tackling-disparities-experienced-lgbtq-cancer-survivors 2024-05-20 https://oncdata.com/highlights-of-ons-congress-2024-maria-badillo 2024-05-20 https://oncdata.com/future-oncology-research-cutting-edge-approaches-using-ai 2024-05-17 https://oncdata.com/discussing-cancer-fatalism-risky-healthy-behaviors 2024-05-16 https://oncdata.com/smith-center-for-healing-and-the-arts-erin-price-and-laura-pole 2024-05-15 https://oncdata.com/launching-genetic-cancer-prevention-clinic 2024-05-14 https://oncdata.com/cancer-support-community-editorial-board 2024-05-14 https://oncdata.com/providing-evidence-new-product-introductions-nursing 2024-05-13 https://oncdata.com/bridging-oncology-nursing-learning-gaps-through-advanced-practice-provider-fellowship 2024-05-10 https://oncdata.com/welcome-ons-new-president-jessica-macintyre 2024-05-09 https://oncdata.com/ons-2024-playlist 2024-05-08 https://oncdata.com/additiona-advances-in-multiple-myeloma-research-and-clinical-trials-rahul-banerjee 2024-05-06 https://oncdata.com/recurrent-metastatic-hnscc-answers-to-frequently-asked-questions-with-assuntina-g-sacco-md 2024-05-03 https://oncdata.com/every-cure-unlocking-drug-potential-through-artificial-intelligence-with-waqas-haque-md-mph-and-tracey-sikora-co-founder 2024-05-02 https://oncdata.com/acute-myeloid-leukemia-aml-awareness-day-evolving-treatment-directions-with-dr-tristan-knight-dr-richa-thakur-and-dr-joseph-kalis 2024-05-01 https://oncdata.com/testicular-cancer-awareness-month-improving-detection-management-and-survivorship-with-samuel-kareff-md-mph-waqas-haque-md-mph-and-matthew-hadfield-do 2024-04-30 https://oncdata.com/tisotumab-vedotin-tftv-approved-for-metastatic-cervical-cancer 2024-04-30 https://oncdata.com/tovorafenib-apporved-for-braf-altered-pediatric-low-grade-glioma 2024-04-30 https://oncdata.com/lutetium-lu-177-dotatate-approved-for-pediatric-patients-with-gep-nets 2024-04-29 https://oncdata.com/celebrating-head-and-neck-cancer-awareness-month-with-samuel-kareff-md-mph-matthew-hadfield-do-and-nagashree-seetharamu-md 2024-04-24 https://oncdata.com/nogapendekin-alfa-inbakicept-pmln-approved-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2024-04-23 https://oncdata.com/advancing-precision-oncology-through-artificial-intelligence 2024-04-22 https://oncdata.com/advancing-precision-oncology-through-artificial-intelligence-2 2024-04-22 https://oncdata.com/alectinib-approved-for-adjuvant-treatment-for-alk-positive-non-small-cell-lung-cancer 2024-04-22 https://oncdata.com/esophageal-cancer-awareness-month-treatment-advances-and-tools-for-maximizing-tolerability-with-joseph-kalis-pharmd-bcop-matthew-hadfield-do-samuel-kareff-md-mph 2024-04-19 https://oncdata.com/linvoseltamab-for-relapsed-refractory-multiple-myeloma-updates-on-the-linker-mm1-trial-from-aacr-2024-with-alankrita-taneja-md-and-sundar-jagannath-md 2024-04-17 https://oncdata.com/linvoseltamab-for-relapsed-refractory-multiple-myeloma-aacr 2024-04-17 https://oncdata.com/improving-breast-cancer-surgical-outcomes-with-lymphovenous-bypass-with-jason-mouabbi-md-valerie-brutus-md-facs-and-elizabeth-stirling-craig-md 2024-04-15 https://oncdata.com/additional-advances-in-her2-positive-metastatic-colorectal-cancer-research-and-clinical-trials-with-christopher-lieu-md 2024-04-12 https://oncdata.com/fighting-hereditary-colorectal-cancer-through-genetic-counseling-with-catherine-skefos-ma-ms-cgc-and-julie-moskowitz-ms 2024-04-10 https://oncdata.com/fam-trastuzumab-deruxtecan-nxki-receives-accelerated-approval-for-her2-positive-solid-tumors 2024-04-09 https://oncdata.com/international-womens-day-perspectives-in-medicine-nursing-and-fellowship 2024-04-09 https://oncdata.com/aya-cancer-awareness-week-creating-welcoming-spaces-for-support-and-advocacy-with-dr-lauren-ghazal-megan-claire-chase-and-allison-rosen 2024-04-05 https://oncdata.com/additional-advances-in-soft-tissue-sarcoma-with-brian-rubin-md-phd 2024-04-02 https://oncdata.com/additional-advances-in-attp-research-and-clinical-trials-with-spero-cataland-md 2024-04-01 https://oncdata.com/predicting-immune-related-adverse-events-through-machine-learning-with-oncohost-dr-waqas-haque-dr-matthew-hadfield-and-dr-ofer-sharon 2024-03-31 https://oncdata.com/creating-educational-opportunities-during-fellowship-board-exam-prep-live-meetings-and-beyond-with-samuel-kareff-md-mph-and-matthew-hadfield-do 2024-03-31 https://oncdata.com/thirty-years-in-the-making-the-groundbreaking-approval-of-lifileucel-for-metastatic-melanoma-with-matthew-hadfield-do-and-richard-carvajal-md 2024-03-31 https://oncdata.com/celebrating-national-doctors-day-with-samuel-kareff-md-mph-and-matthew-hadfield-do 2024-03-29 https://oncdata.com/kidney-cancer-awareness-month-spotlight-on-genetic-counseling-with-hiam-abdel-salam-ms-cgc-and-donika-saporito-ms 2024-03-29 https://oncdata.com/a-case-in-contrasts-how-should-the-media-talk-about-cancer-diagnoses 2024-03-28 https://oncdata.com/additional-advances-in-esophagogastric-cancer-research-and-clinical-trials-with-jaffer-ajani-md 2024-03-28 https://oncdata.com/an-introduction-to-genetic-counseling-with-hiam-abdel-salam-ms-cgc-and-catherine-skefos-ma-ms-cgc 2024-03-27 https://oncdata.com/discovering-research-advances-in-mesothelioma-with-samuel-kareff-md-mph-and-estela-rodriguez-md-mph-2-2 2024-03-26 https://oncdata.com/kidney-cancer-awareness-month-discovering-clinical-strategies-to-improve-outcomes-with-dr-samuel-kareff-dr-waqas-haque-and-dr-ulka-vaishampayan-2 2024-03-26 https://oncdata.com/kidney-cancer-awareness-month-discovering-clinical-strategies-to-improve-outcomes-with-dr-samuel-kareff-dr-waqas-haque-and-dr-ulka-vaishampayan 2024-03-26 https://oncdata.com/mirvetuximab-soravtansine-gynx-approved-for-fra-positive-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer 2024-03-25 https://oncdata.com/multiple-myeloma-awareness-month-2024-what-patients-need-to-know 2024-03-25 https://oncdata.com/thirty-years-in-the-making-the-groundbreaking-approval-of-lifileucel-for-metastatic-melanoma-with-matthew-hadfield-do-and-richard-carvajal-md-2 2024-03-22 https://oncdata.com/discovering-research-advances-in-mesothelioma-with-samuel-kareff-md-mph-and-estela-rodriguez-md-mph-3 2024-03-21 https://oncdata.com/acquiring-expertise-for-improved-patient-outcomes-in-immune-thrombocytopenia 2024-03-20 https://oncdata.com/ponatinib-chemotherapy-granted-accelerated-approval-for-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia 2024-03-20 https://oncdata.com/rare-disease-day-2024-a-live-panel-discussion-with-dr-rahul-banerjee-matthew-hadfield-joseph-kalis-and-nagashree-seetharamu-2 2024-03-19 https://oncdata.com/emerging-technologies-in-therapeutics-and-diagnostics 2024-03-19 https://oncdata.com/garnering-knowledge-gains-for-treatment-of-advanced-renal-cell-carcinoma 2022-07-13